
<html lang="en"     class="pb-page"  data-request-id="f85751ea-7242-4ac3-9a96-29391da7be68"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2013.56.issue-9;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/jm301891t;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant" /></meta><meta name="dc.Creator" content="Seunghee  Hong" /></meta><meta name="dc.Creator" content="Jinhee  Kim" /></meta><meta name="dc.Creator" content="Sun-Mi  Yun" /></meta><meta name="dc.Creator" content="Hyunseung  Lee" /></meta><meta name="dc.Creator" content="Yoonsu  Park" /></meta><meta name="dc.Creator" content="Soon-Sun  Hong" /></meta><meta name="dc.Creator" content="Sungwoo  Hong" /></meta><meta name="dc.Description" content="The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatmen..." /></meta><meta name="Description" content="The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatmen..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 19, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm301891t" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm301891t" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm301891t" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm301891t" /></link>
        
    
    

<title>Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm301891t" /></meta><meta property="og:title" content="Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0015.jpeg" /></meta><meta property="og:description" content="The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm301891t"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm301891t">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm301891t&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm301891t&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm301891t&amp;href=/doi/10.1021/jm301891t" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 9</span><span class="cit-fg-pageRange">, 3531-3545</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/9" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm301879g" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm4004158" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Seunghee++Hong">Seunghee Hong</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jinhee++Kim">Jinhee Kim</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sun-Mi++Yun">Sun-Mi Yun</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hyunseung++Lee">Hyunseung Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yoonsu++Park">Yoonsu Park</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Soon-Sun++Hong">Soon-Sun Hong</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sungwoo++Hong">Sungwoo Hong</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 305-701, Korea</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Biomedical Sciences, College of Medicine, Inha University, Incheon 400-712, Korea</span></div><div class="corresp-info"><strong>*</strong>S. Hong: tel (+82) 42-350-2811; fax (+82) 42-350-2810; e-mail <a href="/cdn-cgi/l/email-protection#452d2a2b222a3722052e242c36316b24266b2e37"><span class="__cf_email__" data-cfemail="6c0403020b031e0b2c070d051f18420d0f42071e">[email protected]</span></a>. S.-S. Hong: tel (+82) 32-890-3683; fax (+82) 32-890-2462; e-mail: <a href="/cdn-cgi/l/email-protection#ff979091988cbf9691979ed19e9cd1948d"><span class="__cf_email__" data-cfemail="523a3d3c3521123b3c3a337c33317c3920">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm301891t&amp;href=/doi/10.1021%2Fjm301891t" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 9</span><span class="cit-pageRange">, 3531–3545</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 19, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>22 December 2012</li><li><span class="item_label"><b>Published</b> online</span>19 April 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 May 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm301891t" title="DOI URL">https://doi.org/10.1021/jm301891t</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3531%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSeunghee%2BHong%252C%2BJinhee%2BKim%252C%2BSun-Mi%2BYun%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D9%26contentID%3Djm301891t%26title%3DDiscovery%2Bof%2BNew%2BBenzothiazole-Based%2BInhibitors%2Bof%2BBreakpoint%2BCluster%2BRegion-Abelson%2BKinase%2BIncluding%2Bthe%2BT315I%2BMutant%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3545%26publicationDate%3DMay%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm301891t"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2282</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">25</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm301891t" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of New Benzothiazole-Based Inhibitors of Breakpoint Cluster Region-Abelson Kinase Including the T315I Mutant&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Seunghee&quot;,&quot;last_name&quot;:&quot;Hong&quot;},{&quot;first_name&quot;:&quot;Jinhee&quot;,&quot;last_name&quot;:&quot;Kim&quot;},{&quot;first_name&quot;:&quot;Sun-Mi&quot;,&quot;last_name&quot;:&quot;Yun&quot;},{&quot;first_name&quot;:&quot;Hyunseung&quot;,&quot;last_name&quot;:&quot;Lee&quot;},{&quot;first_name&quot;:&quot;Yoonsu&quot;,&quot;last_name&quot;:&quot;Park&quot;},{&quot;first_name&quot;:&quot;Soon-Sun&quot;,&quot;last_name&quot;:&quot;Hong&quot;},{&quot;first_name&quot;:&quot;Sungwoo&quot;,&quot;last_name&quot;:&quot;Hong&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;19&quot;,&quot;issue&quot;:&quot;9&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;3531-3545&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm301891t&quot;},&quot;abstract&quot;:&quot;The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301891t&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301891t" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301891t&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301891t" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm301891t&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301891t" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm301891t&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm301891t&amp;href=/doi/10.1021/jm301891t" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm301891t" /></input><a href="/doi/pdf/10.1021/jm301891t" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm301891t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm301891t%26sid%3Dliteratum%253Aachs%26pmid%3D23600806%26genre%3Darticle%26aulast%3DHong%26date%3D2013%26atitle%3DDiscovery%2Bof%2BNew%2BBenzothiazole-Based%2BInhibitors%2Bof%2BBreakpoint%2BCluster%2BRegion-Abelson%2BKinase%2BIncluding%2Bthe%2BT315I%2BMutant%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D9%26spage%3D3531%26epage%3D3545%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291763" title="Noncovalent interactions">Noncovalent interactions</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/9" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jmcmar.2013.56.issue-9/production/jmcmar.2013.56.issue-9.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (Bcr-Abl) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant Bcr-Abl kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type Bcr-Abl and the T315I mutant with IC<sub>50</sub> values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant Bcr-Abl.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01672" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01672" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The appearance of Philadelphia (Ph) chromosome is characteristic of chronic myeloid leukemia (CML) and is a result of the reciprocal translocation between the Abelson (ABL) gene on chromosome 9 and the break-point cluster region (Bcr) gene on chromosome 22. This chimeric Bcr-Abl gene generated by the recombination of two genes leads to the production of Bcr-Abl fusion protein, a constitutively active tyrosine kinase that drives clonal malignancy characterized by unchecked myeloid proliferation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Therefore, the fusion protein Bcr-Abl kinase has become a well-validated target for the development of therapeutics to treat CML as demonstrated by the clinical success of drug imatinib.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Imatinib is a potent first-generation Bcr-Abl kinase inhibitor approved for clinical use and effective for most patients diagnosed with chronic phase disease.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Despite the clear benefits of imatinib, many patients with advanced phases of CML frequently develop resistance to imatinib therapy that is often associated with the emergence of a point mutation in the Bcr-Abl kinase domain that disturbs effective inhibitor binding.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> To date, at least 100 different point mutations have been identified in CML patients with resistance to this drug.<a onclick="showRef(event, 'cit4b'); return false;" href="javascript:void(0);" class="ref cit4b">(4b)</a></div><div class="NLM_p">Several second-generation Bcr-Abl kinase inhibitors (e.g., nilotinib, bafetinib, dasatinib, and bosutinib) have been developed to overcome the imatinib resistance in CML.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> These currently approved drugs are effective against the majority of imatinib-resistant forms of Bcr-Abl, but none of the compounds are capable of inhibiting cases with the gatekeeper T315I mutation in Bcr-Abl that accounts for about 15–20% of all clinically relevant CML mutations.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The T315I mutation is a major obstacle for drug design because mutation at the gatekeeper site can alter the geometry of the ATP-binding pocket to interrupt several critical protein–drug interaction sites and eliminate a critical hydrogen bond required for tight binding of the inhibitors.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> In this regard, the identification of potent Bcr-Abl inhibitors that target the T315I mutation would have important therapeutic implications. Recently, Bcr-Abl inhibitors capable of inhibiting the T315I mutant were disclosed to inhibit the full range of Bcr-Abl kinase domain mutations as well as the wild-type kinase.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Several compounds, such as ponatinib<a onclick="showRef(event, 'cit9a cit9b cit9c'); return false;" href="javascript:void(0);" class="ref cit9a cit9b cit9c">(9a-9c)</a> and rebastinib,<a onclick="showRef(event, 'cit9d'); return false;" href="javascript:void(0);" class="ref cit9d">(9d)</a> are currently under clinical investigation in CML patients harboring the Bcr-Abl T315I mutation.</div><div class="NLM_p">Recently, we have disclosed that nocodazole may serve as a promising starting point for the development of new inhibitors targeting T315I mutant Bcr-Abl to treat CML (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Nocodazole has been used as a standard antimicrotubule agent that interferes with the polymerization of microtubules.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Our enzymatic kinase assays and docking simulation studies have shown that nocodazole is a common inhibitor of various cancer-related kinases including Abl, c-Kit, MEK, and Braf. In particular, nocodazole has submicromolar activities against both phosphorylated wild-type and T315I mutant forms of Bcr-Abl kinase (Abl<sup>phos</sup> IC<sub>50</sub> = 0.21 μM; Abl<sup>T315I</sup> IC<sub>50</sub> = 0.64 μM). We extensively modified the structure of nocodazole using a structure-based drug design strategy and discovered a new class of potent benzothiazole-based inhibitors. Herein, we report our studies on the design and synthesis of a new series of Bcr-Abl inhibitors effective against the wild-type and the T315I mutant of Bcr-Abl kinase and demonstrate the biological activities of these compounds.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of nocodazole.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73445" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73445" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Design of the Lead Compound from Nocodazole</h3><div class="NLM_p">The availability of the 3D structure data for therapeutic targets has enhanced opportunities for the rapid identification of biologically active compounds utilizing structure-based drug design strategies. Conformation of the Asp381-Phe382-Gly383 (DFG) motif in the Abl activation loop is very important for kinase activity because this motif is positioned adjacent to the ATP-binding site. The “DFG-in” conformation is referred to as the side chain of Asp381 is directed toward the ATP-binding site in the active conformation to coordinate an ATP-bound Mg<sup>2+</sup> ion. Biochemical assay results showed that nocodazole derivatives target the active form of the phosphorylated Abl protein. Therefore, the active conformations (DFG-in conformation) of the wild-type and T315I mutant of Abl were selected as the target proteins in the present study. We prepared the receptor models in the DFG-in conformation based on the X-ray crystal structure of the wild-type Abl complexed with dasatinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GQG">2GQG</a>)<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and that of the T315I mutant bound to PPY-A (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QOH">2QOH</a>).<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Structural analysis demonstrated that currently approved drugs (e.g., imatinib, nilotinib, and dasatinib) establish a key hydrogen bond with the OH group at the Thr315 residue. However, a mutation of threonine to isoleucine prevented the formation of this critical hydrogen bond. Furthermore, the increased bulk of the Ile315 side chain caused steric repulsion, thereby blocking the access of the inhibitor to the hydrophobic pocket near the gatekeeper residue (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>c).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">In an effort to identify potent Bcr-Abl inhibitors, our structural design plan was initiated based on the docking and structural analysis of wild-type and T315I mutant of Abl bound to nocodazole (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>a,b). The AutoDock program was used while accounting for the motional flexibility of the amino acid side chains in the ATP-binding site. The docking simulation was initiated by establishing 3D grids of interaction energy for all possible atom types. It was noted that two nitrogen atoms in the aminobenzimidazole group of nocodazole formed two hydrogen bonds with the backbone amidic nitrogen and the aminocarbonyl oxygen of Met318 in the Abl kinase. Interestingly, a larger gatekeeper isoleucine residue was found at the interface formed by van der Waals contacts between nocodazole and the T315I mutant of Abl (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>b), indicating that favorable hydrophobic interactions were formed in the T315I mutant. For these reasons, nocodazole was selected as an initial template for further optimization by in-depth structural modification.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Predicted binding mode of nocodazole with Abl. (b) Predicted binding mode of nocodazole with Abl<sup>T315I</sup>. Carbon atoms of nocodazole are shown in pink. (c) Predicted binding mode of imatinib with Abl<sup>T315I</sup>. Each dotted line represents a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an initial effort to enhance binding affinity, we explored the substituent space on nocodazole at two positions (C2 and C6) and compared the calculated binding free energies of the derivatives with respect to the wild-type and T315I mutant Abl kinase. First, we hypothesized that the overall activity of nocodazole derivatives might be improved by introducing a hydrogen-donating moiety into the molecule to establish an additional hydrogen bond with the hinge region. Thus, the terminal methoxy group was replaced with an ethylamine group to afford the compound <b>1</b> containing an ethyl urea group at the C2 position (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>a). To our delight, this modification led to about a 30-fold increase in inhibitory activity against both Abl wild-type and T315I mutant (Abl IC<sub>50</sub> = 8.67 nM; Abl<sup>T315I</sup> IC<sub>50</sub> = 23.1 nM). This significant enhancement of potency most likely stemmed from the strengthening of hydrogen bonds between the inhibitor and protein groups because the docking study showed that the terminal ethyl urea group in compound <b>1</b> was found to establish multiple hydrogen bonds with Met318 of Abl. The importance of the hydrogen bond network was further demonstrated by removal of the terminal ethyl urea group in other related derivatives (e.g., amide and carbamate). Therefore, the ethyl urea moiety at the C2 position was fixed to catch two pairs of hydrogen bonds when designing the new derivatives.</div><div class="NLM_p">Next, a survey of the C6 group was conducted to evaluate the structural differences affecting the binding pockets of wild-type and T315I mutant Abl kinase. To identify a scaffold that can be easily diversified for our structure–activity relationship (SAR) study, we planned to modify the thiophene-2-one group at the C6 position. Of particular significance was the observation that the benzene ring could form favorable van der Waals interactions with the gatekeeper Ile315 residue of Bcr-Abl without causing steric clash, although this substitution led to a slight loss of potency (<b>2</b>, Abl<sup>T315I</sup> IC<sub>50</sub> = 43.7 nM). Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>b shows the lowest energy conformation of compound <b>2</b> in the ATP binding site as calculated with the modified AutoDock program.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The overall structural features derived from the docking simulations confirmed that the inhibitory activities of compound <b>2</b> were attributed to the multiple hydrogen bonds and hydrophobic interactions established simultaneously in the ATP-binding site of Abl. Considering the enzymatic activity within the active site of the T315I mutant and the synthetic flexibility via standard Suzuki coupling chemistry, compound <b>2</b> was selected as a lead compound from which more potent inhibitors could be derived.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) The overall process for deriving the lead from nocodazole. (b) Predicted binding mode of compound <b>2</b> with Abl<sup>T315I</sup>. Carbon atoms of compound <b>2</b> are indicated in pink. (c) The simplified binding mode of compound <b>2</b> with the ATP binding site of Abl<sup>T315I</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To identify improved enzyme interactions and physicochemical properties of compound <b>2</b>, a systematic evaluation of the structural features necessary to impart activity was performed. We initiated our investigation by modifying the aryl group at the C6 position. The docking simulation predicted that the C6 phenyl group is directed toward the region near the gatekeeper and catalytic lysine region (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>c). In this region, space was available for substituents on the phenyl ring that may participate in hydrogen bonding with Lys271 or Asp381. Based on our structural analysis, we planned to install a variety of substituents as the phenyl group at the C6 position, while the ethyl urea moiety at the C2 position remained fixed.</div><div class="NLM_p">Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> illustrates the general synthetic route for the preparation of benzimidazole derivatives with C6-aryl substitution. A variety of aryl groups were attached to the 6-position of the benzimidazole core using palladium-catalyzed Suzuki couplings of diaminobenzene <b>3</b> with corresponding arylboronic acids. Diaminobenzene <b>4</b> was then reacted with <i>N</i>,<i>N</i>′-bis[(ethylamino)carbonyl] carbamimidothioic acid methyl ester to allow for the facile conversions of <i>o</i>-phenylenediamines directly into the desired product <b>5</b> with high yields (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). Aryl ether derivatives (<b>5v</b> and <b>5w</b>) were obtained from 4-phenoxybenzene-1,2-diamines, which were prepared by a two-step sequence: (1) S<sub>N</sub>Ar reaction between 5-chloro-2-nitroaniline and substituted phenol under basic conditions, followed by (2) reduction of the nitro group with tin chloride. Similarly, amide derivatives (<b>5x</b> and <b>5y</b>) were obtained from 3,4-diaminobenzamides. Thus, 3,4-dinitrobenzoyl chloride was reacted with primary or secondary amines to produce 3,4-dinitrobenzamides, followed by the reduction of the nitro groups by tin chloride.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Arylboronic acid, Pd(dppf)Cl<sub>2</sub><b>·</b>CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O = 3:1, 100 °C, microwave, 90 min; (b) <i>N</i>,<i>N</i>′-bis[(ethylamino)carbonyl] carbamimidothioic acid methyl ester, H<sub>2</sub>O/AcOH = 10:3, 110 °C, 5 h.</p></p></figure><div class="NLM_p">The IC<sub>50</sub> values of the resulting compounds were determined for both wild-type and T315I Abl (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The orientation and pattern of the substitutions on the phenyl ring are critical for enzyme potency. In general, substitution at the <i>ortho</i> position of the phenyl ring enhanced its potency (<b>5e</b>, Abl IC<sub>50</sub> = 7.8 nM; Abl<sup>T315I</sup> IC<sub>50</sub> = 16.9 nM), whereas substitution at the <i>meta</i> or <i>para</i> position led to reduced activity (<b>5a</b> and <b>5c</b>). This prompted us to investigate in detail the potential effect of various substitutions at the <i>ortho</i> position. Substituents at the <i>ortho</i> position of the phenyl ring included ethyl and chloro groups. These derivatives were tolerated for both wild-type and T315I Abl kinase (<b>5f</b>, <b>5g</b>). It was noteworthy that the methoxy derivative <b>5h</b> exerted potent effects on wild-type and T315I mutant of Abl (Abl IC<sub>50</sub> = 18.8 nM; Abl<sup>T315I</sup> IC<sub>50</sub> = 6.2 nM). The oxygen in the 2-methoxy group appeared to establish an additional hydrogen bond with the Asp381 backbone, and such a strengthening of hydrogen bonds would be responsible for the higher inhibitory activity. The optimal compound in this series was obtained by introducing an ethoxy group as exemplified by compound <b>5j</b> (Abl IC<sub>50</sub> = 1.6 nM; Abl<sup>T315I</sup> IC<sub>50</sub> = 2.3 nM). We also examined the effect of size of the groups at the C6 position and observed that inhibitory activity was reduced when the ethoxy group was replaced with more sterically hindered isopropoxy (<b>5k</b>) or phenoxy groups (<b>5l</b>). The next round of analogues had an additional substituent incorporated into the phenyl ring. Attempts to further increase potency through disubstitution at the two <i>ortho</i> positions (<b>5m</b>, <b>5n</b>, <b>5o</b>, and <b>5p</b>) were unremarkable, and no compound offered any advantage relative to the corresponding derivatives with a single substitution. In order to determine whether the methoxy- or ethoxy-phenyl groups at the C6 position were optimal, we next evaluated that the effect of a heteroaryl group, such as pyridyl and pyrazole, at this position and found that these groups decreased the inhibitory activity (<b>5q</b>, <b>5r</b>, <b>5s</b>, <b>5t</b>, and <b>5u</b>). We further attempted to explore the SAR of the side chain linked to the C6 position. Replacement of the aryl group with aryl ether (<b>5v</b> and <b>5w</b>) had a negative effect on potency. In particular, replacement of the aryl group with the amide groups (<b>5x</b> and <b>5y</b>) resulted in a complete loss of activity, thus revealing the indispensable nature of the aryl group at this position for maintaining activity in this series. Based on these findings, we determined that <i>o-</i>methoxy- or ethoxy-phenyl moieties at the C6 position were most effective and planned to explore the potential influence of the imidazole core for further structural modification to investigate SAR.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Exploration of the Groups at C6</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0008.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0009.gif" alt="" id="fx2" /></img><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Identification of Benzothiazole Scaffold</h3><div class="NLM_p">Based on the structures of compounds <b>5h</b> and <b>5j</b>, the enhanced potency due to the ethyl urea group at the C2 position and the 2-methoxy- or 2-ethoxyphenyl moieties at the C6 position suggested a need to more broadly explore analogs incorporating these key functional groups. We therefore turned to our attention to core modification with these groups fixed in position. An investigation was thus conducted to evaluate the impact of core modification on inhibitory activities of the compounds, and a series of derivatives with benzothiazole and benzoxazole cores were synthesized (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). In all cases, an aryl group at C6 was introduced prior to the urea group at C2. Compound <b>6</b> was efficiently converted into the aryl intermediate <b>7</b> by Suzuki coupling with appropriate aryl boronic acid. Finally, the treatment of <b>7</b> with alkyl-isocyanate or carbodiimidazole yielded the desired target compounds <b>8</b> and <b>9</b>.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Arylboronic acid, Pd(dppf)Cl<sub>2</sub><b>·</b>CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O = 3:1, 120 °C, microwave, 90 min; (b) alkyl-isocyanate, 1,4-dioxane, 80 °C, 5 h; (c) carbodiimidazole, R-NH<sub>2</sub>, DMF, rt, 10 h.</p></p></figure><div class="NLM_p">IC<sub>50</sub> values of the synthesized derivatives were then determined as summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Notably, the conversion of benzimidazole into benzothiazole increased in the inhibitory activity compared with the parent compounds. Collectively, the combination of 2-methoxybenzene, the benzothiazole core, and the urea group at the C2 position yielded exceptionally potent inhibitors <b>9a</b> and <b>9b</b> with picomolar activities (<b>9a</b>, Abl IC<sub>50</sub> = 0.06 nM, Abl<sup>T315I</sup> IC<sub>50</sub> = 0.11 nM; <b>9b</b>, Abl IC<sub>50</sub> = 0.03 nM, Abl<sup>T315I</sup> IC<sub>50</sub> = 0.064 nM). Further investigation of alternate scaffolds revealed that the benzothiazole was optimal for this series (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a> and Table S2 in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). To the best of our knowledge, the benzothiazole scaffold is not present in any of the Abl inhibitors reported to date.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Comparison of Core on Enzyme Potency</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0010.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center" char=".">Abl wt IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">Abl T315I IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5h</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="char" char=".">18.8</td><td class="colsep0 rowsep0" align="char" char=".">6.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8a</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="char" char=".">40.8</td><td class="colsep0 rowsep0" align="char" char=".">6.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">0.11</td></tr></tbody></table></div></div><div class="NLM_p">We next prepared more benzothiazole derivatives to investigate the SAR profiles based on our previous docking study. The enzyme potency of the derivatives was decreased when a trifluoromethoxy or propoxy group was introduced (<b>9c</b> and <b>9d</b>), indicating that the ethoxy group is maximum size suitable for this position on the benzothiazole core. We also introduced polar groups at the <i>para</i> position of the C6 aryl ring to establish additional hydrogen bonds with the Lys271 or Asp381 side chains. However, the 4-pyridyl (<b>9h</b> and <b>9l</b>), 4-methoxyphenyl (<b>9i</b> and <b>9k</b>), and 4-aminophenyl derivatives (<b>9j</b>) did not provide any advantages compared with the compounds <b>9a</b> or <b>9b</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure and Activity Relationship of Benzothiazole Derivatives</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0011.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0012.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">5-Methoxy benzothiazole.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">7-<i>N</i>-Benzothiazole.</p></div></div><div></div></div><div class="NLM_p">To obtain structural insight into the mechanisms underlying the inhibitory activities of the newly identified benzothiazole derivatives, binding modes in the ATP-binding sites were investigated using the modified AutoDock scoring function.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The calculated binding modes of compounds <b>9a</b> and <b>5h</b> with the Abl T315I mutant are presented in Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>. The results of the docking simulations were internally consistent in that compounds <b>9a</b> and <b>5h</b> were positioned in similar configurations and had comparable interactions with the amino acid residues in the ATP binding site. The docking study revealed that <b>9a</b> appeared to bind tightly at the ATP binding site by forming multiple hydrogen bonds and hydrophobic interactions with the pocket created by Ile313, Met290, Glu286, Val299, Lys271, and Phe382. One explanation for the differences in potency between compounds <b>9a</b> and <b>5h</b> is that the ethyl urea group of <b>9a</b> can participate in more favorable hydrogen bonding. Although the overall binding mode of benzothiazole <b>9a</b> was similar to the corresponding benzimidazole <b>5h</b>, the urea group of <b>9a</b> was more closely directed toward the pocket around Met318 due to the increased size of the sulfur atom in benzothiazole. The lengths of the two hydrogen bonds between the ethyl urea group in <b>9a</b> and Met318 were calculated to be 1.90 and 2.03 Å, respectively, indicating that these were stronger hydrogen bonds than those formed by <b>5h</b> (2.06 and 3.59 Å). Moreover, the intramolecular hydrogen bond between the NH in benzimidazole and C═O in ethyl urea of <b>5h</b> appeared to fix the geometry in the same plane. This spatial restriction prevented tight hydrogen bond interactions with Met318 by distorting the angle of the urea group (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>b). Unlike the benzimidazole core, the urea group of the benzothiazole derivatives had sufficient flexibility and rotation required for tight hydrogen bonding. We also turned to the energetic features associated with binding of <b>9a</b> and <b>5h</b> in the ATP-binding sites of T315I mutant of ABL. The calculated binding free energies of <b>9a</b> and <b>5h</b> compare reasonably well with their inhibitory activities found in docking simulations. The predicted binding free energy of <b>9a</b> is lower than that of <b>5h</b> by 2.24 kcal/mol (<b>9a</b> −9.78 kcal/mol; <b>5h</b> = −7.54 kcal/mol).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Predicted binding mode of <b>9a</b> with the ATP-binding site of Abl<sup>T315I</sup>. Carbon atoms of the protein and the ligand are indicated in gray and cyan, respectively. (b) Predicted binding mode of <b>5h</b> with the ATP-binding site of Abl<sup>T315I</sup>. Carbon atoms of the protein and the ligand are indicated in gray and green, respectively. Each dotted line represents a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>9a</b> was further subjected to kinase selectivity profiling with a panel of 96 cancer-related kinases at 1 μM concentrations in a high-throughput binding assay (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>, KINOMEscan, Ambit Biosciences).<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Remarkably, compound <b>9a</b> displayed a high degree of selectivity over other kinases including Src, Aurora, and c-Kit, which are known to have high structural similarity to Abl. The only kinase against which <b>9a</b> demonstrated meaningful off-target activity was PDGFRB (POC = 16).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. KINOMEscan Profile of Compound <b>9a</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">POC<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">POC<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">POC<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABL<sup>phos</sup></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left">FLT3</td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="left">PDGFRB</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABL<sup>T315I</sup></td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">GSK3b</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PDPK1</td><td class="colsep0 rowsep0" align="char" char=".">67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ABL<sup>E255K</sup></td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">IGF1R</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PKAC-a</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AKT1</td><td class="colsep0 rowsep0" align="char" char=".">67</td><td class="colsep0 rowsep0" align="left">IKKα</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PLK1</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AURKA</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">JAK2</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PI3KCA</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AURKB</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">JNK1</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PIM1</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BRAF</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">KIT</td><td class="colsep0 rowsep0" align="char" char=".">79</td><td class="colsep0 rowsep0" align="left">PLK1</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">MEK1</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PLK3</td><td class="colsep0 rowsep0" align="char" char=".">87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CDK11</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">MEK2</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">ROCK2</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">MET</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">RSK2</td><td class="colsep0 rowsep0" align="char" char=".">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ERK1</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">P38α</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">SRC</td><td class="colsep0 rowsep0" align="char" char=".">72</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FAK</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PAK1</td><td class="colsep0 rowsep0" align="char" char=".">93</td><td class="colsep0 rowsep0" align="left">TIE2</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR2</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">PDGFRA</td><td class="colsep0 rowsep0" align="char" char=".">79</td><td class="colsep0 rowsep0" align="left">VEGFR2</td><td class="colsep0 rowsep0" align="char" char=".">98</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">A panel of 96 kinases were tested at 1 μM concentrations in a high-throughput binding assay (Ambit Bioscience). Only representative kinases are shown; see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for complete panel.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Lower numbers of POC (percent of control) values indicate stronger hits. Values shown are the average of duplicate measurements.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Optimization for Improving Cell Activity</h3><div class="NLM_p">With the impressive enzyme activity profile, the ability of these inhibitors to suppress the growth of Ba/F3 cells ectopically expressing wild-type or T315I mutant Bcr-Abl was assessed. For this study, cell viability was measured using a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2<i>H</i>-tetrazolium-5-carboanilide inner salt (XTT) assay. Despite their excellent enzymatic inhibition profiles, these derivatives exerted modest effects on cell growth (e.g., <b>9a</b> WT cell IC<sub>50</sub> = 3.57 μM, T315I cell IC<sub>50</sub> = 2.14 μM), which might have been due to poor solubility of the compounds (e.g., <b>9a</b> 0.0227 μg/mL, Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Our docking study suggested that the terminal ethylamine group appeared to orient to the solvent-exposed region of the enzyme and could provide a good location for modulating the physicochemical properties of the compounds (Figures <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Therefore, we hypothesized that the cell activities might be improved by introducing an additional solubilizing group into the terminal ethylamine group without significant influencing the enzyme inhibitory activities. To this end, the water-soluble morpholine moiety was employed to enhance the physicochemical properties. Consistent with our docking analysis, replacement of the terminal ethyl group with morpholinoethane, <b>10a</b>, increased the potency in cellular inhibition in a dose-dependent manner (WT cell IC<sub>50</sub> = 0.10 μM, T315I cell IC<sub>50</sub> = 0.29 μM) while retaining an excellent enzymatic potency. Encouraged by these results, a series of new derivatives were further designed and synthesized by modifying the terminal ethyl group (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). In general, derivatives incorporating a 2-methoxyphenyl group at the C6 position (<b>10a</b>, <b>10b</b>, <b>10c</b>, and <b>10d</b>) were slightly superior to the corresponding 2-ethoxyphenyl (<b>10e</b>, <b>10f</b>, <b>10g</b>, and <b>10h</b>) and 2-ethylphenyl (<b>10i</b> and <b>10j</b>) derivatives in terms of both enzyme and cell growth inhibition. The best result was obtained with <b>10d</b>, in which a widely utilized solubilizing group, methyl piperazine was incorporated. The IC<sub>50</sub> values for <b>10d</b> against wild-type and T315I Ba/F3 cells were 0.046 and 0.078 μM, respectively. On the other hand, imatinib strongly inhibited proliferation of wild-type Ba/F3 cells but not T315I Abl mutant transformed Ba/F3 cells, indicating that the T315I mutation conferred resistance to imatinib. Compound <b>10d</b> also exhibited desirable pharmaceutical properties, such as aqueous solubility, stability, and lipophilicity, and deserves consideration for further development (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Potency Profiles for Selected Benzothiazole Derivatives on Antiproliferative Effects on Bcr-Abl Transformed Ba/F3 Cells</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0013.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0014.gif" alt="" id="fx7" /></img><div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Physicochemical Properties of Lead Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">solubility<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> (μg/mL)</th><th class="colsep0 rowsep0" align="center" char=".">stability<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (%)</th><th class="colsep0 rowsep0" align="center" char=".">log <i>P</i><sub>e</sub>(cm/s)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">clogP<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">MW</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.0227</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">–4.11</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">327.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="char" char=".">7.49</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="char" char=".">–4.29</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">343.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="char" char=".">2240</td><td class="colsep0 rowsep0" align="char" char=".">99.7</td><td class="colsep0 rowsep0" align="char" char=".">–4.93</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td><td class="colsep0 rowsep0" align="char" char=".">425.6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Aqueous solubility determined at 25 °C (pH 6.7).</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Monitored by UPLC for 24 h at 37 °C (pH 6.7).</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Permeability coefficient (log <i>P</i><sub>e</sub>) obtained in PAMPA test.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">Predicted by Pipeline Pilot.</p></div></div></div><div class="NLM_p">The lead compounds <b>10b</b> and <b>10d</b> were further compared with imatinib and ponatinib in both kinase assay and cellular assay including parental Ba/F3 cells. Although <b>10d</b> is about 4-fold less potent in the antiproliferative effects on T315I cells when compared with ponatinib, the ratio for selectivity relative to untransformed Ba/F3 cells of <b>10d</b> is more desirable than that of ponatinib (ponatinib, parental Ba/F3 IC<sub>50</sub> = 1.9 μM) as summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Inhibitory Activities and Potency Profiles for Selected Benzothiazole Derivatives, Imatinib, and Ponatinib</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">Abl T315I kinase IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">WT Ba/F3</th><th class="colsep0 rowsep0" align="center" char=".">T315I Ba/F3</th><th class="colsep0 rowsep0" align="center" char=".">K562</th><th class="colsep0 rowsep0" align="center" char=".">parental Ba/F3</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10b</b></td><td class="colsep0 rowsep0" align="char" char=".">0.064</td><td class="colsep0 rowsep0" align="char" char=".">0.089</td><td class="colsep0 rowsep0" align="char" char=".">0.14</td><td class="colsep0 rowsep0" align="char" char=".">0.12</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10d</b></td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.046</td><td class="colsep0 rowsep0" align="char" char=".">0.078</td><td class="colsep0 rowsep0" align="char" char=".">0.42</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>imatinib</b></td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">0.092</td><td class="colsep0 rowsep0" align="char" char=".">4.79</td><td class="colsep0 rowsep0" align="char" char=".">0.17</td><td class="colsep0 rowsep0" align="char" char=".">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ponatinib</b></td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="char" char=".">0.0023</td><td class="colsep0 rowsep0" align="char" char=".">0.018</td><td class="colsep0 rowsep0" align="char" char=".">0.023</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td></tr></tbody></table></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Effect on Cell Proliferation and Downstream Cell Signaling</h3><div class="NLM_p">As the most potent compounds shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, <b>10b</b> and <b>10d</b> were selected for evaluation with additional biological assays to better understand the antiproliferative activities against leukemia cells. To determine whether the antiproliferative effects of <b>10b</b> and <b>10d</b> were dependent on the inhibition of Bcr-Abl activity, we measured the phosphorylation of Bcr-Abl and the downstream signals, STAT5 and CrkL.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> As shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>, <b>10b</b> and <b>10d</b> strongly inhibited the phosphorylation of Bcr-Abl in Ba/F3 cells expressing either wild-type or T315I mutant. Likewise, the phosphorylation levels of STAT5 and CrkL were effectively suppressed. On the other hand, both imatinib and dasatinib were significantly less able to reduce the phosphorylation levels of Bcr-Abl, STAT5, and CrkL in Ba/F3 cells expressing the T315I mutant (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Western blot showing the inhibition of Bcr-Abl signaling in Ba/F3 cells expressing wild-type Bcr-Abl (left panel) or Bcr-Abl T315I (right panel). Cells were treated with 1 μM of imatinib, dasatinib, <b>10b</b>, and <b>10d</b>, incubated 37 °C for 1 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62855" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62855" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Utilizing a structure-based design strategy, we designed and synthesized a new class of potent benzothiazole-based inhibitors that were effective against the wild-type and T315I mutant of Bcr-Abl kinase. Through the systematic exploration of the functional groups in the C2 and C6 positions along with modulating the core template of the original hit compound, nocodazole, we successfully developed a SAR profile for the series. Our results showed that the urea group at the C2 position and a selection of moieties (e.g., 2-methoxy and 2-ethoxy group on the phenyl ring) at the C6 position of the benzothiazole scaffold resulted in optimal activity of the compounds. This profoundly influenced the enzymatic inhibitory activities and antiproliferative effects on corresponding Ba/F3 cell lines transformed with wild-type or T315I mutant of Bcr-Abl kinase. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in the enhanced physicochemical properties and enhanced potency in cellular inhibition. These new inhibitors may serve as promising lead compounds for further development of new therapeutic agents to treat drug-resistant cases of CML with the T315I mutation.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> General Chemistry</h3><div class="NLM_p last">Unless stated otherwise, reactions were performed in flame-dried glassware under a positive pressure of nitrogen using freshly distilled solvents. Analytical thin layer chromatography (TLC) was performed on precoated silica gel 60 F<sub>254</sub> plates and visualization on TLC was achieved by UV light (254 and 354 nm). Flash column chromatography was undertaken on silica gel (400–630 mesh). <sup>1</sup>H NMR was recorded at 400 or 300 MHz, and chemical shifts were quoted in parts per million (ppm) referenced to the appropriate solvent peak or 0.0 ppm for tetramethylsilane. The following abbreviations were used to describe peak splitting patterns when appropriate: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, m = multiplet, dd = doublet of doublet, td = triplet of doublet, qd = quartet of doublet, ddd = doublet of doublet of doublet. Coupling constants, <i>J</i>, were reported in hertz. <sup>13</sup>C NMR was recorded at 100 MHz, and chemical shifts were reported in ppm referenced to the center line of a triplet at 77.0 ppm of chloroform-<i>d</i>. Mass spectral data were obtained from the KAIST Basic Science Institute using the EI method. High-performance liquid chromatography analyses for checking purity (>95% area) of synthesized compounds were performed on a Waters HPLC equipped with an Agilent Prep-C18 reverse phase column (21.2 mm × 150 mm, 10 μm) and by HRMS. The mobile phase was a mixture of MeOH (0.1% TFA) and H<sub>2</sub>O (0.1% TFA). Compound purity was determined by integrating peak areas of the liquid chromatogram, monitored at 254 nm. Flow rate (10 mL/min). Gradient system: from MeOH (0.1% TFA) 10% and H<sub>2</sub>O (0.1% TFA) 90% (0 min) to MeOH (0.1% TFA) 90% and H<sub>2</sub>O (0.1% TFA) 10% (12 min), the solvent ratio was maintained for 23 min; the solvent ratio was changed to MeOH (0.1% TFA) 10% and H<sub>2</sub>O (0.1% TFA) 90% (25 min). All final compounds were found to have >95% purity. Commercial grade reagents and solvents were used without further purification except as indicated below. Dichloromethane was distilled from calcium hydride. THF was distilled from sodium. Unless otherwise stated, all commercial reagents and solvents were used without additional purification.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> General Procedure (GP I) for Suzuki Coupling</h3><div class="NLM_p last">A solution of 4-bromo-1,2-diaminobenzene <b>3</b> (100 mg, 0.535 mmol), phenylboronic acid (72 mg, 0.59 mmol), K<sub>2</sub>CO<sub>3</sub> (221 mg, 1.60 mmol), and Pd(dppf)Cl<sub>2</sub><b>·</b>CH<sub>2</sub>Cl<sub>2</sub> (87 mg, 0.11 mmol) in 1,4-dioxane/H<sub>2</sub>O = 3:1 (4 mL) was heated to 100 °C for 4 h. The resulting solution was concentrated <i>in vacuo</i> and filtered on silica–Celite using EtOAc and hexane. The filtrate was concentrated and purified with flash column chromatography (EtOAc/hexane) to give a biphenyl-3,4-diamine (30 mg, 30%). <sup>1</sup>H NMR (300 MHz, MeOH-<i>d</i><sub>4</sub>) δ 6.69 (d, <i>J</i> = 8.0 Hz, 1H), 6.81 (dd, <i>J</i> = 2.0, 8.0 Hz, 1H), 6.93 (d, <i>J</i> = 2.0 Hz, 1H), 7.13 (t, <i>J</i> = 7.3 Hz, 1H), 7.23–7.29 (m, 2H), 7.42–7.45 (m, 2H).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedure (GP II) for Introducing 2-Urea</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> 1-Ethyl-3-(6-phenyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>2</b>)</h4><div class="NLM_p last">Biphenyl-3,4-diamine (15 mg, 0.081 mmol) and <i>N</i>,<i>N</i>′-bis[(ethylamino)carbonyl] carbamimidothioic acid methyl ester (23 mg, 0.098 mmol) was dissolved in 0.5 mL of AcOH/H<sub>2</sub>O = 3:10 and stirred for 5 h at 100 °C. The reaction mixture was cooled to room temperature and then neutralized using sat. NaHCO<sub>3</sub>. It was concentrated <i>in vacuo</i> and purified with flash column chromatography to give the product <b>2</b> as a white solid (18 mg, 78% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 3.14–3.27 (m, 2H), 7.27–7.33 (m, 3H), 7.40–7.44 (m, 3H), 7.60–7.63 (m, 3H), 9.89 (s, 1H), 11.54 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.3, 34.1, 119.7, 126.4, 126.6, 128.8, 133.1, 141.5, 148.9, 154.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>16</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 281.1402; found, 281.1401.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> 1-Ethyl-3-(6-(thiophene-2-carbonyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>1</b>)</h4><div class="NLM_p last">The solution of 3,4-dinitrobenzoic acid (300 mg, 1.414 mmol) in thionyl chloride (5 mL) was stirred for 5 h at 60 °C and cooled to room temperature. The mixture was concentrated and 3,4-dinitrobenzoyl chloride was obtained as yellow solid. The yellow solid (326 mg, 1.41 mmol), AlCl<sub>3</sub> (566 mg, 4.25 mmol), and thiophene (113 μL, 1.41 mmol) were dissolved in anhydrous CH<sub>2</sub>Cl<sub>2</sub> and stirred 5 h at 60 °C. The reaction was quenched with H<sub>2</sub>O at 0 °C and filtered to remove solid. The filtrate was extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub> and dried over MgSO<sub>4</sub>. The organic layer was concentrated <i>in vacuo</i> and purified with flash column chromatography (hexane/EtOAc = 5:1) to give 3,4-(dinitrophenyl)(thiophen-2-yl)methanone (59 mg, 15% yield). The 3,4-(dinitrophenyl)(thiophen-2-yl)methanone (42 mg, 0.151 mmol) and SnCl<sub>2</sub><b>·</b>2H<sub>2</sub>O (206 mg, 0.910 mmol) in EtOH/H<sub>2</sub>O = 1:1 were stirred for 12 h at 80 °C. After the mixture cooled to room temperature, sat. NaHCO<sub>3</sub> was added to the reaction mixture. The precipitate was removed by filtration, and the filtrate was extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub>, dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified with flash column chromatography (hexane/EtOAc = 1:2) to give (3,4-diaminophenyl)(thiophen-2-yl)methanone (33 mg, 99.7% yield). Finally, <b>1</b> was prepared (15 mg, 32% yield) according to GP II from (3,4-diaminophenyl)(thiophen-2-yl)methanone (33 mg, 0.15 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.10 (t, <i>J</i> = 7.2 Hz, 3H), 2.95–4.06 (m, 2H), 7.11 (s, 1H), 7.20–7.35 (m, 1H), 7.47 (d, <i>J</i> = 8.3 Hz, 1H), 7.62 (d, <i>J</i> = 8.3 Hz, 1H), 7.73 (d, <i>J</i> = 3.8 Hz, 1H), 7.94 (s, 1H), 8.04 (d, <i>J</i> = 5.0 Hz, 1H), 10.17 (s, 1H), 11.82 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.1, 114.6, 122.7, 128.4, 129.8, 134.3, 134.5, 143.5, 150.5, 153.9, 186.8. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 315.0916; found, 315.0923.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 1-Ethyl-3-(6-<i>p</i>-tolyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5a</b>)</h4><div class="NLM_p last">Compound <b>5a</b> was prepared (12 mg, 55% yield) according to GP II from 4′-methylbiphenyl-3,4-diamine (15 mg, 0.075 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.1 Hz, 3H), 2.32 (s, 3H), 3.16–3.28 (m, 2H), 7.23 (d, <i>J</i> = 7.9 Hz, 2H), 7.26–7.34 (m, 2H), 7.39 (d, <i>J</i> = 8.2 Hz, 1H), 7.50 (d, <i>J</i> = 7.8 Hz, 2H), 7.58 (s, 1H), 9.89 (s, 1H), 11.48 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 20.6, 34.1, 119.5, 126.4, 129.4, 133.0, 135.5, 138.6, 148.9, 154.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 295.1559; found, 295.1537.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 1-Ethyl-3-(6-(3-fluorophenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5b</b>)</h4><div class="NLM_p last">Compound <b>5b</b> was prepared (7 mg, 22% yield) according to GP II from 3′-fluorobiphenyl-3,4-diamine (20 mg, 0.098 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 2.91–3.73 (m, 2H), 7.10 (td, <i>J</i> = 2.9, 6.6 Hz, 1H), 7.27 (s, 1H), 7.35 (dd, <i>J</i> = 1.8, 8.3 Hz, 1H), 7.39–7.50 (m, 4H), 7.66 (s, 1H), 9.98 (s, 1H), 11.51 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.1, 112.8, 113.0, 113.0, 113.2, 119.7, 122.5, 122.6, 130.5, 130.6, 131.6, 144.0, 144.0, 149.1, 154.0, 161.4, 163.9. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>FN<sub>4</sub>O [M + H]<sup>+</sup>, 299.1308; found, 299.1317.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 1-Ethyl-3-(6-<i>m</i>-tolyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5c</b>)</h4><div class="NLM_p last">Compound <b>5c</b> was prepared (4 mg, 19% yield) according to GP II from 3′-methylbiphenyl-3,4-diamine (15 mg, 0.075 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.1 Hz, 3H), 2.36 (s, 3H), 3.18–3.25 (m, 2H), 7.10 (d, <i>J</i> = 7.4 Hz, 1H), 7.28–7.32 (m, 3H), 7.33–7.48 (m, 3H), 7.59 (s, 1H), 9.98 (s, 1H), 11.54 (s, 1H). <sup>13</sup>C NMR (100 MHz DMSO-<i>d</i><sub>6</sub>) δ 15.3, 21.2, 34.1, 113.1, 119.7, 123.8, 127.1, 127.4, 128.7, 133.2, 137.8, 141.5, 149.0, 154.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 295.1559; found, 295.1562.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> 1-(6-(3-Cyanophenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-ethylurea (<b>5d</b>)</h4><div class="NLM_p last">Compound <b>5d</b> was prepared (10 mg, 47% yield) according to GP II from 3′,4′-diaminobiphenyl-3-carbonitrile (15 mg, 0.071 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 3.14–3.27 (m, 2H), 7.25 (s, 1H), 7.39 (dd, <i>J</i> = 1.8, 8.2 Hz, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 1H), 7.63 (t, <i>J</i> = 7.8 Hz, 1H), 7.69 (d <i>J</i> = 1.7 Hz, 1H), 7.74 (d, <i>J</i> = 7.7 Hz, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 1H), 8.08 (s, 1H), 9.93 (s, 1H), 11.64 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.1, 111.9, 118.9, 119.8, 130.0, 130.8, 131.4, 142.6, 149.2, 154.0. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>15</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 306.1355; found, 306.1351.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> 1-Ethyl-3-(6-<i>o</i>-tolyl-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5e</b>)</h4><div class="NLM_p last">Compound <b>5e</b> was prepared (10 mg, 34% yield) according to GP II from 2′-methylbiphenyl-3,4-diamine (20 mg, 0.10 mmol). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.10 (t, <i>J</i> = 7.2 Hz, 3H), 2.22 (s, 3H), 3.16–3.25 (m, 2H), 6.95 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 7.20–7.27 (m, 6H), 7.37 (d, <i>J</i> = 8.1 Hz, 1H), 9.85 (s, 1H), 11.52 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 20.3, 34.0, 121.7, 125.7, 126.6, 129.8, 130.1, 133.7, 134.8, 142.4, 148.7, 154.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 295.1559; found, 295.1557.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> 1-(6-(2-Chlorophenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-ethylurea (<b>5f</b>)</h4><div class="NLM_p last">Compound <b>5f</b> was prepared (5 mg, 38% yield) according to GP II from 2′-chlorobiphenyl-3,4-diamine (15 mg, 0.068 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 3.05–3.29 (m, 2H), 7.07 (dd, <i>J</i> = 1.9, 8.1 Hz, 1H), 7.25 (s, 1H), 7.31–7.45 (m, 5H), 7.53 (dd, <i>J</i> = 1.7, 7.4 Hz, 1H) 10.19 (s, 1H), 11.36 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.1, 113.1, 114.1, 122.1, 127.3, 128.5, 129.7, 131.2, 131.5, 131.8, 136.7, 140.8, 148.9, 154.0. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>ClN<sub>4</sub>O [M + H]<sup>+</sup>, 315.1013; found, 315.1001.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> 1-Ethyl-3-(6-(2-ethylphenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5g</b>)</h4><div class="NLM_p last">Compound <b>5g</b> was prepared (18 mg, 56% yield) according to GP II from 2′-ethylbiphenyl-3,4-diamine (23 mg, 0.10 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.01 (t, <i>J</i> = 7.5 Hz, 3H), 1.10 (t, <i>J</i> = 7.2 Hz, 3H), 2.55 (q, <i>J</i> = 7.5 Hz, 2H), 3.19–3.23 (m, 2H), 6.93 (dd, <i>J</i> = 1.7, 8.1 Hz, 1H), 7.15 (dd, <i>J</i> = 1.6, 7.5 Hz, 1H), 7.20 (td, <i>J</i> = 1.9, 7.1 Hz, 1H), 7.23–7.32 (m, 4H), 7.37 (d, <i>J</i> = 8.1 Hz, 1H), 9.87 (s, 1H), 11.49 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 15.7, 25.6, 34.1, 121.7, 125.5, 126.9, 128.4, 130.0, 133.8, 141.1, 142.1, 148.7, 154.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 309.1715; found, 309.1690.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Ethyl-3-(6-(2-methoxyphenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5h</b>)</h4><div class="NLM_p last">Compound <b>5h</b> was prepared (31 mg, 71% yield) according to GP II from 2′-methoxybiphenyl-3,4-diamine (30 mg, 0.14 mmol). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 3.17–3.26 (m, 2H), 3.75 (s, 3H), 7.00 (t, <i>J</i> = 7.3 Hz, 1H), 7.07 (d, <i>J</i> = 8.2 Hz, 1H), 7.11 (dd, <i>J</i> = 1.7, 8.1 Hz, 1H) 7.26–7.30 (m, 2H), 7.31–7.37 (m, 2H), 7.46 (d, <i>J</i> = 1.6 Hz, 1H), 9.90 (s, 1H), 11.36 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.1, 55.4, 111.7, 120.6, 122.2, 127.9, 130.6, 131.0, 148.7, 154.1, 156.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 311.1508; found, 311.1511.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> 1-Ethyl-3-(6-(2-(trifluoromethoxy)phenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5i</b>)</h4><div class="NLM_p last">Compound <b>5i</b> was prepared (47 mg, 71% yield) according to GP II from 2′-(trifluoromethoxy)biphenyl-3,4-diamine (49 mg, 0.18 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.10 (t, <i>J</i> = 7.2 Hz, 3H), 3.18–3.25 (m, 2H), 7.11 (dd, <i>J</i> = 1.8, 8.2 Hz, 1H), 7.24 (s, 1H), 7.42–7.46 (m, 5H), 7.49–7.53 (m, 1H), 9.94 (s, 1H), 11.61 (s, 1H). HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>15</sub>F<sub>3</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 365.1225; found, 365.1203.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> 1-(6-(2-Ethoxyphenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-ethylurea (<b>5j</b>)</h4><div class="NLM_p last">Compound <b>5j</b> was prepared (15 mg, 62% yield) according to GP II from 2′-ethoxybiphenyl-3,4-diamine (17 mg, 0.072 mmol). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.10 (t, <i>J</i> = 7.2 Hz, 3H), 1.25 (t, <i>J</i> = 6.9 Hz, 3H), 3.16–3.25 (m, 2H), 4.02 (q, <i>J</i> = 6.8 Hz, 2H), 6.99 (t, <i>J</i> = 7.5 Hz, 1H), 7.06 (d, <i>J</i> = 7.9 Hz, 1H), 7.15 (dd, <i>J</i> = 8.2, 1.7 Hz, 1H), 7.23–7.35 (m, 4H), 7.49 (s, 1H), 9.81 (s, 1H), 11.50(s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.6, 15.2, 34.0, 63.5, 112.9, 120.7, 122.2, 127.9, 130.6, 131.1, 148.6, 154.1, 155.3. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 325.1665; found, 325.1653.</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 1-Ethyl-3-(6-(2-isopropoxyphenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5k</b>)</h4><div class="NLM_p last">Compound <b>5k</b> was prepared (10 mg, 55% yield) according to GP II from 2′-isopropoxybiphenyl-3,4-diamine (12 mg, 0.051 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 1.18 (d, <i>J</i> = 6.1 Hz, 6H), 3.15–3.27 (m, 2H), 4.50 (p, J = 6. 0 Hz, 1H), 6.98 (td, <i>J</i> = 1.1, 7.4 Hz, 1H), 7.06 (d, <i>J</i> = 7.4 Hz, 1H), 7.15 (dd, <i>J</i> = 1.7, 8.3 Hz, 1H), 7.20–7.30 (m, 3H), 7.33 (d, <i>J</i> = 8.2 Hz, 1H), 7.50(s, 1H), 9.85 (s, 1H), 11.52 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.3, 21.8, 34.1, 69.8, 115.0, 120.8, 122.2, 127.7, 130.9, 132.1, 148.6, 153.9, 154.2. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 339.1821; found, 339.1798.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 1-Ethyl-3-(6-(2-phenoxyphenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5l</b>)</h4><div class="NLM_p last">Compound <b>5l</b> was prepared (13 mg, 62% yield) according to GP II from 2′-phenoxybiphenyl-3,4-diamine (15 mg, 0.054 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.09 (t, <i>J</i> = 7.2 Hz, 3H), 3.18–3.22 (m, 2H), 6.87 (d, <i>J</i> = 7.6 Hz, 2H), 7.01 (t, <i>J</i> = 7.2 Hz, 2H), 7.18 (dd, <i>J</i> = 1.7, 8.3 Hz, 1H), 7.21–7.36 (m, 6H), 7.45–7.55 (m, 2H), 9.82 (s, 1H), 11.51 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.0, 117.4, 120.4, 121.8, 122.5, 124.5, 128.3, 129.8, 131.4, 134.3, 148.8, 152.6, 154.0, 157.4. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 373.1665; found, 373.1646.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 1-(6-(2,6-Dimethylphenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-ethylurea (<b>5m</b>)</h4><div class="NLM_p last">Compound <b>5m</b> was prepared (10 mg, 44% yield) according to GP II from 2′,6′-dimethylbiphenyl-3,4-diamine (15 mg, 0.070 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.10 (t, <i>J</i> = 7.2 Hz, 3H), 1.95 (s, 6H), 3.18–3.23 (m, 2H), 6.73 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 7.03–7.15 (m, 4H), 7.32 (s, 1H), 7.39 (d, <i>J</i> = 8.0 Hz, 1H), 9.85 (s, 1H), 11.51 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 20.6, 34.0, 121.2, 126.5, 127.1, 132.6, 135.6, 142.4, 148.6, 154.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 309.1715; found, 309.1716.</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-(6-(2-chloro-6-methylphenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-ethylurea (<b>5n</b>)</h4><div class="NLM_p last">Compound <b>5n</b> was prepared (5 mg, 41% yield) according to GP II from 2′-chloro-6′-methylbiphenyl-3,4-diamine (8 mg, 0.035 mmol). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.3 Hz, 3H), 2.02 (s, 3H), 3.18–3.23 (m, 2H), 6.79 (d, <i>J</i> = 8.2 Hz, 1H), 7.12 (s, 1H), 7.26–7.42 (m, 5H), 9.88 (s, 1H), 11.58 (s, 1H). HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>17</sub>ClN<sub>4</sub>O [M + Na]<sup>+</sup>, 351.0989; found, 351.0983.</div></div><div id="sec4_3_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(6-(2,6-dichlorophenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-ethylurea (<b>5o</b>)</h4><div class="NLM_p last">Compound <b>5o</b> was prepared (9 mg, 45% yield) according to GP II from 2′,6′-dichlorobiphenyl-3,4-diamine (15 mg, 0.059 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 3.15–3.26 (m, 2H), 6.85 (dd, <i>J</i> = 1.6, 8.1 Hz, 1H), 7.19 (s, 1H), 7.24 (s, 1H), 7.36–7.43 (m, 2H), 7.55 (d, <i>J</i> = 8.0 Hz, 2H), 9.91 (s, 1H), 11.64 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.1, 121.8, 128.2, 129.6, 134.5, 139.8, 149.0, 154.0. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>4</sub>O [M + H]<sup>+</sup>, 349.0623; found, 349.0607.</div></div><div id="sec4_3_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-(6-(2,6-Dimethoxyphenyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-ethylurea (<b>5p</b>)</h4><div class="NLM_p last">Compound <b>5p</b> was prepared (16 mg, 26% yield) according to GP II from 2′,6′-dimethoxybiphenyl-3,4-diamine (40 mg, 0.17 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 3.21 (qd, <i>J</i> = 5.4, 7.1 Hz, 2H), 3.62 (s, 6H), 6.71 (d, <i>J</i> = 8.4 Hz, 2H), 6.83 (dd, <i>J</i> = 1.5, 8.1 Hz, 1H), 7.15 (s, 1H), 7.20–7.38 (m, 2H), 7.33 (s, 1H), 9.79 (s, 1H), 11.37 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.3, 34.1, 55.6, 104.4, 119.8, 123.5, 126.2, 128.3, 148.3, 154.2, 157.4. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 341.1614; found, 341.1605.</div></div><div id="sec4_3_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-Ethyl-3-(6-(pyridin-4-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5q</b>)</h4><div class="NLM_p last">Compound <b>5q</b> was prepared (9 mg, 30% yield) according to GP II from 4-(pyridin-4-yl)benzene-1,2-diamine (20 mg, 0.10 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 3.19–3.26 (m, 2H), 7.23 (s, 1H), 7.47 (s, 2H), 7.66 (d, <i>J</i> = 6.1 Hz, 2H), 7.78 (s, 1H), 8.53–8.60 (m, 2H), 9.97 (s, 1H), 11.69 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.1, 119.6, 121.0, 129.6, 148.1, 149.4, 150.0, 154.0. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>15</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 282.1355; found, 282.1360.</div></div><div id="sec4_3_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-Ethyl-3-(6-(2-methylpyridin-4-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5r</b>)</h4><div class="NLM_p last">Compound <b>5r</b> was prepared (14 mg, 48% yield) according to GP II from 4-(2-methylpyridin-4-yl)benzene-1,2-diamine (20 mg, 0.10 mmol). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.08 (t, <i>J</i> = 7.1, 3H), 2.48 (s, 3H), 3.14–3.23 (m, 2H), 7.31 (s, 1H), 7.42 (s, 3H), 7.50 (s, 1H), 7.71 (s, 1H), 9.93 (d, <i>J</i> = 5.2 Hz, 1H). HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 296.1511; found, 296.1498.</div></div><div id="sec4_3_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> 1-Ethyl-3-(6-(3-methylpyridin-4-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5s</b>)</h4><div class="NLM_p last">Compound <b>5s</b> was prepared (6 mg, 20% yield) according to GP II from 4-(3-methylpyridin-4-yl)benzene-1,2-diamine (20 mg, 0.10 mmol). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.13–1.18 (m, 3H), 2.27 (s, 3H), 3.04–3.10 (m, 2H), 7.08–7.11 (m, 2H), 7.30 (s, 1H), 7.40 (d, <i>J</i> = 8.2 Hz, 1H), 8.44 (d, <i>J</i> = 4.8 Hz, 1H), 8.49 (s, 1H). HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>17</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 296.1511; found, 296.1497.</div></div><div id="sec4_3_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> 1-Ethyl-3-(6-(pyridin-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5t</b>)</h4><div class="NLM_p last">Compound <b>5t</b> was prepared (10 mg, 46% yield) according to GP II from 4-(pyridin-3-yl)benzene-1,2-diamine (15 mg, 0.081 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 3.17–3.26 (m, 2H), 7.26 (s, 1H), 7.36 (dd, <i>J</i> = 1.8, 8.3 Hz, 1H), 7.41–7.47 (m, 2H), 7.67 (d, <i>J</i> = 1.7 Hz, 1H), 8.02 (d, <i>J</i> = 7.9 Hz, 1H), 8.50 (dd, <i>J</i> = 1.6, 4.7 Hz, 1H), 8.85 (d, <i>J</i> = 2.6 Hz, 1H), 9.92 (s, 1H), 11.64 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.1, 119.8, 123.7, 129.8, 133.9, 136.8, 147.4, 147.6, 149.1, 154.0. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>15</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 282.1355; found, 282.1343.</div></div><div id="sec4_3_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> 1-Ethyl-3-(6-(1-ethyl-1<i>H</i>-pyrazol-5-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5u</b>)</h4><div class="NLM_p last">Compound <b>5u</b> was prepared (15 mg, 50% yield) according to GP II from 4-(1-ethyl-1<i>H</i>-pyrazol-5-yl)benzene-1,2-diamine (20 mg, 0.099 mmol). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.12 (t, <i>J</i> = 7.2 Hz, 3H), 1.32 (t, <i>J</i> = 7.2 Hz, 3H), 3.17–3.26 (m, 2H), 4.11 (q, <i>J</i> = 7.2 Hz, 2H), 6.27 (d, <i>J</i> = 1.8 Hz, 1H), 7.09 (dd, <i>J</i> = 1.7, 8.1 Hz, 1H), 7.20 (s, 1H), 7.40–45 (m, 2H), 7.47 (d, <i>J</i> = 1.8 Hz, 1H), 9.96 (s, 1H), 11.69 (s, 1H). HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>18</sub>N<sub>6</sub>O [M + H]<sup>+</sup>, 299.1620; found, 299.1613.</div></div><div id="sec4_3_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 1-(6-(2-Chlorophenoxy)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-3-ethylurea (<b>5v</b>)</h4><div class="NLM_p last">2-Chlorophenol (125 μL, 1.23 mmol) and 60% NaH (70 mg, 1.75 mmol) in anhydrous DMF were stirred for 10 min at 90 °C, and 5-chloro-2-nitroaniline (200 mg, 1.16 mmol) was added to reaction mixture. It was additionally stirred for 24 h and cooled to room temperature. To the reaction mixture was added sat. NH<sub>4</sub>Cl, and the generated precipitate was filtered. The solid was purified with flash column chromatography to give the 5-(2-chlorophenoxy)-2-nitroaniline (31 mg, 11% yield). The 5-(2-chlorophenoxy)-2-nitroaniline (31 mg, 0.12 mmol) and SnCl<sub>2</sub><b>·</b>2H<sub>2</sub>O (133 mg, 0.59 mmol) in EtOH/H<sub>2</sub>O = 4:1 were stirred for 12 h at 80 °C. After the mixture cooled to room temperature, sat. NaHCO<sub>3</sub> was added to the reaction mixture. The precipitate was removed by filtration, and the filtrate was extracted 3 times with CH<sub>2</sub>Cl<sub>2</sub>, dried over MgSO<sub>4</sub>, and concentrated <i>in vacuo</i>. The residue was purified with flash column chromatography (hexane/EtOAc) to give 4-(2-chlorophenoxy)-benzene-1,2-diamine (14 mg, 48% yield). Compound <b>5v</b> was prepared (10 mg, 52% yield) according to GP II from 4-(2-chlorophenoxy)-benzene-1,2-diamine (14 mg, 0.058 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.09 (t, <i>J</i> = 7.2 Hz, 3H), 3.19 (qd, <i>J</i> = 5.5, 7.2 Hz, 2H), 6.73 (dd, <i>J</i> = 2.4, 8.5 Hz, 1H), 6.89 (dd, <i>J</i> = 1.5, 8.2 Hz, 1H), 6.97 (s, 1H), 7.10 (td, <i>J</i> = 1.5, 7.7 Hz, 1H), 7.21 (s, 1H), 7.27 (ddd, <i>J</i> = 1.6, 7.4, 8.2 Hz, 1H), 7.35 (d, <i>J</i> = 8.5 Hz, 1H), 7.54 (dd, <i>J</i> = 1.6, 8.0 Hz, 1H), 9.90 (s, 1H), 11.52 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.3, 34.1, 112.1, 119.1, 123.3, 124.0, 128.5, 130.5, 149.2, 150.3, 153.5, 154.0. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>ClN<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 331.0962; found, 331.0952.</div></div><div id="sec4_3_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-Ethyl-3-(6-(3-methoxyphenoxy)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5w</b>)</h4><div class="NLM_p last">Compound <b>5v</b> was prepared (17 mg, 43% yield) according to GP II from 4-(3-methoxyphenoxy)-benzene-1,2-diamine (28 mg, 0.12 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.09 (t, <i>J</i> = 7.2 Hz, 3H), 3.19 (qd, <i>J</i> = 5.4, 7.1 Hz, 2H), 3.69 (s, 3H), 6.44 (ddd, <i>J</i> = 0.9, 2.4, 8.2 Hz, 1H), 6.48 (t, <i>J</i> = 2.3 Hz, 1H), 6.55–6.66 (m, 1H), 6.75 (dd, <i>J</i> = 2.3, 8.5 Hz, 1H), 7.02 (s, 1H), 7.20 (t, <i>J</i> = 8.2 Hz, 2H), 7.34 (d, <i>J</i> = 8.5 Hz, 1H), 9.87 (s, 1H), 11.52 (s, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.1, 55.1, 103.3, 107.8, 109.2, 113.0, 130.2, 149.0, 150.0, 154.0, 159.8, 160.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>18</sub>N<sub>4</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 327.1457; found, 327.1453.</div></div><div id="sec4_3_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-Ethyl-3-(6-(4-methylpiperazine-1-carbonyl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)urea (<b>5x</b>)</h4><div class="NLM_p last">Compound <b>5x</b> was prepared (17 mg, 35% yield) according to GP II from (3,4-diaminophenyl)(4-methylpiperazin-1-yl)methanone (40 mg, 0.17 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, 55 °C) δ 1.09 (t, <i>J</i> = 7.2 Hz, 3H), 2.17 (s, 3H), 2.24–2.36 (m, 4H), 3.19 (qd, <i>J</i> = 7.2, 5.6 Hz, 2H), 3.47 (t, <i>J</i> = 5.0 Hz, 4H), 7.03 (dd, <i>J</i> = 8.1, 1.6 Hz, 1H), 7.18 (t, <i>J</i> = 5.4 Hz, 1H), 7.34 (d, <i>J</i> = 8.2 Hz, 1H), 7.36 (s, 1H), 10.58 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>, 55 °C) δ 14.8, 33.8, 44.4, 45.3, 54.4, 112.4, 119.7, 127.9, 149.3, 153.8, 169.8. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>21</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 331.1882; found, 331.1866.</div></div><div id="sec4_3_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 2-(3-Ethylureido)-<i>N</i>-(pyridin-4-yl)-1<i>H</i>-benzo[<i>d</i>]imidazole-6-carboxamide (<b>5y</b>)</h4><div class="NLM_p last">Compound <b>5y</b> was prepared (10 mg, 21% yield) according to GP II from 3,4-diamino-<i>N</i>-(pyridin-4-yl)benzamide (32 mg, 0.14 mmol). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.11 (t, <i>J</i> = 7.2 Hz, 3H), 3.17–3.26 (m, 2H), 7.30 (s, 1H), 7.44 (d, <i>J</i> = 8.3 Hz, 1H), 7.70 (dd, <i>J</i> = 1.6, 8.3 Hz, 1H), 7.80 (d, <i>J</i> = 6.4 Hz, 2H), 8.01 (d, <i>J</i> = 1.3 Hz, 1H), 8.44 (d, <i>J</i> = 6.3 Hz, 2H), 10.13 (s, 1H), 10.45 (s, 1H), 12.0 (s, 1H).HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>16</sub>N<sub>6</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 325.1413; found, 325.1397.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> General Procedure (GP III) for Preparation of 6-Aryl 2-Aminobenzothiazole</h3><div class="NLM_p last">A solution of 2-amino-6-bromobenzothiazole (300 mg, 1.31 mmol), 2-methoxyphenylboronic acid (299 mg, 1.96 mmol), K<sub>2</sub>CO<sub>3</sub> (543 mg, 3.93 mmol), and Pd(dppf)Cl<sub>2</sub><b>·</b>CH<sub>2</sub>Cl<sub>2</sub> (214 mg, 0.26 mmol) in 1,4-dioxane/H<sub>2</sub>O = 3:1 (4 mL) was heated to 120 °C for 6 h. The resulting solution was concentrated <i>in vacuo</i> and filtered on silica–Celite using EtOAc and hexane. The filtrate was concentrated and purified with flash column chromatography (EtOAc/hexane) to give the 6-(2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (188 mg, 56%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.82 (s, 3H), 5.27 (m, 2H), 6.99 (dd, <i>J</i> = 1.0, 8.2 Hz, 1H), 7.03 (td, <i>J</i> = 1.1, 7.5 Hz, 1H), 7.28–7.38 (m, 2H), 7.48 (dd, <i>J</i> = 1.8, 8.3 Hz, 1H), 7.58 (dd, <i>J</i> = 0.6, 8.3 Hz, 1H), 7.77 (dd, <i>J</i> = 0.5, 1.8 Hz, 1H).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> General Procedure (GP IV) for Introducing 2-Urea</h3><div id="sec4_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 1-Ethyl-3-(6-(2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)urea (<b>9a</b>)</h4><div class="NLM_p last">To a solution of 6-(2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (26 mg, 0.10 mmol) in 1,4-dioxane was added ethyl isocyanate (40 μL, 0.50 mmol), and the mixture was stirred for 15 h at 90 °C. After the reaction finished, the resulting solution was concentrated <i>in vacuo,</i> and then, H<sub>2</sub>O was added. It was heated to 100 °C for 3 h. The resulting solid was filtered and washed with H<sub>2</sub>O and additionally purified with flash column chromatography to give compound <b>9a</b> (18 mg, 54% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.25 (t, <i>J</i> = 7.2 Hz, 3H), 3.37–3.46 (m, 2H), 3.81 (s, 3H), 6.75–7.12 (m, 2H), 7.29–7.35 (m, 2H), 7.56 (dd, <i>J</i> = 1.8, 8.4 Hz, 1H), 7.76 (d, <i>J</i> = 8.4 Hz, 1H), 7.89 (d, <i>J</i> = 1.7 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 15.1, 35.1, 55.5, 111.2, 119.1, 120.9, 122.0, 127.9, 128.6, 130.0, 130.9, 130.9, 133.9, 148.0, 154.7, 156.4, 161.9. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 328.1120; found, 328.1117.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 1-(6-(2-Ethoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)-3-ethylurea (<b>9b</b>)</h4><div class="NLM_p last">Compound <b>9b</b> was prepared (27 mg, 64% yield) according to GP IV from 6-(2-ethoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (33 mg, 0.12 mmol). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.26 (t, <i>J</i> = 7.2 Hz, 3H), 1.33 (t, <i>J</i> = 7.0 Hz, 3H), 3.44 (p, <i>J</i> = 6.9 Hz, 2H), 4.04 (q, <i>J</i> = 6.9 Hz, 2H), 6.85–7.09 (m, 2H), 7.25–7.33 (m, 1H), 7.36 (dd, <i>J</i> = 1.7, 7.5 Hz, 1H), 7.55–7.67 (m, 1H), 7.76 (d, <i>J</i> = 8.4 Hz, 1H), 7.91 (d, <i>J</i> = 1.7 Hz, 1H), 10.95 (s, 1H).<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 14.8, 15.1, 35.2, 64.0, 112.7, 119.1, 120.9, 122.0, 128.0, 128.6, 130.2, 130.7, 130.9, 134.2, 148.0, 154.7, 155.8, 161.9. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>S [M + Na]<sup>+</sup>, 364.1096; found, 364.1073.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 1-Ethyl-3-(6-(2-(trifluoromethoxy)phenyl)benzo[<i>d</i>]thiazol-2-yl)urea (<b>9c</b>)</h4><div class="NLM_p last">Compound <b>9c</b> was prepared (51 mg, 69% yield) according to GP IV from 6-(2-(trifluoromethoxy)phenyl)benzo[<i>d</i>]thiazol-2-amine (60 mg, 0.19 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.27 (t, <i>J</i> = 7.2 Hz, 1H), 3.45 (qd, <i>J</i> = 5.3, 7.1 Hz, 1H), 7.28–7.40 (m, 3H), 7.44–7.48 (m, 1H), 7.50 (dd, <i>J</i> = 1.8, 8.4 Hz, 1H), 7.79 (d, <i>J</i> = 8.5 Hz, 1H), 7.81 (d, <i>J</i> = 1.8 Hz, 1H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.5, 34.7, 116.6, 119.1, 119.7, 121.7, 122.0, 122.2, 124.3, 127.3, 128.3, 129.5, 130.9, 132.2, 135.1, 145.8, 149.2, 154.1, 161.1. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>14</sub>F<sub>3</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 382.0837; found, 382.0814.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 1-Ethyl-3-(6-(2-propoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)urea (<b>9d</b>)</h4><div class="NLM_p last">Compound <b>9d</b> was prepared (50 mg, 68% yield) according to GP IV from 6-(2-propoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (58 mg, 0.20 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.94 (t, <i>J</i> = 7.4 Hz, 3H), 1.27 (t, <i>J</i> = 7.2 Hz, 3H), 1.72 (h, <i>J</i> = 7.1 Hz, 2H), 3.19–3.54 (m, 2H), 3.92 (t, <i>J</i> = 6.4 Hz, 2H), 6.90–7.10 (m, 2H), 7.28 (t, <i>J</i> = 7.9 Hz, 1H), 7.36 (dd, <i>J</i> = 1.8, 7.3 Hz, 1H), 7.49 (s, 1H), 7.56–7.65 (m, 1H), 7.75 (d, <i>J</i> = 8.4 Hz, 1H), 7.91 (s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 10.7, 15.2, 22.6, 35.2, 70.0, 112.5, 119.1, 120.8, 122.1, 128.1, 128.6, 130.2, 130.6, 130.8, 134.2, 147.9, 154.7, 156.0, 161.9. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 356.1433; found, 356.1413.</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-Ethyl-3-(5-methoxy-6-(2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)urea (<b>9e</b>)</h4><div class="NLM_p last">Compound <b>9e</b> was prepared (51 mg, 69% yield) according to GP IV from 5-methoxy-6-(2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (60 mg, 0.19 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.06 (t, <i>J</i> = 7.2 Hz, 3H), 3.15 (qd, <i>J</i> = 5.4, 7.1 Hz, 2H), 3.65 (s, 3H), 3.69 (s, 3H), 6.72 (t, <i>J</i> = 5.7 Hz, 1H), 6.93 (td, <i>J</i> = 1.1, 7.4 Hz, 1H), 7.01 (dd, <i>J</i> = 1.0, 8.3 Hz, 1H), 7.11 (dd, <i>J</i> = 1.8, 7.4 Hz, 1H), 7.22 (s, 1H), 7.28 (ddd, <i>J</i> = 1.8, 7.4, 8.2 Hz, 1H), 7.51 (s, 1H), 10.62 (s, 1H).<sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.3, 55.4, 55.7, 102.2, 111.2, 120.0, 122.5, 122.8, 123.6, 127.5, 128.5, 131.3, 149.9, 153.6, 156.0, 156.9, 160.8. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S [M + Na]<sup>+</sup>, 380.1045; found, 380.1031.</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-Ethyl-3-(5-(2-methoxyphenyl)thiazolo[5,4-<i>b</i>]pyridin-2-yl)urea (<b>9f</b>)</h4><div class="NLM_p last">Compound <b>9f</b> was prepared (16 mg, 83% yield) according to GP IV from 5-(2-methoxyphenyl)thiazolo[5,4-<i>b</i>]pyridin-2-amine (15 mg, 0.05 mmol). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.32 (t, <i>J</i> = 7.2 Hz, 3H), 3.37–3.59 (m, 2H), 3.91 (s, 3H), 7.05 (d, <i>J</i> = 8.3 Hz, 1H), 7.12 (td, <i>J</i> = 1.1, 7.5 Hz, 1H), 7.41 (ddd, <i>J</i> = 1.8, 7.4, 8.9 Hz, 1H), 7.57 (s, 1H), 7.84 (dd, <i>J</i> = 1.8, 7.6 Hz, 1H), 7.92 (d, <i>J</i> = 8.5 Hz, 1H), 8.02 (d, <i>J</i> = 8.5 Hz, 1H), 10.90 (s, 1H).<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 15.2, 35.2, 55.6, 111.5, 121.1, 123.2, 126.0, 128.5, 130.0, 131.2, 141.4, 152.0, 154.4, 154.4, 156.9, 161.4. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 329.1072; found, 329.1061.</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-Ethyl-3-(6-phenylbenzo[<i>d</i>]thiazol-2-yl)urea (<b>9g</b>)</h4><div class="NLM_p last">Compound <b>9g</b> was prepared (24 mg, 48% yield) according to GP IV from 6-phenylbenzo[<i>d</i>]thiazol-2-amine (38 mg, 0.17 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.06 (t, <i>J</i> = 7.2 Hz, 3H), 3.04–3.22 (m, 2H), 6.72 (t, <i>J</i> = 5.7 Hz, 1H), 7.30 (t, <i>J</i> = 7.3 Hz, 1H), 7.41 (t, <i>J</i> = 7.6 Hz, 2H), 7.55–7.74 (m, 4H), 8.16 (s, 1H), 10.72 (s, 1H).<sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.2, 34.3, 119.4, 119.8, 124.7, 126.7, 127.1, 128.9, 132.4, 134.8, 140.1, 148.6, 153.7, 160.3. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>OS [M + Na]<sup>+</sup>, 320.0834; found, 320.0817.</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 1-Ethyl-3-(6-(pyridin-4-yl)benzo[<i>d</i>]thiazol-2-yl)urea (<b>9h</b>)</h4><div class="NLM_p last">Compound <b>9h</b> was prepared (10 mg, 25% yield) according to GP IV from 6-(pyridin-4-yl)benzo[<i>d</i>]thiazol-2-amine (41.2 mg, 0.137 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.26 (t, <i>J</i> = 7.2 Hz, 3H), 3.43 (qd, <i>J</i> = 5.4, 7.2 Hz, 2H), 7.41–7.56 (m, 2H), 7.62 (dd, <i>J</i> = 1.8, 8.5 Hz, 1H), 7.77 (d, <i>J</i> = 8.4 Hz, 1H), 7.94 (d, <i>J</i> = 1.8 Hz, 1H), 8.47–8.80 (m, 2H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 15.1, 35.2, 104.1, 119.7, 120.4, 121.5, 125.2, 132.1, 133.3, 147.9, 150.1, 154.5, 162.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>14</sub>N<sub>4</sub>OS [M + H]<sup>+</sup>, 299.0967; found, 299.0960.</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 1-Ethyl-3-(6-(4-methoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)urea (<b>9i</b>)</h4><div class="NLM_p last">Compound <b>9i</b> was prepared (12 mg, 47% yield) according to GP IV from 6-(4-methoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (20 mg, 0.07 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.06 (t, <i>J</i> = 7.2 Hz, 3H), 2.31 (s, 3H), 3.16 (qd, <i>J</i> = 5.5, 7.2 Hz, 2H), 6.72 (t, <i>J</i> = 5.8 Hz, 1H), 7.23 (d, <i>J</i> = 8.0 Hz, 2H), 7.43–7.74 (m, 4H), 7.82–8.61 (m, 1H), 10.69 (s, 1H).<sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.6, 21.1, 34.7, 119.4, 120.2, 124.9, 126.9, 129.9, 132.8, 135.2, 136.7, 137.6, 148.9, 154.1, 160.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>19</sub>N<sub>3</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 328.1120; found, 328.1118.</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 1-(6-(4-Amino-2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)-3-ethylurea (<b>9j</b>)</h4><div class="NLM_p last">Compound <b>9j</b> was prepared (4.9 mg, 7.1% yield) according to GP III from 1-(6-bromobenzo[<i>d</i>]thiazol-2-yl)-3-ethylurea (60 mg, 0.2 mmol) and 3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (74 mg, 0.30 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.26 (t, <i>J</i> = 7.1 Hz, 3H), 3.18 (s, 2H), 3.32–3.53 (m, 2H), 3.77 (s, 3H), 6.33 (d, <i>J</i> = 2.1 Hz, 1H), 6.36 (dd, <i>J</i> = 2.2, 8.1 Hz, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.48–7.54 (m, 1H), 7.71 (d, <i>J</i> = 8.4 Hz, 1H), 7.83 (d, <i>J</i> = 1.6 Hz, 1H). HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub>S [M + Na]+, 380.1045; found, 380.1021.</div></div><div id="sec4_5_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1-(6-(2,4-Dimethoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)-3-ethylurea (<b>9k</b>)</h4><div class="NLM_p last">Compound <b>9k</b> was prepared (8 mg, 35% yield) according to GP IV from 6-(2,4-dimethoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (28 mg, 0.098 mmol). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.08 (t, <i>J</i> = 7.2 Hz, 3H), 3.11–3.26 (m, 2H), 3.75 (s, 3H), 3.79 (s, 3H), 6.60 (dd, <i>J</i> = 2.4, 8.4 Hz, 1H), 6.65 (d, <i>J</i> = 2.5 Hz, 1H), 6.73 (t, <i>J</i> = 5.9 Hz, 1H), 7.23 (d, <i>J</i> = 8.4 Hz, 1H), 7.39 (dd, <i>J</i> = 1.8, 8.3 Hz, 1H), 7.57 (d, <i>J</i> = 8.4 Hz, 1H), 7.87 (s, 1H), 10.64 (s, 1H). HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S [M + Na]<sup>+</sup>, 380.1045; found, 380.1021.</div></div><div id="sec4_5_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 1-Ethyl-3-(6-(3-methoxypyridin-4-yl)benzo[<i>d</i>]thiazol-2-yl)urea (<b>9l</b>)</h4><div class="NLM_p last">Compound <b>9l</b> was prepared (5.2 mg, 27% yield) according to GP IV from 6-(3-methoxypyridin-4-yl)benzo[<i>d</i>]thiazol-2-amine (15 mg, 0.058 mmol). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.31 (t, <i>J</i> = 7.3 Hz, 3H), 3.35–3.54 (m, 2H), 3.97 (s, 3H), 7.32 (d, <i>J</i> = 4.9 Hz, 1H), 7.64 (dd, <i>J</i> = 1.8, 8.4 Hz, 1H), 7.83 (d, <i>J</i> = 8.5 Hz, 1H), 8.00 (d, <i>J</i> = 1.7 Hz, 1H), 8.36 (d, <i>J</i> = 4.8 Hz, 1H), 8.42 (s, 1H), 10.99 (s, 1H). HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 329.1072; found, 329.1059.</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> General Procedure (GP V) for Introducing 2-Urea</h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-(6-(2-Methoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)-3-(2-morpholinoethyl)urea (<b>10a</b>)</h4><div class="NLM_p last">6-(2-Methoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (58 mg, 0.23 mmol) and carbonyldiimidazole (112 mg, 0.679 mmol) was dissolved into anhydrous DMF and stirred for 8 h at room temperature. 2-Morpholinoethanamine (150 μL, 1.13 mmol) was added. After the reaction finished, the resulting solution was concentrated <i>in vacuo.</i> Then the crude mixture was purified with flash column chromatography to give compound <b>10a</b> (74 mg, 79% yield). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, 55 °C) δ 2.46–2.56 (m, 4H), 2.61 (t, <i>J</i> = 5.9 Hz, 3H), 3.50 (q, <i>J</i> = 5.6 Hz, 2H), 3.68–3.77 (m, 4H), 3.80 (s, 3H), 6.87–7.10 (m, 2H), 7.26–7.40 (m, 2H), 7.53 (dd, <i>J</i> = 1.7, 8.4 Hz, 1H), 7.60 (s, 1H), 7.71 (dd, <i>J</i> = 0.6, 8.4 Hz, 1H), 7.87 (dd, <i>J</i> = 0.5, 1.8 Hz, 1H).<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, 55 °C) δ 37.3, 53.6, 55.7, 57.8, 66.9, 111.8, 119.3, 121.1, 122.0, 128.0, 128.7, 130.5, 131.0, 131.2, 134.3, 148.4, 154.9, 156.7, 161.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 413.1647; found, 413.1635.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 1-(2-Hydroxyethyl)-3-(6-(2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)urea (<b>10b</b>)</h4><div class="NLM_p last">Compound <b>10b</b> was prepared (13 mg, 66% yield) according to GP V from 6-(2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (15 mg, 0.058 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.59 (q, <i>J</i> = 5.3 Hz, 2H), 3.82 (s, 3H), 3.89 (t, <i>J</i> = 5.1 Hz, 2H), 4.63 (br, 1H), 6.98–7.04 (m, 2H), 7.29–7.33 (m, 2H), 7.52 (dd, <i>J</i> = 8.4 Hz, 1.7 Hz, 1H), 7.66 (d, <i>J</i> = 8.4 Hz, 1H), 7.84 (d, <i>J</i> = 1.4 Hz, 1H), 8.05 (s, 1H), 10.26 (br, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 42.7, 55.5, 61.9, 104.1, 111.2, 119.2, 120.9, 121.9, 128.0, 128.7, 130.0, 130.7, 131.0, 134.1, 155.3, 156.4, 161.3. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>S [M + Na]<sup>+</sup>, 366.0888; found, 366.0878.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 1-(3-Hydroxypropyl)-3-(6-(2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)urea (<b>10c</b>)</h4><div class="NLM_p last">Compound <b>10c</b> was prepared (12 mg, 57% yield) according to GP V from 6-(2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (15 mg, 0.059 mmol). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.86 (p, <i>J</i> = 6.0 Hz, 2H), 3.62 (q, <i>J</i> = 6.2 Hz, 2H), 3.79 (t, <i>J</i> = 5.6 Hz, 2H), 3.83 (s, 3H), 6.97–7.09 (m, 2H), 7.31–7.36 (m, 2H), 7.57 (dd, <i>J</i> = 1.7, 8.4 Hz, 1H), 7.77 (d, <i>J</i> = 8.4 Hz, 1H), 7.90 (d, <i>J</i> = 1.7 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 32.4, 37.0, 55.6, 59.5, 111.3, 119.4, 120.9, 122.1, 128.0, 128.7, 130.0, 130.7, 131.0, 134.2, 155.6, 156.4, 161.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 358.1225; found, 358.1212.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 1-(6-(2-Methoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)-3-(2-(4-methylpiperazin-1-yl)ethyl)urea (<b>10d</b>)</h4><div class="NLM_p last">Compound <b>10d</b> was prepared (53 mg, 40% yield) according to GP V from 6-(2-methoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (79 mg, 0.308 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.26 (s, 3H), 2.43 (s, 4H), 2.53 (s, 6H), 3.41 (s, 2H), 3.78 (s, 3H), 6.87–7.14 (m, 2H), 7.25–7.32 (m, 2H), 7.39 (s, 1H), 7.50 (dd, <i>J</i> = 1.7, 8.4 Hz, 1H), 7.69 (d, <i>J</i> = 8.3 Hz, 1H), 7.86 (dd, <i>J</i> = 0.6, 1.8 Hz, 1H), 10.89 (s, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 37.6, 45.8, 52.9, 55.0, 55.7, 57.2, 111.7, 119.2, 121.0, 122.0, 127.8, 128.6, 130.5, 130.9, 131.4, 134.1, 148.3, 154.9, 156.7, 161.7. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 426.1964; found, 426.1955.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 1-(6-(2-Ethoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)-3-(2-morpholinoethyl)urea (<b>10e</b>)</h4><div class="NLM_p last">Compound <b>10e</b> was prepared (39 mg, 83% yield) according to GP V from 6-(2-ethoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (30 mg, 0.11 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 55 °C) δ 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 2.54 (d, <i>J</i> = 4.6 Hz, 4H), 2.62 (t, <i>J</i> = 6.0 Hz, 2H), 3.52 (q, <i>J</i> = 5.7 Hz, 2H), 3.75 (t, <i>J</i> = 4.4 Hz, 4H), 4.06 (q, <i>J</i> = 7.0 Hz, 2H), 6.96–7.07 (m, 2H), 7.29 (ddd, <i>J</i> = 1.8, 7.4, 8.2 Hz, 1H), 7.36 (dd, <i>J</i> = 1.8, 7.5 Hz, 1H), 7.59 (dd, <i>J</i> = 1.8, 8.4 Hz, 1H), 7.62 (s, 1H), 7.74 (d, <i>J</i> = 8.4 Hz, 1H), 7.93 (d, <i>J</i> = 1.6 Hz, 1H) 10.84 (br, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, 55 °C) δ 14.8, 37.4, 53.6, 57.8, 64.4, 67.0, 113.3, 119.2, 121.1, 122.0, 128.0, 128.6, 130.7, 130.9, 131.1, 134.4, 148.4, 155.0, 156.1, 161.6. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>26</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup>, 427.1804; found, 427.1792.</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 1-(6-(2-Ethoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)-3-(2-hydroxyethyl)urea (<b>10f</b>)</h4><div class="NLM_p last">Compound <b>10f</b> was prepared (28 mg, 67% yield) according to GP V from 6-(2-ethoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (32 mg, 0.11 mmol). <sup>1</sup>H NMR (400 MHz, MeOH-<i>d</i><sub><i>4</i></sub>) δ 1.29 (t, <i>J</i> = 7.0 Hz, 3H), 3.41 (t, <i>J</i> = 5.5 Hz, 2H), 3.69 (t, <i>J</i> = 5.5 Hz, 2H), 4.02 (q, <i>J</i> = 7.0 Hz, 2H), 6.95–7.05 (m, 2H), 7.23–7.33 (m, 2H), 7.52 (dd, <i>J</i> = 1.8, 8.4 Hz, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 1H), 7.88 (d, <i>J</i> = 1.7 Hz, 1H). <sup>13</sup>C NMR (100 MHz, MeOH-<i>d</i><sub><i>4</i></sub>) δ 15.1, 43.4, 61.9, 65.2, 114.0, 119.9, 122.0, 122.8, 129.0, 129.7, 131.7, 131.8, 132.4, 135.6, 149.0, 156.3, 157.2, 162.2. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>S [M + Na]<sup>+</sup>, 380.1045; found, 380.1027.</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 1-(6-(2-Ethoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)-3-(3-hydroxypropyl)urea (<b>10g</b>)</h4><div class="NLM_p last">Compound <b>10g</b> was prepared (26 mg, 61% yield) according to GP V from 6-(2-ethoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (31 mg, 0.11 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.34 (t, <i>J</i> = 6.9 Hz, 3H), 1.81–1.90 (m, 2H), 3.60 (q, <i>J</i> = 6.1 Hz, 2H), 3.80 (t, <i>J</i> = 5.6 Hz, 2H), 4.05 (q, <i>J</i> = 7.0 Hz, 2H), 6.95–7.06 (m, 2H), 7.27–7.33 (m, 1H), 7.35 (dd, <i>J</i> = 1.8, 7.6 Hz, 1H), 7.60 (dd, <i>J</i> = 1.7, 8.4 Hz, 1H), 7.75 (d, <i>J</i> = 8.4 Hz, 1H), 7.91 (d, <i>J</i> = 1.7 Hz, 1H) 8.08 (br, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 14.7, 32.4, 37.1, 59.5, 64.0, 112.7, 119.2, 120.9, 122.0, 128.0, 128.6, 130.1, 130.6, 130.9, 134.3, 147.8, 155.6, 155.8, 161.5. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>21</sub>N<sub>3</sub>O<sub>3</sub>S [M + Na]<sup>+</sup>, 394.1201; found, 394.1191.</div></div><div id="sec4_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 1-(6-(2-Ethoxyphenyl)benzo[<i>d</i>]thiazol-2-yl)-3-(2-(piperazin-1-yl)ethyl)urea (<b>10h</b>)</h4><div class="NLM_p last">Compound <b>10h</b> (TFA salt) was prepared (11 mg, 23% yield) according to GP V from 6-(2-ethoxyphenyl)benzo[<i>d</i>]thiazol-2-amine (30 mg, 0.11 mmol). <sup>1</sup>H NMR (300 MHz, MeOH-<i>d</i><sub>4</sub>) δ 1.30 (t, <i>J</i> = 7.0 Hz, 3H), 2.57–2.64 (m, 6H), 3.06 (br, 4H), 3.43 (t, <i>J</i> = 6.1 Hz, 2H), 4.03 (q, <i>J</i> = 6.9 Hz, 2H), 6.95–7.08 (m, 2H), 7.22–7.35 (m, 2H), 7.53 (dd, <i>J</i> = 1.7, 8.4 Hz, 1H) 7.64 (d, <i>J</i> = 8.4 Hz, 1H), 7.89 (d, <i>J</i> = 1.7 Hz, 1H). <sup>1</sup>C NMR (100 MHz, MeOH-<i>d</i><sub>4</sub>) δ 15.1, 37.8, 45.9, 53.7, 58.6, 65.2, 114.0, 119.9, 122.0, 122.8, 129.0, 129.7, 131.7, 131.8, 132.4, 135.5, 149.0, 157.2, 162.3. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 426.1964; found, 426.1940.</div></div><div id="sec4_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 1-(6-(2-Ethylphenyl)benzo[<i>d</i>]thiazol-2-yl)-3-(2-morpholinoethyl)urea (<b>10i</b>)</h4><div class="NLM_p last">Compound <b>10i</b> was prepared (31 mg, 64% yield) according to GP V from 6-(2-ethylphenyl)benzo[<i>d</i>]thiazol-2-amine (30 mg, 0.12 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, 55 °C) δ 1.09 (t, <i>J</i> = 7.5 Hz, 3H), 2.54–2.59 (m, 4H), 2.59–2.69 (m, 4H), 3.52 (q, <i>J</i> = 5.6 Hz, 2H), 3.62–4.04 (m, 4H), 7.16–7.22 (m, 2H), 7.27–7.37 (m, 3H), 7.64 (dd, <i>J</i> = 0.5, 1.7 Hz, 1H), 7.72 (dd, <i>J</i> = 0.6, 8.2 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, 55 °C) δ 15.5, 26.2, 37.4, 53.7, 57.9, 66.9, 119.5, 121.6, 125.6, 127.7, 127.7, 128.6, 130.2, 131.2, 137.8, 141.1, 141.8, 148.5, 155.0, 161.4. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub>S [M + H]<sup>+</sup>, 411.1855; found, 411.1849.</div></div><div id="sec4_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 1-(2-(Dimethylamino)ethyl)-3-(6-(2-ethylphenyl)benzo[<i>d</i>]thiazol-2-yl)urea (<b>10j</b>)</h4><div class="NLM_p last">Compound <b>10j</b> was prepared (18 mg, 41% yield) according to GP V from 6-(2-ethylphenyl)benzo[<i>d</i>]thiazol-2-amine (30 mg, 0.12 mmol). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.07 (t, <i>J</i> = 7.5 Hz, 3H), 2.38 (s, 6H), 2.59 (q, <i>J</i> = 7.5 Hz, 2H), 2.65 (t, <i>J</i> = 5.8 Hz, 2H), 3.52 (d, <i>J</i> = 6.1 Hz, 2H), 7.14–7.23 (m, 2H), 7.25–7.33 (m, 3H), 7.60 (d, <i>J</i> = 1.7 Hz, 1H), 7.64 (d, <i>J</i> = 8.2 Hz, 1H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 15.6, 26.1, 45.1, 119.2, 121.4, 125.5, 127.4, 127.5, 128.5, 130.2, 137.2, 141.1, 141.7, 148.0, 161.3. HRMS (EI+) <i>m</i>/<i>z</i> calcd for C<sub>20</sub>H<sub>24</sub>N<sub>4</sub>OS [M + H]<sup>+</sup>, 369.1749; found, 369.1741.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Docking Study</h3><div class="NLM_p last">The active conformations of the wild-type and T315I mutant of ABL were selected as the target proteins in this study. We prepared the two receptor models in the “DFG-in” conformation from the X-ray crystal structure of the wild-type Abl in complex with dasatinib (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GQG">2GQG</a>) and that of T315I mutant in complex with PPY-A (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QOH">2QOH</a>). We used the AutoDock program because the outperformance of its scoring function over those of the others had been shown in several target proteins. To obtain the all-atom models for the two receptors, hydrogen atoms were added to each protein atom in the wild-type and mutant enzymes. A special attention was paid to assign the protonation states of the ionizable aspartate, glutamate, histidine, and lysine residues in the X-ray crystal structures of the wild-type and T315I mutant. The side chains of aspartate and glutamate residues were assumed to be neutral if one of their carboxylate oxygens pointed toward a hydrogen bond accepting group including the backbone aminocarbonyl oxygen at a distance within 3.5 Å, a generally accepted distance limit for a hydrogen bond of moderate strength. Similarly, the lysine side chains were assumed to be protonated unless the NZ atom was in proximity to a hydrogen bond donating group. The same procedure was also applied to determine the protonation states of ND and NE atoms in histidine residues.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Biological Assays and Methods</h3><div id="sec4_8_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Enzyme Assay</h4><div class="NLM_p last">The IC<sub>50</sub> determinations were performed using radiometric kinase assays ([γ-<sup>33</sup>P]-ATP) with 1 μM ATP at the Reaction Biology Corp. (Malvern, PA, U.S.A.). Compounds were tested in a 10-dose IC<sub>50</sub> mode with 3-fold serial dilution starting at 1 μM. POC and <i>K</i><sub>d</sub> determinateions were performed at the Ambit Bioscience Corp. (San Diego, CA, USA). Compound <b>9a</b> was profiled at 1 μM against a panel of 96 kinases in a high-throughput binding assay (Ambit Bioscience).</div></div><div id="sec4_8_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> Cells and Reagents</h4><div class="NLM_p last">Ba/F3 cells were kindly provided by Dr. Deininger (Huntsman Cancer Institute, Salt Lake City, UT). Ba/F3<sup>WT</sup> and Ba/F3<sup>T315I</sup> cells, which inducibly express Bcr-Abl with wild-type and Bcr-Abl with T315I mutation, respectively, were derived as described previously by retroviral transfection using the mammalian expression vector pSRα.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Ba/F3<sup>WT</sup> and Ba/F3<sup>T315I</sup> cells were grown in Roswell Park Memorial Institute media 1640 (RPMI 1640) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. RPMI 1640, FBS, and penicillin/streptomycin were purchased from Gibco (Grand Island, NY). Imatinib and dasatinib were purchased from LC laboratories (Woburn, MA). XTT was purchased from WELGENE Inc. (Daegu, Korea). Antibodies against p-Bcr-Abl, p-STAT5, p-CrkL, and elF4E were all purchased from Cell Signaling Technology Inc. (Danvers, MA).</div></div><div id="sec4_8_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> Cellular Antiproliferation Assay Using XTT Assay</h4><div class="NLM_p last">Cellular antiproliferation effect of corresponding compounds was determined by sodium 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2<i>H</i>-tetrazolium-5-carboxanilide inner salt (XTT) assay. Cells were plated at a density of 2.5 × 10<sup>3</sup> cells/well in 96-well culture dishes and incubated in 37 °C for 24 h. Cells were treated with the corresponding compounds or control at the indicated concentration (0.001–50 μM) for 48 h. Then 10 μL of XTT labeling mixture (1 mL of XTT/20 μL of PMS (phenazine methosulfate)) was added into each well and incubated for 2 h. Optical density (OD) was measured by a microplate reader at OD540 and OD620. Absorbance rate for each well was calculated as OD540 – OD620. The data were further analyzed using Graphpad Prism5 (Graphpad Software, Inc.)</div></div><div id="sec4_8_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> Western Blot Analysis</h4><div class="NLM_p last">After cells were treated with 1 μM imatinib, dasatinib, <b>10b</b>, or <b>10d</b> and incubated 37 °C for 1 h, cells were collected and washed with ice-cold phosphate-buffered saline (PBS). Cells were lysed with buffer containing 1% Triton X-100, 1% Nonidet P-40 (NP-40), followed by protease and phosphatase inhibitor cocktails (GenDEPOT, Barker, TX). Cell lysates were collected by dissolving cells in 1× SDS sample lysis buffer then boiling. Equal amounts of cell lysates were loaded to 12% sodium dodecyl sulfate polyacrylamide gels (SDS-PAGE) and separated by electrophoresis. Separated proteins were then electrically transferred onto poly(vinylidene fluoride) (PVDF) membranes (Millipore, Bedford, MA). The film was blocked with 1× TBS containing 0.1% Tween-20 and 5% bovine serum albumin (BSA) and then incubated with primary antibody followed by horseradish peroxidase (HRP)-conjugated secondary antibody. The protein lanes were visualized using an enhanced chemiluminescence (ECL) plus system (Amersham Biosciences, Piscataway, NJ). Primary monoclonal antibodies against the following factors were used: pBcr-Abl (Tyr<sup>245</sup>), pSTAT5 (Tyr<sup>694</sup>), pCrkL (Tyr<sup>207</sup>), and elF4E (Cell Signaling Technology Inc., Danvers, MA). The secondary antibodies were purchased from Amersham Biosciences (Piscataway, NJ).</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i77"><a href="/doi/suppl/10.1021/jm301891t">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44120" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44120" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Spectra, more chemical information, and biological data. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301891t/suppl_file/jm301891t_si_001.pdf">jm301891t_si_001.pdf (12.7 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm301891t" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88533" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88533" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Soon-Sun Hong</span> - <span class="hlFld-Affiliation affiliation">Department of Biomedical Sciences,
College of Medicine, Inha University, Incheon
400-712, Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a4cccbcac3cbd6c3e4cfc5cdd7d08ac5c78acfd684cccbcac3d7e4cdcaccc58ac5c78acfd6"><span class="__cf_email__" data-cfemail="056d6a6b626a7762456e646c76712b64662b6e77">[email protected]</span> <span class="__cf_email__" data-cfemail="355d5a5b5246755c5b5d541b54561b5e47">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sungwoo Hong</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Daejeon 305-701, Korea</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#3e56515059514c597e555f574d4a105f5d10554c1e565150594d7e5750565f105f5d10554c"><span class="__cf_email__" data-cfemail="b1d9dedfd6dec3d6f1dad0d8c2c59fd0d29fdac3">[email protected]</span> <span class="__cf_email__" data-cfemail="8ee6e1e0e9fdcee7e0e6efa0efeda0e5fc">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Seunghee Hong</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Daejeon 305-701, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jinhee Kim</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Daejeon 305-701, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sun-Mi Yun</span> - <span class="hlFld-Affiliation affiliation">Department of Biomedical Sciences,
College of Medicine, Inha University, Incheon
400-712, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hyunseung Lee</span> - <span class="hlFld-Affiliation affiliation">Department of Biomedical Sciences,
College of Medicine, Inha University, Incheon
400-712, Korea</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yoonsu Park</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry, Korea Advanced Institute of
Science and Technology (KAIST), Daejeon 305-701, Korea</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Seunghee Hong, Jinhee Kim, and Sun-Mi Yun contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d85e5224-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Dedicated to Professor Deukjoon Kim on the occasion of his retirement. This research was supported by National Research Foundation of Korea (NRF) through General Research Grants NRF-2010-0022179, 2011-0016436, and 2011-0020322.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i80" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i80"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i81" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i81"> Abbreviations Used</h2><tr><td class="NLM_term">Bcr-Abl</td><td class="NLM_def"><p class="first last">break-point cluster region–Abelson tyrosine kinase</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myeloid leukemia</p></td></tr><tr><td class="NLM_term">c-Kit</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase for the cytokine stem cell factor</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">Asp-Phe-Gly</p></td></tr><tr><td class="NLM_term">MEK1</td><td class="NLM_def"><p class="first last">MAP kinase kinase 1</p></td></tr><tr><td class="NLM_term">Braf</td><td class="NLM_def"><p class="first last">v-Raf murine sarcoma viral oncogene homolog B1</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine-5′-triphosphate</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DIPE</td><td class="NLM_def"><p class="first last">diisopropyl ether</p></td></tr><tr><td class="NLM_term">DPPF(dppf)</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">carbondiimidazole</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">XTT</td><td class="NLM_def"><p class="first last">2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboanilid inner salt</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i82">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12204" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12204" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 18 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Molecular biology of bcr-abl1-positive chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1630</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1182%2Fblood-2008-03-144790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=18827185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisV2iurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=1619-1630&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Molecular+biology+of+bcr-abl1-positive+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular biology of bcr-abl1-positive chronic myeloid leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1619-1630</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique mol. event, the BCR-ABL1 oncogene.  Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culminated in the development of highly efficacious therapeutics that, like imatinib mesylate, target the oncogenic kinase activity of BCR-ABL1.  In recent years, most research efforts in CML have been devoted to developing novel tyrosine kinase inhibitors (TKIs) as well as to elucidating the mechanisms of resistance to imatinib and other TKIs.  Nonetheless, primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, or the cross-talk between BCR-ABL1 and other oncogenic signaling pathways, still remain poorly understood.  Herein, the authors synthesize the most relevant and current knowledge on such areas of the pathogenesis of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsPO2wdma5UrVg90H21EOLACvtfcHk0liNU2y-Ebrifg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisV2iurs%253D&md5=bcd7d53c3e06d3b9833fb84799f75ea7</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-03-144790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-03-144790%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DMolecular%2520biology%2520of%2520bcr-abl1-positive%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D1619%26epage%3D1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span> </span><span class="NLM_article-title">Chronic myelogenous leukemia: Update on biology and treatment</span> <span class="citation_source-journal">Oncology (Williston Park, N.Y.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=10079468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A280%3ADyaK1M7nvFWrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=169-184&author=S.+Faderlauthor=H.+M.+Kantarjianauthor=M.+Talpaz&title=Chronic+myelogenous+leukemia%3A+Update+on+biology+and+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic myelogenous leukemia: update on biology and treatment</span></div><div class="casAuthors">Faderl S; Kantarjian H M; Talpaz M</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-80; discussion 181, 184</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">Chronic myelogenous leukemia (CML) is a myeloproliferative disorder that follows a characteristic clinical course in which a chronic phase of variable duration precedes an accelerated, and ultimately blastic, phase, which is generally fatal.  This disorder results from a clonal expansion of transformed hematopoietic progenitor cells and includes myeloid, monocytic, erythroid, megakaryocytic, and lymphoid lineages.  At the molecular level, CML is characterized by the bcr-abl fusion gene, which results from the reciprocal translocation t(9;22)(q34;q11), creating the Philadelphia (Ph) chromosome.  Chronic myelogenous leukemia was the first human disease for which a specific karyotype abnormality was demonstrated and could be linked to pathogenetic events of leukemogenesis.  The outlook for patients with CML has changed dramatically over the last decade.  The median survival time of patients has doubled to 5 to 7 years, with up to 50% of patients alive at 5 years.  This development is due to refinements in allogeneic stem-cell transplantation and growing expertise in the use of interferon-alfa (Intron A, Roferon-A), a biological agent that has been shown to suppress the leukemic clone and to prolong survival in patients with CML.  This review provides a concise update of the biology of CML, as well as current therapeutic options and management strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSi1tF-wuzZwTEwO064Z95rfW6udTcc2ebshZwGV_Ru_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M7nvFWrtw%253D%253D&md5=410df90075242ef7aaa45435dce844bd</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DTalpaz%26aufirst%3DM.%26atitle%3DChronic%2520myelogenous%2520leukemia%253A%2520Update%2520on%2520biology%2520and%2520treatment%26jtitle%3DOncology%2520%2528Williston%2520Park%252C%2520N.Y.%2529%26date%3D1999%26volume%3D13%26spage%3D169%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span> </span><span class="NLM_article-title">The interplay of structural information and functional studies in kinase drug design: Insights from BCR-Abl</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1016%2Fj.ceb.2009.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=19217274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVCksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=288-295&author=M.+J.+Eckauthor=P.+W.+Manley&title=The+interplay+of+structural+information+and+functional+studies+in+kinase+drug+design%3A+Insights+from+BCR-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl</span></div><div class="casAuthors">Eck, Michael J.; Manley, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-295</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  As an inhibitor of the tyrosine kinase activity of the BCR-Abl oncoprotein, imatinib sets a new paradigm for the treatment of cancer with molecularly targeted therapies.  Subsequent structural studies have provided in depth knowledge of how this antileukemia drug interacts with the catalytic site of the enzyme and allowed the rationalization of mechanisms of drug-resistance which can lead to patient relapse.  This understanding has facilitated the design of new inhibitors of BCR-Abl, as well as the discovery of inhibitors of many other kinases.  As structural information accumulates for more of the 518 kinases encoded within the human genome, the design of many more highly selective, well-tolerated kinase inhibitors should be possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ43L3RP84a7Vg90H21EOLACvtfcHk0liNU2y-Ebrifg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVCksrw%253D&md5=7de62ae82b301ea5cd10575a8e98701c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2009.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2009.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DManley%26aufirst%3DP.%2BW.%26atitle%3DThe%2520interplay%2520of%2520structural%2520information%2520and%2520functional%2520studies%2520in%2520kinase%2520drug%2520design%253A%2520Insights%2520from%2520BCR-Abl%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26spage%3D288%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-503&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0liGUOwIX18QFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resta, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Efficacy and safety of a specific inhibitor of the BCR ABL tyrosine kinase in chronic myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">1031</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1056%2FNEJM200104053441401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=11287972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFGnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1031-1037&author=B.+J.+Drukerauthor=M.+Talpazauthor=D.+J.+Restaauthor=B.+Pengauthor=E.+Buchdungerauthor=J.+M.+Fordauthor=N.+B.+Lydonauthor=H.+Kantarjianauthor=R.+Capdevilleauthor=S.+Ohno+Jonesauthor=C.+L.+Sawyers&title=Efficacy+and+safety+of+a+specific+inhibitor+of+the+BCR+ABL+tyrosine+kinase+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia</span></div><div class="casAuthors">Druker, Brian J.; Talpaz, Moshe; Resta, Debra J.; Peng, Bin; Buchdunger, Elisabeth; Ford, John M.; Lydon, Nicholas B.; Kantarjian, Hagop; Capdeville, Renaud; Ohno-Jones, Sayuri; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1031-1037</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML).  Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML.  Methods: We conducted a phase 1, dose-escalating trial of STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase.  STI571 was administered orally to 83 patients with CML in the chronic phase in whom treatment with interferon alpha had failed.  Patients were successively assigned to 1 of 14 doses ranging from 25 to 1000 mg per day.  Results: Adverse effects of STI571 were minimal; the most common were nausea, myalgias, edema, and diarrhea.  A maximal tolerated dose was not identified.  Complete hematol. responses were obsd. in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy.  Of the 54 patients treated with doses of 300 mg or more, cytogenetic responses occurred in 29, including 17 (31 percent of the 54 patients who received this dose) with major responses (0 to 35 percent of cells in metaphase pos. for the Philadelphia chromosome); 7 of these patients had complete cytogenetic remissions.  Conclusion: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alpha had failed.  Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific mol. abnormality present in a human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrprbDzKoC0ubVg90H21EOLACvtfcHk0liGUOwIX18QFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFGnu70%253D&md5=1554407678838243a753aa056ffd4f7c</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441401%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DResta%26aufirst%3DD.%2BJ.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DOhno%2BJones%26aufirst%3DS.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520a%2520specific%2520inhibitor%2520of%2520the%2520BCR%2520ABL%2520tyrosine%2520kinase%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1031%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2242</span><span class="NLM_x">–</span> <span class="NLM_lpage">2249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2242-2249&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=M.+W.+Deininger&title=Bcr-Abl+kinase+domain+mutations%2C+drug+resistance%2C+and+the+road+to+a+cure+for+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DBcr-Abl%2520kinase%2520domain%2520mutations%252C%2520drug%2520resistance%252C%2520and%2520the%2520road%2520to%2520a%2520cure%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2242%26epage%3D2249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+M.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.+L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-ylamino%29thiazole-5-carboxamide+%28BMS-354825%29%2C+a+dual+Src%2FAbl+kinase+inhibitor+with+potent+antitumor+activity+in+preclinical+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-ylamino%2529thiazole-5-carboxamide%2520%2528BMS-354825%2529%252C%2520a%2520dual%2520Src%252FAbl%2520kinase%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brüggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Br%C3%BCggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=M.+Azamauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lgx1rWrJ0WEtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBr%25C3%25BCggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3965</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0102250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3965-3977&author=D.+H.+Boschelliauthor=F.+Yeauthor=Y.+D.+Wangauthor=M.+Dutiaauthor=S.+L.+Johnsonauthor=B.+Wuauthor=K.+Millerauthor=D.+W.+Powellauthor=D.+Yaczkoauthor=M.+Youngauthor=M.+Tischlerauthor=K.+Arndtauthor=C.+Discafaniauthor=C.+Etienneauthor=J.+Gibbonsauthor=J.+Grodauthor=J.+Lucasauthor=J.+M.+Weberauthor=F.+Boschelli&title=Optimization+of+4-phenylamino-3-quinolinecarbonitriles+as+potent+inhibitors+of+Src+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity</span></div><div class="casAuthors">Boschelli, Diane H.; Ye, Fei; Wang, Yanong D.; Dutia, Minu; Johnson, Steve L.; Wu, Biqi; Miller, Karen; Powell, Dennis W.; Yaczko, Deanna; Young, Mairead; Tischler, Mark; Arndt, Kim; Discafani, Carolyn; Etienne, Carlo; Gibbons, Jay; Grod, Janet; Lucas, Judy; Weber, Jennifer M.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3965-3977</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Subsequent to the discovery of 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as an inhibitor of Src kinase activity (IC50 = 30 nM), several addnl. analogs were prepd.  Optimization of the C-4 anilino group led to I [R = Me].  Replacement of the methoxy group at C-7 with a 3-(morpholin-4-yl)propoxy group provided I [R = morpholinopropyl], resulting in increased inhibition of both Src kinase activity and Src-mediated cell proliferation.  Analogs of I [R = morpholinopropyl] with other trisubstituted anilines at C-4 were also potent Src inhibitors, and the propoxy group was preferred over ethoxy, butoxy, or pentoxy.  Replacement of the morpholine group with a 4-methylpiperazine group provided I [R = 4-methylpiperazinopropyl], which had an IC50 of 1.2 nM in the Src enzymic assay, an IC50 of 100 nM for the inhibition of Src-dependent cell proliferation and was selective for Src over non-Src family kinases.  I [R = 4-methylpiperazinopropyl], which had higher 1 and 4 h plasma levels than I [R = 4-morpholinopropyl], effectively inhibited tumor growth in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIfrD66BPWqrVg90H21EOLACvtfcHk0lgx1rWrJ0WEtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D&md5=88c2d8aa690b9aedbff034682aa3d73e</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1021%2Fjm0102250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0102250%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DD.%2BW.%26aulast%3DYaczko%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DTischler%26aufirst%3DM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DGrod%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DOptimization%2520of%25204-phenylamino-3-quinolinecarbonitriles%2520as%2520potent%2520inhibitors%2520of%2520Src%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3965%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span> </span><span class="NLM_article-title">Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1754</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=3-13&author=P.+W.+Manleyauthor=S.+W.+Cowan-Jacobauthor=J.+Mestan&title=Advances+in+the+structural+biology%2C+design+and+clinical+development+of+Bcr-Abl+kinase+inhibitors+for+the+treatment+of+chronic+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520structural%2520biology%252C%2520design%2520and%2520clinical%2520development%2520of%2520Bcr-Abl%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2005%26volume%3D1754%26spage%3D3%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Treatment selection after imatinib resistance in chronic myeloid leukemia</span> <span class="citation_source-journal">Target Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1007%2Fs11523-008-0100-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A280%3ADC%252BD1M3ls1ShsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=3-10&author=E.+Jabbourauthor=J.+Cortesauthor=H.+Kantarjian&title=Treatment+selection+after+imatinib+resistance+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment selection after imatinib resistance in chronic myeloid leukemia</span></div><div class="casAuthors">Jabbour Elias; Cortes Jorge; Kantarjian Hagop</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic myeloid leukemia (CML) is a progressive and often fatal malignancy of the blood.  The harbinger of CML is a chromosomal translocation that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase.  The advent of imatinib, an inhibitor targeted specifically for BCR-ABL, represented a significant medical advance in CML therapy.  However, patients with CML can exhibit varying responses to first-line treatment with imatinib.  While most patients respond to treatment, some may experience a loss of response or require treatment discontinuation due to toxicity.  Frequent monitoring for resistance or intolerance is a requirement for recognition of suboptimal response.  Mutational analysis of the patient's BCR-ABL alleles is also informative and may be predictive of a response to therapy.  Published physician guidelines have highlighted these recommendations, but it is not clear if these guidelines are universally followed.  One option in patients showing poor response to standard-dose imatinib of 400 mg is to escalate the dose.  However, this option should be reserved for patients with minimal disease burden.  Clinically available options mainly include second-generation tyrosine kinase inhibitors, such as dasatinib and nilotinib.  Allogenic stem cell transplantations (for eligible patients) also should be considered.  The disease and patient characteristics at the time of imatinib failure should be evaluated before choosing second-line therapy to optimize the therapeutic benefit without unnecessary delay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWQ8OirUTX9q_dlEzl_fBafW6udTcc2eakuM0Yr82Qubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3ls1ShsA%253D%253D&md5=1481eff66a60910fc8243055af8fa924</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs11523-008-0100-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-008-0100-y%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DTreatment%2520selection%2520after%2520imatinib%2520resistance%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DTarget%2520Oncol.%26date%3D2009%26volume%3D4%26spage%3D3%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Therapeutic options against BCR-ABL1 T315I positive chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4399</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1158%2F1078-0432.CCR-08-0117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=18628453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4392-4399&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Therapeutic+options+against+BCR-ABL1+T315I+positive+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4399</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease.  Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib.  Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid.  This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket.  To expedite the identification of strategies to override the resistance imposed by the T315I mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1.  Recent insights gained regarding the structural biol. of T315I have led to the development of a variety of compds. against this mutant.  We herein summarize the most clin. promising anti-T315I therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplJ8bpmJXGkrVg90H21EOLACvtfcHk0lhxF0ZG6EamiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D&md5=01688b0795daf1ca29c7ad4a98e3977b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0117%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DTherapeutic%2520options%2520against%2520BCR-ABL1%2520T315I%2520positive%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4392%26epage%3D4399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span> </span><span class="NLM_article-title">A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5439</span><span class="NLM_x">–</span> <span class="NLM_lpage">5448</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901808w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5439-5448&author=H.+G.+Choiauthor=P.+Renauthor=F.+Adrianauthor=F.+Sunauthor=H.+S.+Leeauthor=X.+Wangauthor=Q.+Dingauthor=G.+Zhangauthor=Y.+Xieauthor=J.+Zhangauthor=Y.+Liuauthor=T.+Tuntlandauthor=M.+Warmuthauthor=P.+W.+Manleyauthor=J.+Mestanauthor=N.+S.+Grayauthor=T.+Sim&title=A+type-II+kinase+inhibitor+capable+of+inhibiting+the+T315I+%E2%80%9Cgatekeeper%E2%80%9D+mutant+of+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fjm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520type-II%2520kinase%2520inhibitor%2520capable%2520of%2520inhibiting%2520the%2520T315I%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutant%2520of%2520Bcr-Abl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5439%26epage%3D5448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojciechowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rummel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Expanding the diversity of allosteric Bcr-Abl inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6934</span><span class="NLM_x">–</span> <span class="NLM_lpage">6946</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6934-6946&author=Q.+Dingauthor=J.+Zhangauthor=Y.+Choiauthor=F.+J.+Adrianauthor=A.+Wojciechowskiauthor=G.+Zhangauthor=J.+Cheauthor=B.+Bursulayaauthor=S.+W.+Cowan-Jacobauthor=G.+Rummelauthor=T.+Simauthor=N.+S.+Gray&title=Expanding+the+diversity+of+allosteric+Bcr-Abl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRummel%26aufirst%3DG.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExpanding%2520the%2520diversity%2520of%2520allosteric%2520Bcr-Abl%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6934%26epage%3D6946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 3-(1<i>H</i><sup>–</sup>1,2,3-triazol-1-yl)benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine<sup>315</sup>→isoleucine<sup>315</sup> mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">10033</span><span class="NLM_x">–</span> <span class="NLM_lpage">10046</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=10033-10046&author=Y.+Liauthor=M.+Shenauthor=Z.+Zhangauthor=J.+Luoauthor=X.+Panauthor=X.+Luauthor=H.+Longauthor=D.+Wenauthor=F.+Zhangauthor=F.+Lengauthor=Y.+Liauthor=Z.+Tuauthor=X.+Renauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+3-%281H%E2%80%931%2C2%2C3-triazol-1-yl%29benzamide+derivatives+as+potent+pan+Bcr-Abl+inhibitors+including+the+threonine315%E2%86%92isoleucine315+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLeng%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25203-%25281H%25E2%2580%25931%252C2%252C3-triazol-1-yl%2529benzamide%2520derivatives%2520as%2520potent%2520pan%2520Bcr-Abl%2520inhibitors%2520including%2520the%2520threonine315%25E2%2586%2592isoleucine315%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D53%26spage%3D10033%26epage%3D10046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region–Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">894</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301581y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=879-894&author=X.+Renauthor=X.+Panauthor=Z.+Zhangauthor=D.+Wangauthor=X.+Luauthor=Y.+Liauthor=D.+Wenauthor=H.+Longauthor=J.+Luoauthor=Y.+Fengauthor=X.+Zhuangauthor=F.+Zhangauthor=J.+Liuauthor=F.+Lengauthor=X.+Langauthor=Y.+Baiauthor=M.+Sheauthor=Z.+Tuauthor=J.+Panauthor=K.+Ding&title=Identification+of+GZD824+as+an+orally+bioavailable+inhibitor+that+targets+phosphorylated+and+nonphosphorylated+breakpoint+cluster+region%E2%80%93Abelson+%28Bcr-Abl%29+kinase+and+overcomes+clinically+acquired+mutation-induced+resistance+against+imatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=10.1021%2Fjm301581y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301581y%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DZhuang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLeng%26aufirst%3DF.%26aulast%3DLang%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DShe%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520GZD824%2520as%2520an%2520orally%2520bioavailable%2520inhibitor%2520that%2520targets%2520phosphorylated%2520and%2520nonphosphorylated%2520breakpoint%2520cluster%2520region%25E2%2580%2593Abelson%2520%2528Bcr-Abl%2529%2520kinase%2520and%2520overcomes%2520clinically%2520acquired%2520mutation-induced%2520resistance%2520against%2520imatinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D879%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Lu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2146</span><span class="NLM_x">–</span> <span class="NLM_lpage">2157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.2174%2F092986711795656135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=21517764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2146-2157&author=X.+Y.+Luauthor=Q.+Caiauthor=K.+Ding&title=Recent+developments+in+the+third+generation+inhibitors+of+Bcr-Abl+for+overriding+T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8eR"><div class="casContent"><span class="casTitleNuber">8e</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation</span></div><div class="casAuthors">Lu, X. Y.; Cai, Q.; Ding, K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2146-2157</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In the treatment of chronic myeloid leukemia (CML) with Bcr-Abl kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents, such as imatinib, nilotinib and dasatinib, by disrupting important contact interactions between the inhibitors and the enzyme.  To overcome this particular resistance, several different strategies have been explored and many mols. have been investigated as capable of potently inhibiting Bcr-Abl T315I.  Herein, this review reports on some predominant examples of third generation inhibitors of Bcr-Abl active against the T315I mutation, and special attentions are paid to the "hybrid-design" strategy for creating type-II class ATP-competitive inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFoM774pVEqrVg90H21EOLACvtfcHk0lhcvTnMxHv5YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D&md5=23109d1eb81a48f93cdf9ffbb4728c7a</span></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=10.2174%2F092986711795656135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795656135%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DRecent%2520developments%2520in%2520the%2520third%2520generation%2520inhibitors%2520of%2520Bcr-Abl%2520for%2520overriding%2520T315I%2520mutation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2146%26epage%3D2157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khosravi-Far, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melo, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">4206</span><span class="NLM_x">–</span> <span class="NLM_lpage">4216</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=4206-4216&author=E.+Weisbergauthor=H.+G.+Choiauthor=A.+Rayauthor=R.+Barrettauthor=J.+Zhangauthor=T.+Simauthor=W.+Zhouauthor=M.+Seeligerauthor=M.+Cameronauthor=M.+Azamauthor=J.+A.+Fletcherauthor=M.+Debiec-Rychterauthor=M.+Mayedaauthor=D.+Morenoauthor=A.+L.+Kungauthor=P.+A.+Janneauthor=R.+Khosravi-Farauthor=J.+V.+Meloauthor=P.+W.+Manleyauthor=S.+Adamiaauthor=C.+Wuauthor=N.+Grayauthor=J.+D.+Griffin&title=Discovery+of+a+small-molecule+type+II+inhibitor+of+wild-type+and+gatekeeper+mutants+of+BCR-ABL%2C+PDGFRalpha%2C+Kit%2C+and+Src+kinases%3A+novel+type+II+inhibitor+of+gatekeeper+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DSeeliger%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DM.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DMayeda%26aufirst%3DM.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKhosravi-Far%26aufirst%3DR.%26aulast%3DMelo%26aufirst%3DJ.%2BV.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DAdamia%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520small-molecule%2520type%2520II%2520inhibitor%2520of%2520wild-type%2520and%2520gatekeeper%2520mutants%2520of%2520BCR-ABL%252C%2520PDGFRalpha%252C%2520Kit%252C%2520and%2520Src%2520kinases%253A%2520novel%2520type%2520II%2520inhibitor%2520of%2520gatekeeper%2520mutants%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D4206%26epage%3D4216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Modugno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soncini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosettani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">7987</span><span class="NLM_x">–</span> <span class="NLM_lpage">7990</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=7987-7990&author=M.+Modugnoauthor=E.+Casaleauthor=C.+Sonciniauthor=P.+Rosettaniauthor=R.+Colomboauthor=R.+Lupiauthor=L.+Rusconiauthor=D.+Fancelliauthor=P.+Carpinelliauthor=A.+D.+Cameronauthor=A.+Isacchiauthor=J.+Moll&title=Crystal+structure+of+the+T315I+Abl+mutant+in+complex+with+the+aurora+kinases+inhibitor+PHA-739358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DModugno%26aufirst%3DM.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DRosettani%26aufirst%3DP.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DA.%2BD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520Abl%2520mutant%2520in%2520complex%2520with%2520the%2520aurora%2520kinases%2520inhibitor%2520PHA-739358%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D7987%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Young, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1014</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8h&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1158%2F0008-5472.CAN-05-2788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8h&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=16424036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8h&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFOhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1007-1014&author=M.+A.+Youngauthor=N.+P.+Shahauthor=L.+H.+Chaoauthor=M.+Seeligerauthor=Z.+V.+Milanovauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhartauthor=C.+L.+Sawyersauthor=J.+Kuriyan&title=Structure+of+the+kinase+domain+of+an+imatinib-resistant+Abl+mutant+in+complex+with+the+Aurora+kinase+inhibitor+VX-680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8hR"><div class="casContent"><span class="casTitleNuber">8h</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680</span></div><div class="casAuthors">Young, Matthew A.; Shah, Neil P.; Chao, Luke H.; Seeliger, Markus; Milanov, Zdravko V.; Biggs, William H., III; Treiber, Daniel K.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.; Sawyers, Charles L.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1007-1014</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We present a high-resoln. (2.0 Å) crystal structure of the catalytic domain of a mutant form of the Abl tyrosine kinase (H396P; Abl-1a numbering) that is resistant to the Abl inhibitor imatinib.  The structure is detd. in complex with the small-mol. inhibitor VX-680 (Vertex Pharmaceuticals, Cambridge, MA), which blocks the activity of various imatinib-resistant mutant forms of Abl, including one (T315I) that is resistant to both imatinib and BMS-354825 (dasatinib), a dual Src/Abl inhibitor that seems to be clin. effective against all other imatinib-resistant forms of BCR-Abl.  VX-680 is shown to have significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples.  The Abl kinase domain bound to VX-680 is not phosphorylated on the activation loop in the crystal structure but is nevertheless in an active conformation, previously unobserved for Abl and inconsistent with the binding of imatinib.  The adoption of an active conformation is most likely the result of synergy between the His396Pro mutation, which destabilizes the inactive conformation required for imatinib binding, and the binding of VX-680, which favors the active conformation through hydrogen bonding and steric effects.  VX-680 is bound to Abl in a mode that accommodates the substitution of isoleucine for threonine at residue 315 (the "gatekeeper" position).  The avoidance of the innermost cavity of the Abl kinase domain by VX-680 and the specific recognition of the active conformation explain the effectiveness of this compd. against mutant forms of BCR-Abl, including those with mutations at the gatekeeper position.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNV6YSmt1NWrVg90H21EOLACvtfcHk0lhcvTnMxHv5YA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFOhtw%253D%253D&md5=a31ed99bdc51cf266c8c10dfceb1800c</span></div><a href="/servlet/linkout?suffix=cit8h&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2788%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DChao%26aufirst%3DL.%2BH.%26aulast%3DSeeliger%26aufirst%3DM.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520kinase%2520domain%2520of%2520an%2520imatinib-resistant%2520Abl%2520mutant%2520in%2520complex%2520with%2520the%2520Aurora%2520kinase%2520inhibitor%2520VX-680%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1007%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><div class="note"><p class="first last">During preparation of manuscript, ponatinib was recently approved by the FDA for the treatment of CML patients.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=During+preparation+of+manuscript%2C+ponatinib+was+recently+approved+by+the+FDA+for+the+treatment+of+CML+patients."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+pan-BCR-ABL+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+T315I+mutant+and+overcomes+mutation-based+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520pan-BCR-ABL%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520T315I%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Discovery of 3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4701</span><span class="NLM_x">–</span> <span class="NLM_lpage">4719</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&author=W.+S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-N-%7B4-%5B%284-methylpiperazin-1-yl%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28AP24534%29%2C+a+potent%2C+orally+active+pan-inhibitor+of+breakpoint+cluster+region-Abelson+%28BCR-ABL%29+kinase+including+the+T315I+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-yl%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528AP24534%2529%252C%2520a%2520potent%252C%2520orally%2520active%2520pan-inhibitor%2520of%2520breakpoint%2520cluster%2520region-Abelson%2520%2528BCR-ABL%2529%2520kinase%2520including%2520the%2520T315I%2520gatekeeper%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4701%26epage%3D4719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mac Partlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petillo, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">3189</span><span class="NLM_x">–</span> <span class="NLM_lpage">3195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3189-3195&author=C.+A.+Eideauthor=L.+T.+Adrianauthor=J.+W.+Tynerauthor=M.+Mac+Partlinauthor=D.+J.+Andersonauthor=S.+C.+Wiseauthor=B.+D.+Smithauthor=P.+A.+Petilloauthor=D.+L.+Flynnauthor=M.+W.+Deiningerauthor=T.+O%E2%80%99Hareauthor=B.+J.+Druker&title=The+ABL+switch+control+inhibitor+DCC-2036+is+active+against+the+chronic+myeloid+leukemia+mutant+BCR-ABLT315I+and+exhibits+a+narrow+resistance+profile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DMac%2BPartlin%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DPetillo%26aufirst%3DP.%2BA.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520ABL%2520switch%2520control%2520inhibitor%2520DCC-2036%2520is%2520active%2520against%2520the%2520chronic%2520myeloid%2520leukemia%2520mutant%2520BCR-ABLT315I%2520and%2520exhibits%2520a%2520narrow%2520resistance%2520profile%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3189%26epage%3D3195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Park, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Nocodazole is a high-affinity ligand for the cancer-related kinases ABL, c-KIT, BRAF, and MEK</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=53-56&author=H.+Parkauthor=S.+Hongauthor=S.+Hong&title=Nocodazole+is+a+high-affinity+ligand+for+the+cancer-related+kinases+ABL%2C+c-KIT%2C+BRAF%2C+and+MEK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DNocodazole%2520is%2520a%2520high-affinity%2520ligand%2520for%2520the%2520cancer-related%2520kinases%2520ABL%252C%2520c-KIT%252C%2520BRAF%252C%2520and%2520MEK%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D53%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">De Brabander, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Veire, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aerts, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, P. A.</span><span> </span><span class="NLM_article-title">The effects of methyl (5-(2-thienylcarbonyl)-1<i>H</i>-benzimidazol-2-yl) carbamate, (R 17934; NSC 238159), a new synthetic antitumoral drug interfering with microtubules, on mammalian cells cultured in vitro</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1976&pages=905-916&author=M.+J.+De+Brabanderauthor=R.+M.+Van+de+Veireauthor=F.+E.+Aertsauthor=M.+Borgersauthor=P.+A.+Janssen&title=The+effects+of+methyl+%285-%282-thienylcarbonyl%29-1H-benzimidazol-2-yl%29+carbamate%2C+%28R+17934%3B+NSC+238159%29%2C+a+new+synthetic+antitumoral+drug+interfering+with+microtubules%2C+on+mammalian+cells+cultured+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBrabander%26aufirst%3DM.%2BJ.%26aulast%3DVan%2Bde%2BVeire%26aufirst%3DR.%2BM.%26aulast%3DAerts%26aufirst%3DF.%2BE.%26aulast%3DBorgers%26aufirst%3DM.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26atitle%3DThe%2520effects%2520of%2520methyl%2520%25285-%25282-thienylcarbonyl%2529-1H-benzimidazol-2-yl%2529%2520carbamate%252C%2520%2528R%252017934%253B%2520NSC%2520238159%2529%252C%2520a%2520new%2520synthetic%2520antitumoral%2520drug%2520interfering%2520with%2520microtubules%252C%2520on%2520mammalian%2520cells%2520cultured%2520in%2520vitro%26jtitle%3DCancer%2520Res.%26date%3D1976%26volume%3D36%26spage%3D905%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Drumma, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deiningera, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirana, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillota, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaoa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronkina, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamosa, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanga, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiana, S.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver-Shafferb, P.</span><span> </span><span class="NLM_article-title">Facile preparation of fused ring azolylureas</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5535</span><span class="NLM_x">–</span> <span class="NLM_lpage">5538</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=5535-5538&author=J.+E.+Drummaauthor=D.+D.+Deiningeraauthor=A.+L.+Tiranaauthor=T.+Wangaauthor=A.-L.+Grillotaauthor=Y.+Liaoaauthor=S.+M.+Ronkinaauthor=D.+P.+Stamosaauthor=Q.+Tangaauthor=S.-K.+Tianaauthor=P.+Oliver-Shafferb&title=Facile+preparation+of+fused+ring+azolylureas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrumma%26aufirst%3DJ.%2BE.%26aulast%3DDeiningera%26aufirst%3DD.%2BD.%26aulast%3DTirana%26aufirst%3DA.%2BL.%26aulast%3DWanga%26aufirst%3DT.%26aulast%3DGrillota%26aufirst%3DA.-L.%26aulast%3DLiaoa%26aufirst%3DY.%26aulast%3DRonkina%26aufirst%3DS.%2BM.%26aulast%3DStamosa%26aufirst%3DD.%2BP.%26aulast%3DTanga%26aufirst%3DQ.%26aulast%3DTiana%26aufirst%3DS.-K.%26aulast%3DOliver-Shafferb%26aufirst%3DP.%26atitle%3DFacile%2520preparation%2520of%2520fused%2520ring%2520azolylureas%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D5535%26epage%3D5538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittekind, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzillerri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span> </span><span class="NLM_article-title">The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">5790</span><span class="NLM_x">–</span> <span class="NLM_lpage">5797</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5790-5797&author=J.+S.+Tokarskiauthor=J.+A.+Newittauthor=C.+Y.+J.+Changauthor=J.+D.+Chengauthor=M.+Wittekindauthor=S.+E.+Kieferauthor=K.+Kishauthor=F.+Y.+F.+Leeauthor=R.+Borzillerriauthor=L.+J.+Lombardoauthor=D.+Xieauthor=Y.+Zhangauthor=H.+E.+Klei&title=The+structure+of+dasatinib+%28BMS-354825%29+bound+to+activated+ABL+kinase+domain+elucidates+its+inhibitory+activity+against+imatinib-resistant+ABL+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DC.%2BY.%2BJ.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DWittekind%26aufirst%3DM.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DF.%2BY.%2BF.%26aulast%3DBorzillerri%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26atitle%3DThe%2520structure%2520of%2520dasatinib%2520%2528BMS-354825%2529%2520bound%2520to%2520activated%2520ABL%2520kinase%2520domain%2520elucidates%2520its%2520inhibitory%2520activity%2520against%2520imatinib-resistant%2520ABL%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D5790%26epage%3D5797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parillon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I mutant of AbI kinase</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1111%2Fj.1747-0285.2007.00556.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=17718712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=171-181&author=T.+Zhouauthor=L.+Parillonauthor=F.+Liauthor=Y.+Wangauthor=J.+Keatsauthor=S.+Lamoreauthor=Q.+Xuauthor=W.+Shakespeareauthor=D.+Dalgarnoauthor=X.+Zhu&title=Crystal+structure+of+the+T315I+mutant+of+AbI+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the T315I mutant of Abl kinase</span></div><div class="casAuthors">Zhou, Tianjun; Parillon, Lois; Li, Feng; Wang, Yihan; Keats, Jeff; Lamore, Sarah; Xu, Qihong; Shakespeare, William; Dalgarno, David; Zhu, Xiaotian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a disease characterized by the presence of a constitutively activated chimeric tyrosine kinase protein Bcr-Abl.  However, drug resistance often occurs at later stages of the disease, principally because of the occurrence of mutations in the kinase domain.  Second generation Bcr-Abl inhibitors, such as dasatinib and nilotinib are capable of inhibiting many imatinib-resistant forms of the kinase but not the form in which threonine is mutated to isoleucine at the gatekeeper position (T315I).  In this study, we present the crystal structure of the kinase domain of the c-Abl T315I mutant, as well as the wild-type form, in complex with a pyrrolopyridine inhibitor, PPY-A.  The side chain of Ile315 is accommodated in the Abl T315I mutant structure without large conformational changes proximal to the site of mutation.  In contrast to other inhibitors, such as imatinib and dasatinib, PPY-A does not occupy the hydrophobic pocket behind the gate-keeper residue.  This binding mode, coupled with augmented contacts with the glycine-rich loop, appears to be crit. for its ability to override the T315I mutation.  The data presented here may provide structural guidance for the design of clin. useful inhibitors of Bcr-Abl T315I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcbSxFWWpadbVg90H21EOLACvtfcHk0lhj61gmxVpnyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F&md5=b15c60121b02e33d71783db3abd5ce72</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00556.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00556.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DLamore%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DShakespeare%26aufirst%3DW.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520mutant%2520of%2520AbI%2520kinase%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D171%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structural mechanism for STI-571 inhibition of abelson tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+mechanism+for+STI-571+inhibition+of+abelson+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0lhj61gmxVpnyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520STI-571%2520inhibition%2520of%2520abelson%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D1938%26epage%3D1942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittekind, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzillerri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span> </span><span class="NLM_article-title">The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">5790</span><span class="NLM_x">–</span> <span class="NLM_lpage">5797</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5790-5797&author=J.+S.+Tokarskiauthor=J.+A.+Newittauthor=C.+Y.+Changauthor=J.+D.+Chengauthor=M.+Wittekindauthor=S.+E.+Kieferauthor=K.+Kishauthor=F.+Y.+Leeauthor=R.+Borzillerriauthor=L.+J.+Lombardoauthor=D.+Xieauthor=Y.+Zhangauthor=H.+E.+Klei&title=The+structure+of+dasatinib+%28BMS-354825%29+bound+to+activated+ABL+kinase+domain+elucidates+its+inhibitory+activity+against+imatinib-resistant+ABL+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DWittekind%26aufirst%3DM.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DBorzillerri%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26atitle%3DThe%2520structure%2520of%2520dasatinib%2520%2528BMS-354825%2529%2520bound%2520to%2520activated%2520ABL%2520kinase%2520domain%2520elucidates%2520its%2520inhibitory%2520activity%2520against%2520imatinib-resistant%2520ABL%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D5790%26epage%3D5797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Park, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2986</span><span class="NLM_x">–</span> <span class="NLM_lpage">2993</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci200378s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGjt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2986-2993&author=H.+Parkauthor=O.+Chiauthor=J.+Kimauthor=S.+Hong&title=Identification+of+novel+inhibitors+of+tropomyosin-related+kinase+A+through+the+structure-based+virtual+screening+with+homology-modeled+protein+structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Inhibitors of Tropomyosin-Related Kinase A through the Structure-Based Virtual Screening with Homology-Modeled Protein Structure</span></div><div class="casAuthors">Park, Hwangseo; Chi, Okyung; Kim, Jinhee; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2986-2993</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tropomyosin-related kinase A (TrkA) is a promising target for the development of cancer and pain therapeutics.  Here, we report the first successful example of the use of a structure-based virtual screening to identify novel TrkA inhibitors.  The accuracy of the virtual screening was improved by introducing an accurate solvation free energy term into the original AutoDock scoring function.  We applied a drug design protocol involving homol. modeling, docking anal. of a large chem. library, and enzyme inhibition assays to identify six structurally diverse TrkA inhibitors with Kd values ranging from 3 to 40 μM.  The significant potencies and good physicochem. properties of these drug candidates strongly support their consideration in a development effort that would involve structure-activity relationship (SAR) studies to optimize the inhibitory activities.  We also addressed the structural and energetic features assocd. with binding of the newly identified inhibitors in the ATP-binding site of TrkA.  The results indicate that any structural modifications introduced for the purpose of enhancing the activity of TrkA inhibitors should maximize the attractive interactions within the ATP-binding site and simultaneously minimize the desolvation cost for complexation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbeYo4P3Dw-LVg90H21EOLACvtfcHk0lgksDjQ5dropg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGjt7nE&md5=24656238aa8c161dcf1cc2967054ca35</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fci200378s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200378s%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DChi%26aufirst%3DO.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520novel%2520inhibitors%2520of%2520tropomyosin-related%2520kinase%2520A%2520through%2520the%2520structure-based%2520virtual%2520screening%2520with%2520homology-modeled%2520protein%2520structure%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2986%26epage%3D2993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="note"><p class="first last">POC determinations were performed by the Ambit Bioscience Corp. (San Diego, CA, USA).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Oda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagopian, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">22925</span><span class="NLM_x">–</span> <span class="NLM_lpage">22928</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=22925-22928&author=T.+Odaauthor=C.+Heaneyauthor=J.+R.+Hagopianauthor=K.+Okudaauthor=J.+D.+Griffinauthor=B.+J.+Druker&title=Crkl+is+the+major+tyrosine-phosphorylated+protein+in+neutrophils+from+patients+with+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOda%26aufirst%3DT.%26aulast%3DHeaney%26aufirst%3DC.%26aulast%3DHagopian%26aufirst%3DJ.%2BR.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DCrkl%2520is%2520the%2520major%2520tyrosine-phosphorylated%2520protein%2520in%2520neutrophils%2520from%2520patients%2520with%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D22925%26epage%3D22928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shuai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halpern, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ten Hoeve, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">254</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1996&pages=247-254&author=K.+Shuaiauthor=J.+Halpernauthor=J.+ten+Hoeveauthor=X.+Raoauthor=C.+L.+Sawyers&title=Constitutive+activation+of+STAT5+by+the+BCR-ABL+oncogene+in+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DHalpern%26aufirst%3DJ.%26aulast%3Dten%2BHoeve%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DX.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DConstitutive%2520activation%2520of%2520STAT5%2520by%2520the%2520BCR-ABL%2520oncogene%2520in%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DOncogene%26date%3D1996%26volume%3D13%26spage%3D247%26epage%3D254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">La Rosée, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">7149</span><span class="NLM_x">–</span> <span class="NLM_lpage">7153</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=7149-7153&author=P.+La+Ros%C3%A9eauthor=A.+S.+Corbinauthor=E.+P.+Stoffregenauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=Activity+of+the+Bcr-Abl+kinase+inhibitor+PD180970+against+clinically+relevant+Bcr-Abl+isoforms+that+cause+resistance+to+imatinib+mesylate+%28Gleevec%2C+STI571%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRos%25C3%25A9e%26aufirst%3DP.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DActivity%2520of%2520the%2520Bcr-Abl%2520kinase%2520inhibitor%2520PD180970%2520against%2520clinically%2520relevant%2520Bcr-Abl%2520isoforms%2520that%2520cause%2520resistance%2520to%2520imatinib%2520mesylate%2520%2528Gleevec%252C%2520STI571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D7149%26epage%3D7153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b','cit5c','cit5d'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8a','cit8b','cit8c','cit8d','cit8e','cit8f','cit8g','cit8h'],'ref9':['cit9a','cit9b','cit9c','cit9d'],'ref10':['cit10'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':[],'ref17':['cit17a','cit17b'],'ref18':['cit18']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 25 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brett R.  Beno</span>, <span class="hlFld-ContribAuthor ">Kap-Sun  Yeung</span>, <span class="hlFld-ContribAuthor ">Michael D.  Bartberger</span>, <span class="hlFld-ContribAuthor ">Lewis D.  Pennington</span>, and <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (11)
                                     , 4383-4438. <a href="https://doi.org/10.1021/jm501853m" title="DOI URL">https://doi.org/10.1021/jm501853m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501853m%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BSurvey%252Bof%252Bthe%252BRole%252Bof%252BNoncovalent%252BSulfur%252BInteractions%252Bin%252BDrug%252BDesign%26aulast%3DBeno%26aufirst%3DBrett%2BR.%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D01122014%26date%3D03032015%26date%3D11062015%26volume%3D58%26issue%3D11%26spage%3D4383%26epage%3D4438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juan  Liu</span>, <span class="hlFld-ContribAuthor ">Yuan  Zhang</span>, <span class="hlFld-ContribAuthor ">Honglin  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Lei</span>, <span class="hlFld-ContribAuthor ">Guotao  Tang</span>, <span class="hlFld-ContribAuthor ">Xuan  Cao</span>, <span class="hlFld-ContribAuthor ">Junmei  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in Bcr‐Abl tyrosine kinase inhibitors for overriding T315I mutation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>97 </em>
                                    (3)
                                     , 649-664. <a href="https://doi.org/10.1111/cbdd.13801" title="DOI URL">https://doi.org/10.1111/cbdd.13801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13801%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DRecent%252Badvances%252Bin%252BBcr%2525E2%252580%252590Abl%252Btyrosine%252Bkinase%252Binhibitors%252Bfor%252Boverriding%252BT315I%252Bmutation%26aulast%3DLiu%26aufirst%3DJuan%26date%3D2021%26date%3D2020%26volume%3D97%26issue%3D3%26spage%3D649%26epage%3D664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fanyong  Yan</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Sun</span>, <span class="hlFld-ContribAuthor ">Tengchuang  Ma</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yingxia  Jiang</span>, <span class="hlFld-ContribAuthor ">Ruijie  Wang</span>, <span class="hlFld-ContribAuthor ">Cong  Ma</span>, <span class="hlFld-ContribAuthor ">Junfu  Wei</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>, <span class="hlFld-ContribAuthor ">Yali  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">A viscosity-dependent carbon dots with anti-VEGF properties for monitoring and promoting apoptosis in cancerous cell. </span><span class="cited-content_cbyCitation_journal-name">Chemical Engineering Journal</span><span> <strong>2021,</strong> <em>407 </em>, 127801. <a href="https://doi.org/10.1016/j.cej.2020.127801" title="DOI URL">https://doi.org/10.1016/j.cej.2020.127801</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cej.2020.127801&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cej.2020.127801%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Engineering%2520Journal%26atitle%3DA%252Bviscosity-dependent%252Bcarbon%252Bdots%252Bwith%252Banti-VEGF%252Bproperties%252Bfor%252Bmonitoring%252Band%252Bpromoting%252Bapoptosis%252Bin%252Bcancerous%252Bcell%26aulast%3DYan%26aufirst%3DFanyong%26date%3D2021%26volume%3D407%26spage%3D127801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pranav  Gupta</span>, <span class="hlFld-ContribAuthor ">Yunali V.  Ashar</span>, <span class="hlFld-ContribAuthor ">Charles R.  Ashby</span>, <span class="hlFld-ContribAuthor ">Lusheng  Lin</span>, <span class="hlFld-ContribAuthor ">Zhe-Sheng  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">The Oncogenic Protein, Breakpoint Cluster (BCR)-Abelson Kinase (ABL) and Chronic Myelocytic Leukemia (CML): Insight Into the Drug Resistance Mechanisms and Approaches for Targeting BCR-ABL in CML. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,<a href="https://doi.org/10.1016/B978-0-12-820472-6.00047-5" title="DOI URL">https://doi.org/10.1016/B978-0-12-820472-6.00047-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-820472-6.00047-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-820472-6.00047-5%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BOncogenic%252BProtein%25252C%252BBreakpoint%252BCluster%252B%252528BCR%252529-Abelson%252BKinase%252B%252528ABL%252529%252Band%252BChronic%252BMyelocytic%252BLeukemia%252B%252528CML%252529%25253A%252BInsight%252BInto%252Bthe%252BDrug%252BResistance%252BMechanisms%252Band%252BApproaches%252Bfor%252BTargeting%252BBCR-ABL%252Bin%252BCML%26aulast%3DGupta%26aufirst%3DPranav%26date%3D2021%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BBiomedical%252BSciences%26date%3D2021%26volume%3D106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandra  Ammazzalorso</span>, <span class="hlFld-ContribAuthor ">Simone  Carradori</span>, <span class="hlFld-ContribAuthor ">Rosa  Amoroso</span>, <span class="hlFld-ContribAuthor ">Inmaculada Fernández  Fernández</span>. </span><span class="cited-content_cbyCitation_article-title">2-substituted benzothiazoles as antiproliferative agents: Novel insights on structure-activity relationships. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112762. <a href="https://doi.org/10.1016/j.ejmech.2020.112762" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112762</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112762%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D2-substituted%252Bbenzothiazoles%252Bas%252Bantiproliferative%252Bagents%25253A%252BNovel%252Binsights%252Bon%252Bstructure-activity%252Brelationships%26aulast%3DAmmazzalorso%26aufirst%3DAlessandra%26date%3D2020%26volume%3D207%26spage%3D112762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed H.  Abdelazeem</span>, <span class="hlFld-ContribAuthor ">Alaa M.  Alqahtani</span>, <span class="hlFld-ContribAuthor ">Hany A.  Omar</span>, <span class="hlFld-ContribAuthor ">Syed Nasir Abbas  Bukhari</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  Gouda</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, biological evaluation and kinase profiling of novel S-benzo[4,5]thiazolo[2,3-c][1,2,4]triazole derivatives as cytotoxic agents with apoptosis-inducing activity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2020,</strong> <em>1219 </em>, 128567. <a href="https://doi.org/10.1016/j.molstruc.2020.128567" title="DOI URL">https://doi.org/10.1016/j.molstruc.2020.128567</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2020.128567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2020.128567%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DSynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bkinase%252Bprofiling%252Bof%252Bnovel%252BS-benzo%25255B4%25252C5%25255Dthiazolo%25255B2%25252C3-c%25255D%25255B1%25252C2%25252C4%25255Dtriazole%252Bderivatives%252Bas%252Bcytotoxic%252Bagents%252Bwith%252Bapoptosis-inducing%252Bactivity%26aulast%3DAbdelazeem%26aufirst%3DAhmed%2BH.%26date%3D2020%26volume%3D1219%26spage%3D128567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thuraya  Al-Harthy</span>, <span class="hlFld-ContribAuthor ">Wajdi  Zoghaib</span>, <span class="hlFld-ContribAuthor ">Raid  Abdel-Jalil</span>. </span><span class="cited-content_cbyCitation_article-title">Importance of Fluorine in Benzazole Compounds. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (20)
                                     , 4677. <a href="https://doi.org/10.3390/molecules25204677" title="DOI URL">https://doi.org/10.3390/molecules25204677</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25204677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25204677%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DImportance%252Bof%252BFluorine%252Bin%252BBenzazole%252BCompounds%26aulast%3DAl-Harthy%26aufirst%3DThuraya%26date%3D2020%26date%3D2020%26volume%3D25%26issue%3D20%26spage%3D4677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fiona  Scott</span>, <span class="hlFld-ContribAuthor ">Angela M.  Fala</span>, <span class="hlFld-ContribAuthor ">Lewis E.  Pennicott</span>, <span class="hlFld-ContribAuthor ">Tristan D.  Reuillon</span>, <span class="hlFld-ContribAuthor ">Katlin B.  Massirer</span>, <span class="hlFld-ContribAuthor ">Jonathan M.  Elkins</span>, <span class="hlFld-ContribAuthor ">Simon E.  Ward</span>. </span><span class="cited-content_cbyCitation_article-title">Development of 2-(4-pyridyl)-benzimidazoles as PKN2 chemical tools to probe cancer. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>30 </em>
                                    (8)
                                     , 127040. <a href="https://doi.org/10.1016/j.bmcl.2020.127040" title="DOI URL">https://doi.org/10.1016/j.bmcl.2020.127040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2020.127040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2020.127040%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDevelopment%252Bof%252B2-%2525284-pyridyl%252529-benzimidazoles%252Bas%252BPKN2%252Bchemical%252Btools%252Bto%252Bprobe%252Bcancer%26aulast%3DScott%26aufirst%3DFiona%26date%3D2020%26volume%3D30%26issue%3D8%26spage%3D127040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yousef  Najajreh</span>. </span><span class="cited-content_cbyCitation_article-title">Benzimidazoles: From Antiproliferative to Multitargeted Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,<a href="https://doi.org/10.5772/intechopen.86249" title="DOI URL">https://doi.org/10.5772/intechopen.86249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5772/intechopen.86249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5772%2Fintechopen.86249%26sid%3Dliteratum%253Aachs%26atitle%3DBenzimidazoles%25253A%252BFrom%252BAntiproliferative%252Bto%252BMultitargeted%252BAnticancer%252BAgents%26aulast%3DNajajreh%26aufirst%3DYousef%26date%3D2019%26date%3D2019%26pub%3DIntechOpen%26atitle%3DChemistry%252Band%252BApplications%252Bof%252BBenzimidazole%252Band%252Bits%252BDerivatives%26aulast%3DMarinescu%26aufirst%3DMaria%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rupesh  Chikhale</span>, <span class="hlFld-ContribAuthor ">Sonali  Thorat</span>, <span class="hlFld-ContribAuthor ">Rajan Kumar  Choudhary</span>, <span class="hlFld-ContribAuthor ">Nikhil  Gadewal</span>, <span class="hlFld-ContribAuthor ">Pramod  Khedekar</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and anticancer studies of novel aminobenzazolyl pyrimidines as tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2018,</strong> <em>77 </em>, 84-100. <a href="https://doi.org/10.1016/j.bioorg.2018.01.008" title="DOI URL">https://doi.org/10.1016/j.bioorg.2018.01.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2018.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2018.01.008%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Banticancer%252Bstudies%252Bof%252Bnovel%252Baminobenzazolyl%252Bpyrimidines%252Bas%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DChikhale%26aufirst%3DRupesh%26date%3D2018%26volume%3D77%26spage%3D84%26epage%3D100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eder João  Lenardão</span>, <span class="hlFld-ContribAuthor ">Claudio  Santi</span>, <span class="hlFld-ContribAuthor ">Luca  Sancineto</span>. </span><span class="cited-content_cbyCitation_article-title">Nonbonded Interaction: The Chalcogen Bond. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 157-183. <a href="https://doi.org/10.1007/978-3-319-92405-2_4" title="DOI URL">https://doi.org/10.1007/978-3-319-92405-2_4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-92405-2_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-92405-2_4%26sid%3Dliteratum%253Aachs%26atitle%3DNonbonded%252BInteraction%25253A%252BThe%252BChalcogen%252BBond%26aulast%3DLenard%25C3%25A3o%26aufirst%3DEder%2BJo%25C3%25A3o%26date%3D2018%26date%3D2018%26spage%3D157%26epage%3D183%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DNew%252BFrontiers%252Bin%252BOrganoselenium%252BCompounds%26aulast%3DLenard%25C3%25A3o%26aufirst%3DEder%2BJo%25C3%25A3o%26date%3D2018%26volume%3D49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-cong  Lin</span>, <span class="hlFld-ContribAuthor ">She-pei  Tan</span>, <span class="hlFld-ContribAuthor ">Sheng-fu  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiao-jie  Zheng</span>, <span class="hlFld-ContribAuthor ">Wen-juan  Wu</span>, <span class="hlFld-ContribAuthor ">Kang-cheng  Zheng</span>. </span><span class="cited-content_cbyCitation_article-title">Binding Mechanism and Molecular Design of Benzimidazole/Benzothiazole Derivatives as Potent Abl T315I Mutant Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chinese Journal of Chemical Physics</span><span> <strong>2017,</strong> <em>30 </em>
                                    (4)
                                     , 429-442. <a href="https://doi.org/10.1063/1674-0068/30/cjcp1704066" title="DOI URL">https://doi.org/10.1063/1674-0068/30/cjcp1704066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1063/1674-0068/30/cjcp1704066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1063%2F1674-0068%2F30%2Fcjcp1704066%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Journal%2520of%2520Chemical%2520Physics%26atitle%3DBinding%252BMechanism%252Band%252BMolecular%252BDesign%252Bof%252BBenzimidazole%25252FBenzothiazole%252BDerivatives%252Bas%252BPotent%252BAbl%252BT315I%252BMutant%252BInhibitors%26aulast%3DLin%26aufirst%3DWei-cong%26date%3D2017%26volume%3D30%26issue%3D4%26spage%3D429%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">A Synopsis of the Properties and Applications of Heteroaromatic Rings in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 245-361. <a href="https://doi.org/10.1016/bs.aihch.2016.11.002" title="DOI URL">https://doi.org/10.1016/bs.aihch.2016.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2016.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2016.11.002%26sid%3Dliteratum%253Aachs%26atitle%3DA%252BSynopsis%252Bof%252Bthe%252BProperties%252Band%252BApplications%252Bof%252BHeteroaromatic%252BRings%252Bin%252BMedicinal%252BChemistry%26aulast%3DMeanwell%26aufirst%3DN.A.%26date%3D2017%26spage%3D245%26epage%3D361%26pub%3DElsevier%26date%3D2017%26volume%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinhee  Kim</span>, <span class="hlFld-ContribAuthor ">Yonghoon  Moon</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of lead small molecule inhibitors of glycogen synthase kinase-3 beta using a fragment-linking strategy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (23)
                                     , 5669-5673. <a href="https://doi.org/10.1016/j.bmcl.2016.10.060" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.10.060</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.10.060&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.10.060%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Bof%252Blead%252Bsmall%252Bmolecule%252Binhibitors%252Bof%252Bglycogen%252Bsynthase%252Bkinase-3%252Bbeta%252Busing%252Ba%252Bfragment-linking%252Bstrategy%26aulast%3DKim%26aufirst%3DJinhee%26date%3D2016%26volume%3D26%26issue%3D23%26spage%3D5669%26epage%3D5673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashraf Kareem  El-Damasy</span>, <span class="hlFld-ContribAuthor ">Ju-Hyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Seon Hee  Seo</span>, <span class="hlFld-ContribAuthor ">Nam-Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-RafV600E and C-Raf kinase inhibitory activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>115 </em>, 201-216. <a href="https://doi.org/10.1016/j.ejmech.2016.02.039" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.02.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.02.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.02.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnew%252Bpotent%252Banticancer%252Bbenzothiazole%252Bamides%252Band%252Bureas%252Bfeaturing%252Bpyridylamide%252Bmoiety%252Band%252Bpossessing%252Bdual%252BB-RafV600E%252Band%252BC-Raf%252Bkinase%252Binhibitory%252Bactivities%26aulast%3DEl-Damasy%26aufirst%3DAshraf%2BKareem%26date%3D2016%26volume%3D115%26spage%3D201%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammed  Al-Ghorbani</span>, <span class="hlFld-ContribAuthor ">G.S.  Pavankumar</span>, <span class="hlFld-ContribAuthor ">P.  Naveen</span>, <span class="hlFld-ContribAuthor ">Prabhu  Thirusangu</span>, <span class="hlFld-ContribAuthor ">B.T.  Prabhakar</span>, <span class="hlFld-ContribAuthor ">Shaukath Ara  Khanum</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and an angiolytic role of novel piperazine–benzothiazole analogues on neovascularization, a chief tumoral parameter in neoplastic development. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2016,</strong> <em>65 </em>, 110-117. <a href="https://doi.org/10.1016/j.bioorg.2016.02.006" title="DOI URL">https://doi.org/10.1016/j.bioorg.2016.02.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2016.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2016.02.006%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Band%252Ban%252Bangiolytic%252Brole%252Bof%252Bnovel%252Bpiperazine%2525E2%252580%252593benzothiazole%252Banalogues%252Bon%252Bneovascularization%25252C%252Ba%252Bchief%252Btumoral%252Bparameter%252Bin%252Bneoplastic%252Bdevelopment%26aulast%3DAl-Ghorbani%26aufirst%3DMohammed%26date%3D2016%26volume%3D65%26spage%3D110%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao-Xiao  Xie</span>, <span class="hlFld-ContribAuthor ">Huan  Li</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Shuai  Mao</span>, <span class="hlFld-ContribAuthor ">Min-Hang  Xin</span>, <span class="hlFld-ContribAuthor ">She-Min  Lu</span>, <span class="hlFld-ContribAuthor ">Qi-Bing  Mei</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and anticancer effects evaluation of 1-alkyl-3-(6-(2-methoxy-3-sulfonylaminopyridin-5-yl)benzo[d]thiazol-2-yl)urea as anticancer agents with low toxicity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (19)
                                     , 6477-6485. <a href="https://doi.org/10.1016/j.bmc.2015.08.013" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.08.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.08.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Banticancer%252Beffects%252Bevaluation%252Bof%252B1-alkyl-3-%2525286-%2525282-methoxy-3-sulfonylaminopyridin-5-yl%252529benzo%25255Bd%25255Dthiazol-2-yl%252529urea%252Bas%252Banticancer%252Bagents%252Bwith%252Blow%252Btoxicity%26aulast%3DXie%26aufirst%3DXiao-Xiao%26date%3D2015%26volume%3D23%26issue%3D19%26spage%3D6477%26epage%3D6485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashraf Kareem  El-Damasy</span>, <span class="hlFld-ContribAuthor ">Nam-Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Soon Bang  Kang</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">ABL kinase inhibitory and antiproliferative activity of novel picolinamide based benzothiazoles. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (10)
                                     , 2162-2168. <a href="https://doi.org/10.1016/j.bmcl.2015.03.067" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.03.067</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.03.067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.03.067%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DABL%252Bkinase%252Binhibitory%252Band%252Bantiproliferative%252Bactivity%252Bof%252Bnovel%252Bpicolinamide%252Bbased%252Bbenzothiazoles%26aulast%3DEl-Damasy%26aufirst%3DAshraf%2BKareem%26date%3D2015%26volume%3D25%26issue%3D10%26spage%3D2162%26epage%3D2168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Malik A.  Waseem</span>, <span class="hlFld-ContribAuthor ">Shireen</span>, <span class="hlFld-ContribAuthor ">Arjita  Srivastava</span>, <span class="hlFld-ContribAuthor ">Anjali  Srivastava</span>, <span class="hlFld-ContribAuthor ">Rahila</span>, <span class="hlFld-ContribAuthor ">I.R.  Siddiqui</span>. </span><span class="cited-content_cbyCitation_article-title">Water and ionic liquid synergy: A novel approach for the synthesis of benzothiazole-2(3H)-one. </span><span class="cited-content_cbyCitation_journal-name">Journal of Saudi Chemical Society</span><span> <strong>2015,</strong> <em>19 </em>
                                    (3)
                                     , 334-339. <a href="https://doi.org/10.1016/j.jscs.2014.05.006" title="DOI URL">https://doi.org/10.1016/j.jscs.2014.05.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jscs.2014.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jscs.2014.05.006%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Saudi%2520Chemical%2520Society%26atitle%3DWater%252Band%252Bionic%252Bliquid%252Bsynergy%25253A%252BA%252Bnovel%252Bapproach%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bbenzothiazole-2%2525283H%252529-one%26aulast%3DWaseem%26aufirst%3DMalik%2BA.%26date%3D2015%26volume%3D19%26issue%3D3%26spage%3D334%26epage%3D339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Soo Jung  Kim</span>, <span class="hlFld-ContribAuthor ">Kyung Hee  Jung</span>, <span class="hlFld-ContribAuthor ">Hong Hua  Yan</span>, <span class="hlFld-ContribAuthor ">Mi Kwon  Son</span>, <span class="hlFld-ContribAuthor ">Zhenghuan  Fang</span>, <span class="hlFld-ContribAuthor ">Ye-Lim  Ryu</span>, <span class="hlFld-ContribAuthor ">Hyunseung  Lee</span>, <span class="hlFld-ContribAuthor ">Joo Han  Lim</span>, <span class="hlFld-ContribAuthor ">Jun-Kyu  Suh</span>, <span class="hlFld-ContribAuthor ">JinHee  Kim</span>, <span class="hlFld-ContribAuthor ">Soyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>, <span class="hlFld-ContribAuthor ">Soon-Sun  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2015,</strong> <em>6 </em>
                                    (3)
                                     , 1507-1518. <a href="https://doi.org/10.18632/oncotarget.2837" title="DOI URL">https://doi.org/10.18632/oncotarget.2837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.2837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.2837%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DHS-543%252Binduces%252Bapoptosis%252Bof%252BImatinib-resistant%252Bchronic%252Bmyelogenous%252Bleukemia%252Bwith%252BT315I%252Bmutation%26aulast%3DKim%26aufirst%3DSoo%2BJung%26date%3D2015%26date%3D2014%26volume%3D6%26issue%3D3%26spage%3D1507%26epage%3D1518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rangappa S.  Keri</span>, <span class="hlFld-ContribAuthor ">Mahadeo R.  Patil</span>, <span class="hlFld-ContribAuthor ">Siddappa A.  Patil</span>, <span class="hlFld-ContribAuthor ">Srinivasa  Budagumpi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>89 </em>, 207-251. <a href="https://doi.org/10.1016/j.ejmech.2014.10.059" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.10.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.10.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.10.059%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Breview%252Bin%252Bcurrent%252Bdevelopments%252Bof%252Bbenzothiazole-based%252Bmolecules%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DKeri%26aufirst%3DRangappa%2BS.%26date%3D2015%26volume%3D89%26spage%3D207%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huan  Li</span>, <span class="hlFld-ContribAuthor ">Xiao-Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Teng  Shao</span>, <span class="hlFld-ContribAuthor ">Yi-Ping  Li</span>, <span class="hlFld-ContribAuthor ">Qi-Bing  Mei</span>, <span class="hlFld-ContribAuthor ">She-Min  Lu</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Combination of 2-methoxy-3-phenylsulfonylaminobenzamide and 2-aminobenzothiazole to discover novel anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2014,</strong> <em>22 </em>
                                    (14)
                                     , 3739-3748. <a href="https://doi.org/10.1016/j.bmc.2014.04.064" title="DOI URL">https://doi.org/10.1016/j.bmc.2014.04.064</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2014.04.064&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2014.04.064%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DCombination%252Bof%252B2-methoxy-3-phenylsulfonylaminobenzamide%252Band%252B2-aminobenzothiazole%252Bto%252Bdiscover%252Bnovel%252Banticancer%252Bagents%26aulast%3DLi%26aufirst%3DHuan%26date%3D2014%26volume%3D22%26issue%3D14%26spage%3D3739%26epage%3D3748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sun-Mi  Yun</span>, <span class="hlFld-ContribAuthor ">Kyung Hee  Jung</span>, <span class="hlFld-ContribAuthor ">Soo Jung  Kim</span>, <span class="hlFld-ContribAuthor ">Zhenghuan  Fang</span>, <span class="hlFld-ContribAuthor ">Mi Kwon  Son</span>, <span class="hlFld-ContribAuthor ">Hong Hua  Yan</span>, <span class="hlFld-ContribAuthor ">Hyunseung  Lee</span>, <span class="hlFld-ContribAuthor ">JinHee  Kim</span>, <span class="hlFld-ContribAuthor ">Sanghye  Shin</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>, <span class="hlFld-ContribAuthor ">Soon-Sun  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2014,</strong> <em>348 </em>
                                    (1-2)
                                     , 50-60. <a href="https://doi.org/10.1016/j.canlet.2014.03.012" title="DOI URL">https://doi.org/10.1016/j.canlet.2014.03.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2014.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2014.03.012%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DHS-438%25252C%252Ba%252Bnew%252Binhibitor%252Bof%252BImatinib-resistant%252BBCR-ABL%252BT315I%252Bmutation%252Bin%252Bchronic%252Bmyeloid%252Bleukemia%26aulast%3DYun%26aufirst%3DSun-Mi%26date%3D2014%26volume%3D348%26issue%3D1-2%26spage%3D50%26epage%3D60" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xilei  Xie</span>, <span class="hlFld-ContribAuthor ">Yu  Yan</span>, <span class="hlFld-ContribAuthor ">Ning  Zhu</span>, <span class="hlFld-ContribAuthor ">Gang  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Benzothiazoles exhibit broad-spectrum antitumor activity: Their potency, structure–activity and structure–metabolism relationships. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>76 </em>, 67-78. <a href="https://doi.org/10.1016/j.ejmech.2014.02.007" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.02.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.02.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.02.007%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBenzothiazoles%252Bexhibit%252Bbroad-spectrum%252Bantitumor%252Bactivity%25253A%252BTheir%252Bpotency%25252C%252Bstructure%2525E2%252580%252593activity%252Band%252Bstructure%2525E2%252580%252593metabolism%252Brelationships%26aulast%3DXie%26aufirst%3DXilei%26date%3D2014%26volume%3D76%26spage%3D67%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyeonjeong  Choe</span>, <span class="hlFld-ContribAuthor ">Jieun  Kim</span>, <span class="hlFld-ContribAuthor ">Sungwoo  Hong</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design of flavone-based inhibitors of wild-type and T315I mutant of ABL. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (15)
                                     , 4324-4327. <a href="https://doi.org/10.1016/j.bmcl.2013.05.095" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.05.095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.05.095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.05.095%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DStructure-based%252Bdesign%252Bof%252Bflavone-based%252Binhibitors%252Bof%252Bwild-type%252Band%252BT315I%252Bmutant%252Bof%252BABL%26aulast%3DChoe%26aufirst%3DHyeonjeong%26date%3D2013%26volume%3D23%26issue%3D15%26spage%3D4324%26epage%3D4327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0015.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structure of nocodazole.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) Predicted binding mode of nocodazole with Abl. (b) Predicted binding mode of nocodazole with Abl<sup>T315I</sup>. Carbon atoms of nocodazole are shown in pink. (c) Predicted binding mode of imatinib with Abl<sup>T315I</sup>. Each dotted line represents a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) The overall process for deriving the lead from nocodazole. (b) Predicted binding mode of compound <b>2</b> with Abl<sup>T315I</sup>. Carbon atoms of compound <b>2</b> are indicated in pink. (c) The simplified binding mode of compound <b>2</b> with the ATP binding site of Abl<sup>T315I</sup>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Arylboronic acid, Pd(dppf)Cl<sub>2</sub><b>·</b>CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O = 3:1, 100 °C, microwave, 90 min; (b) <i>N</i>,<i>N</i>′-bis[(ethylamino)carbonyl] carbamimidothioic acid methyl ester, H<sub>2</sub>O/AcOH = 10:3, 110 °C, 5 h.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Arylboronic acid, Pd(dppf)Cl<sub>2</sub><b>·</b>CH<sub>2</sub>Cl<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O = 3:1, 120 °C, microwave, 90 min; (b) alkyl-isocyanate, 1,4-dioxane, 80 °C, 5 h; (c) carbodiimidazole, R-NH<sub>2</sub>, DMF, rt, 10 h.</p></p></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) Predicted binding mode of <b>9a</b> with the ATP-binding site of Abl<sup>T315I</sup>. Carbon atoms of the protein and the ligand are indicated in gray and cyan, respectively. (b) Predicted binding mode of <b>5h</b> with the ATP-binding site of Abl<sup>T315I</sup>. Carbon atoms of the protein and the ligand are indicated in gray and green, respectively. Each dotted line represents a hydrogen bond.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/medium/jm-2012-01891t_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Western blot showing the inhibition of Bcr-Abl signaling in Ba/F3 cells expressing wild-type Bcr-Abl (left panel) or Bcr-Abl T315I (right panel). Cells were treated with 1 μM of imatinib, dasatinib, <b>10b</b>, and <b>10d</b>, incubated 37 °C for 1 h.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-9/jm301891t/production/images/large/jm-2012-01891t_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm301891t&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i82">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 18 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Molecular biology of bcr-abl1-positive chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x">, </span> <span class="NLM_fpage">1619</span><span class="NLM_x">–</span> <span class="NLM_lpage">1630</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1182%2Fblood-2008-03-144790" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=18827185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisV2iurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2009&pages=1619-1630&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Molecular+biology+of+bcr-abl1-positive+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular biology of bcr-abl1-positive chronic myeloid leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1619-1630</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">A review.  Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a malignancy defined by a unique mol. event, the BCR-ABL1 oncogene.  Decades of research zeroing in on the role of BCR-ABL1 kinase in the pathogenesis of CML have culminated in the development of highly efficacious therapeutics that, like imatinib mesylate, target the oncogenic kinase activity of BCR-ABL1.  In recent years, most research efforts in CML have been devoted to developing novel tyrosine kinase inhibitors (TKIs) as well as to elucidating the mechanisms of resistance to imatinib and other TKIs.  Nonetheless, primordial aspects of the pathogenesis of CML, such as the mechanisms responsible for the transition from chronic phase to blast crisis, the causes of genomic instability and faulty DNA repair, the phenomenon of stem cell quiescence, the role of tumor suppressors in TKI resistance and CML progression, or the cross-talk between BCR-ABL1 and other oncogenic signaling pathways, still remain poorly understood.  Herein, the authors synthesize the most relevant and current knowledge on such areas of the pathogenesis of CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsPO2wdma5UrVg90H21EOLACvtfcHk0lh6VSbvc0ilLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisV2iurs%253D&md5=bcd7d53c3e06d3b9833fb84799f75ea7</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1182%2Fblood-2008-03-144790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2008-03-144790%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DMolecular%2520biology%2520of%2520bcr-abl1-positive%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2009%26volume%3D113%26spage%3D1619%26epage%3D1630" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Faderl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span> </span><span class="NLM_article-title">Chronic myelogenous leukemia: Update on biology and treatment</span> <span class="citation_source-journal">Oncology (Williston Park, N.Y.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">184</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=10079468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A280%3ADyaK1M7nvFWrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1999&pages=169-184&author=S.+Faderlauthor=H.+M.+Kantarjianauthor=M.+Talpaz&title=Chronic+myelogenous+leukemia%3A+Update+on+biology+and+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic myelogenous leukemia: update on biology and treatment</span></div><div class="casAuthors">Faderl S; Kantarjian H M; Talpaz M</div><div class="citationInfo"><span class="NLM_cas:title">Oncology (Williston Park, N.Y.)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-80; discussion 181, 184</span>
        ISSN:<span class="NLM_cas:issn">0890-9091</span>.
    </div><div class="casAbstract">Chronic myelogenous leukemia (CML) is a myeloproliferative disorder that follows a characteristic clinical course in which a chronic phase of variable duration precedes an accelerated, and ultimately blastic, phase, which is generally fatal.  This disorder results from a clonal expansion of transformed hematopoietic progenitor cells and includes myeloid, monocytic, erythroid, megakaryocytic, and lymphoid lineages.  At the molecular level, CML is characterized by the bcr-abl fusion gene, which results from the reciprocal translocation t(9;22)(q34;q11), creating the Philadelphia (Ph) chromosome.  Chronic myelogenous leukemia was the first human disease for which a specific karyotype abnormality was demonstrated and could be linked to pathogenetic events of leukemogenesis.  The outlook for patients with CML has changed dramatically over the last decade.  The median survival time of patients has doubled to 5 to 7 years, with up to 50% of patients alive at 5 years.  This development is due to refinements in allogeneic stem-cell transplantation and growing expertise in the use of interferon-alfa (Intron A, Roferon-A), a biological agent that has been shown to suppress the leukemic clone and to prolong survival in patients with CML.  This review provides a concise update of the biology of CML, as well as current therapeutic options and management strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSi1tF-wuzZwTEwO064Z95rfW6udTcc2ebpTYvyg0_wAbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1M7nvFWrtw%253D%253D&md5=410df90075242ef7aaa45435dce844bd</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFaderl%26aufirst%3DS.%26aulast%3DKantarjian%26aufirst%3DH.%2BM.%26aulast%3DTalpaz%26aufirst%3DM.%26atitle%3DChronic%2520myelogenous%2520leukemia%253A%2520Update%2520on%2520biology%2520and%2520treatment%26jtitle%3DOncology%2520%2528Williston%2520Park%252C%2520N.Y.%2529%26date%3D1999%26volume%3D13%26spage%3D169%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span> </span><span class="NLM_article-title">The interplay of structural information and functional studies in kinase drug design: Insights from BCR-Abl</span> <span class="citation_source-journal">Curr. Opin. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">288</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1016%2Fj.ceb.2009.01.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=19217274" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksVCksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2009&pages=288-295&author=M.+J.+Eckauthor=P.+W.+Manley&title=The+interplay+of+structural+information+and+functional+studies+in+kinase+drug+design%3A+Insights+from+BCR-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl</span></div><div class="casAuthors">Eck, Michael J.; Manley, Paul W.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">288-295</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  As an inhibitor of the tyrosine kinase activity of the BCR-Abl oncoprotein, imatinib sets a new paradigm for the treatment of cancer with molecularly targeted therapies.  Subsequent structural studies have provided in depth knowledge of how this antileukemia drug interacts with the catalytic site of the enzyme and allowed the rationalization of mechanisms of drug-resistance which can lead to patient relapse.  This understanding has facilitated the design of new inhibitors of BCR-Abl, as well as the discovery of inhibitors of many other kinases.  As structural information accumulates for more of the 518 kinases encoded within the human genome, the design of many more highly selective, well-tolerated kinase inhibitors should be possible.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ43L3RP84a7Vg90H21EOLACvtfcHk0lh6VSbvc0ilLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksVCksrw%253D&md5=7de62ae82b301ea5cd10575a8e98701c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2009.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2009.01.014%26sid%3Dliteratum%253Aachs%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DManley%26aufirst%3DP.%2BW.%26atitle%3DThe%2520interplay%2520of%2520structural%2520information%2520and%2520functional%2520studies%2520in%2520kinase%2520drug%2520design%253A%2520Insights%2520from%2520BCR-Abl%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2009%26volume%3D21%26spage%3D288%26epage%3D295" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">503</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-503&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28STI571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lhPsi2gJ83itg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528STI571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D503" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talpaz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Resta, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lydon, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohno Jones, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Efficacy and safety of a specific inhibitor of the BCR ABL tyrosine kinase in chronic myeloid leukemia</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">1031</span><span class="NLM_x">–</span> <span class="NLM_lpage">1037</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1056%2FNEJM200104053441401" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=11287972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivFGnu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2001&pages=1031-1037&author=B.+J.+Drukerauthor=M.+Talpazauthor=D.+J.+Restaauthor=B.+Pengauthor=E.+Buchdungerauthor=J.+M.+Fordauthor=N.+B.+Lydonauthor=H.+Kantarjianauthor=R.+Capdevilleauthor=S.+Ohno+Jonesauthor=C.+L.+Sawyers&title=Efficacy+and+safety+of+a+specific+inhibitor+of+the+BCR+ABL+tyrosine+kinase+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia</span></div><div class="casAuthors">Druker, Brian J.; Talpaz, Moshe; Resta, Debra J.; Peng, Bin; Buchdunger, Elisabeth; Ford, John M.; Lydon, Nicholas B.; Kantarjian, Hagop; Capdeville, Renaud; Ohno-Jones, Sayuri; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">344</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1031-1037</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML).  Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML.  Methods: We conducted a phase 1, dose-escalating trial of STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase.  STI571 was administered orally to 83 patients with CML in the chronic phase in whom treatment with interferon alpha had failed.  Patients were successively assigned to 1 of 14 doses ranging from 25 to 1000 mg per day.  Results: Adverse effects of STI571 were minimal; the most common were nausea, myalgias, edema, and diarrhea.  A maximal tolerated dose was not identified.  Complete hematol. responses were obsd. in 53 of 54 patients treated with daily doses of 300 mg or more and typically occurred in the first four weeks of therapy.  Of the 54 patients treated with doses of 300 mg or more, cytogenetic responses occurred in 29, including 17 (31 percent of the 54 patients who received this dose) with major responses (0 to 35 percent of cells in metaphase pos. for the Philadelphia chromosome); 7 of these patients had complete cytogenetic remissions.  Conclusion: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alpha had failed.  Our results provide evidence of the essential role of BCR-ABL tyrosine kinase activity in CML and demonstrate the potential for the development of anticancer drugs based on the specific mol. abnormality present in a human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrprbDzKoC0ubVg90H21EOLACvtfcHk0lhPsi2gJ83itg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivFGnu70%253D&md5=1554407678838243a753aa056ffd4f7c</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1056%2FNEJM200104053441401&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM200104053441401%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DTalpaz%26aufirst%3DM.%26aulast%3DResta%26aufirst%3DD.%2BJ.%26aulast%3DPeng%26aufirst%3DB.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DLydon%26aufirst%3DN.%2BB.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DOhno%2BJones%26aufirst%3DS.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520a%2520specific%2520inhibitor%2520of%2520the%2520BCR%2520ABL%2520tyrosine%2520kinase%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2001%26volume%3D344%26spage%3D1031%26epage%3D1037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span> </span><span class="NLM_article-title">Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">2242</span><span class="NLM_x">–</span> <span class="NLM_lpage">2249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2007&pages=2242-2249&author=T.+O%E2%80%99Hareauthor=C.+A.+Eideauthor=M.+W.+Deininger&title=Bcr-Abl+kinase+domain+mutations%2C+drug+resistance%2C+and+the+road+to+a+cure+for+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26atitle%3DBcr-Abl%2520kinase%2520domain%2520mutations%252C%2520drug%2520resistance%252C%2520and%2520the%2520road%2520to%2520a%2520cure%2520for%2520chronic%2520myeloid%2520leukemia%26jtitle%3DBlood%26date%3D2007%26volume%3D110%26spage%3D2242%26epage%3D2249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behnia, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castaneda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fairchild, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inigo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peterson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">6658</span><span class="NLM_x">–</span> <span class="NLM_lpage">6661</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049486a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=6658-6661&author=L.+J.+Lombardoauthor=F.+Y.+Leeauthor=P.+Chenauthor=D.+Norrisauthor=J.+C.+Barrishauthor=K.+Behniaauthor=S.+Castanedaauthor=L.+A.+M.+Corneliusauthor=J.+Dasauthor=A.+M.+Doweykoauthor=C.+Fairchildauthor=J.+T.+Huntauthor=I.+Inigoauthor=K.+Johnstonauthor=A.+Kamathauthor=D.+Kanauthor=H.+Kleiauthor=P.+Maratheauthor=S.+Pangauthor=R.+Petersonauthor=S.+Pittauthor=G.+L.+Schievenauthor=R.+J.+Schmidtauthor=J.+Tokarskiauthor=M.+L.+Wenauthor=J.+Wityakauthor=R.+M.+Borzilleri&title=Discovery+of+N-%282-chloro-6-methyl-phenyl%29-2-%286-%284-%282-hydroxyethyl%29-piperazin-1-yl%29-2-methylpyrimidin-4-ylamino%29thiazole-5-carboxamide+%28BMS-354825%29%2C+a+dual+Src%2FAbl+kinase+inhibitor+with+potent+antitumor+activity+in+preclinical+assays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=10.1021%2Fjm049486a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049486a%26sid%3Dliteratum%253Aachs%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DNorris%26aufirst%3DD.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DBehnia%26aufirst%3DK.%26aulast%3DCastaneda%26aufirst%3DS.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%2BM.%26aulast%3DDas%26aufirst%3DJ.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DFairchild%26aufirst%3DC.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DInigo%26aufirst%3DI.%26aulast%3DJohnston%26aufirst%3DK.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKan%26aufirst%3DD.%26aulast%3DKlei%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DPang%26aufirst%3DS.%26aulast%3DPeterson%26aufirst%3DR.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DTokarski%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DM.%2BL.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25282-chloro-6-methyl-phenyl%2529-2-%25286-%25284-%25282-hydroxyethyl%2529-piperazin-1-yl%2529-2-methylpyrimidin-4-ylamino%2529thiazole-5-carboxamide%2520%2528BMS-354825%2529%252C%2520a%2520dual%2520Src%252FAbl%2520kinase%2520inhibitor%2520with%2520potent%2520antitumor%2520activity%2520in%2520preclinical%2520assays%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D6658%26epage%3D6661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenstein, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brüggen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huntly, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fendrich, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall-Meyers, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daley, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callahan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catley, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavazza, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neuberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">141</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1016%2Fj.ccr.2005.01.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=15710326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5b&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=129-141&author=E.+Weisbergauthor=P.+W.+Manleyauthor=W.+Breitensteinauthor=J.+Br%C3%BCggenauthor=S.+W.+Cowan-Jacobauthor=A.+Rayauthor=B.+Huntlyauthor=D.+Fabbroauthor=G.+Fendrichauthor=E.+Hall-Meyersauthor=A.+L.+Kungauthor=J.+Mestanauthor=G.+Q.+Daleyauthor=L.+Callahanauthor=L.+Catleyauthor=C.+Cavazzaauthor=M.+Azamauthor=D.+Neubergauthor=R.+D.+Wrightauthor=D.+G.+Gillilandauthor=J.+D.+Griffin&title=Characterization+of+AMN107%2C+a+selective+inhibitor+of+native+and+mutant+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5bR"><div class="casContent"><span class="casTitleNuber">5b</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl</span></div><div class="casAuthors">Weisberg, Ellen; Manley, Paul W.; Breitenstein, Werner; Brueggen, Josef; Cowan-Jacob, Sandra W.; Ray, Arghya; Huntly, Brian; Fabbro, Doriano; Fendrich, Gabriele; Hall-Meyers, Elizabeth; Kung, Andrew L.; Mestan, Juergen; Daley, George Q.; Callahan, Linda; Catley, Laurie; Cavazza, Cara; Mohammed, Azam; Neuberg, Donna; Wright, Renee D.; Gilliland, D. Gary; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-141</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-pos. (Ph+) acute lymphoblastic leukemia (ALL).  We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 < 30 nM), which is significantly more potent than imatinib, and active against a no. of imatinib-resistant Bcr-Abl mutants.  Crystallog. anal. of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl.  Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models.  AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGow6QF3qX2uO7Vg90H21EOLACvtfcHk0lit0B3APhx31g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitFygu7o%253D&md5=d28e1a54b982951f8d3e6ef1d2d3b2eb</span></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.01.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.01.007%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DBreitenstein%26aufirst%3DW.%26aulast%3DBr%25C3%25BCggen%26aufirst%3DJ.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DHuntly%26aufirst%3DB.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DFendrich%26aufirst%3DG.%26aulast%3DHall-Meyers%26aufirst%3DE.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DDaley%26aufirst%3DG.%2BQ.%26aulast%3DCallahan%26aufirst%3DL.%26aulast%3DCatley%26aufirst%3DL.%26aulast%3DCavazza%26aufirst%3DC.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DNeuberg%26aufirst%3DD.%26aulast%3DWright%26aufirst%3DR.%2BD.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DCharacterization%2520of%2520AMN107%252C%2520a%2520selective%2520inhibitor%2520of%2520native%2520and%2520mutant%2520Bcr-Abl%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D129%26epage%3D141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Boschelli, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaczko, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tischler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arndt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etienne, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grod, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boschelli, F.</span><span> </span><span class="NLM_article-title">Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">3965</span><span class="NLM_x">–</span> <span class="NLM_lpage">3977</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0102250" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref5/cit5c&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=3965-3977&author=D.+H.+Boschelliauthor=F.+Yeauthor=Y.+D.+Wangauthor=M.+Dutiaauthor=S.+L.+Johnsonauthor=B.+Wuauthor=K.+Millerauthor=D.+W.+Powellauthor=D.+Yaczkoauthor=M.+Youngauthor=M.+Tischlerauthor=K.+Arndtauthor=C.+Discafaniauthor=C.+Etienneauthor=J.+Gibbonsauthor=J.+Grodauthor=J.+Lucasauthor=J.+M.+Weberauthor=F.+Boschelli&title=Optimization+of+4-phenylamino-3-quinolinecarbonitriles+as+potent+inhibitors+of+Src+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5cR"><div class="casContent"><span class="casTitleNuber">5c</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity</span></div><div class="casAuthors">Boschelli, Diane H.; Ye, Fei; Wang, Yanong D.; Dutia, Minu; Johnson, Steve L.; Wu, Biqi; Miller, Karen; Powell, Dennis W.; Yaczko, Deanna; Young, Mairead; Tischler, Mark; Arndt, Kim; Discafani, Carolyn; Etienne, Carlo; Gibbons, Jay; Grod, Janet; Lucas, Judy; Weber, Jennifer M.; Boschelli, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">3965-3977</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Subsequent to the discovery of 4-[(2,4-dichlorophenyl)amino]-6,7-dimethoxy-3-quinolinecarbonitrile as an inhibitor of Src kinase activity (IC50 = 30 nM), several addnl. analogs were prepd.  Optimization of the C-4 anilino group led to I [R = Me].  Replacement of the methoxy group at C-7 with a 3-(morpholin-4-yl)propoxy group provided I [R = morpholinopropyl], resulting in increased inhibition of both Src kinase activity and Src-mediated cell proliferation.  Analogs of I [R = morpholinopropyl] with other trisubstituted anilines at C-4 were also potent Src inhibitors, and the propoxy group was preferred over ethoxy, butoxy, or pentoxy.  Replacement of the morpholine group with a 4-methylpiperazine group provided I [R = 4-methylpiperazinopropyl], which had an IC50 of 1.2 nM in the Src enzymic assay, an IC50 of 100 nM for the inhibition of Src-dependent cell proliferation and was selective for Src over non-Src family kinases.  I [R = 4-methylpiperazinopropyl], which had higher 1 and 4 h plasma levels than I [R = 4-morpholinopropyl], effectively inhibited tumor growth in xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIfrD66BPWqrVg90H21EOLACvtfcHk0lit0B3APhx31g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXnsFyhsrk%253D&md5=88c2d8aa690b9aedbff034682aa3d73e</span></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=10.1021%2Fjm0102250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0102250%26sid%3Dliteratum%253Aachs%26aulast%3DBoschelli%26aufirst%3DD.%2BH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%2BD.%26aulast%3DDutia%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DS.%2BL.%26aulast%3DWu%26aufirst%3DB.%26aulast%3DMiller%26aufirst%3DK.%26aulast%3DPowell%26aufirst%3DD.%2BW.%26aulast%3DYaczko%26aufirst%3DD.%26aulast%3DYoung%26aufirst%3DM.%26aulast%3DTischler%26aufirst%3DM.%26aulast%3DArndt%26aufirst%3DK.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DEtienne%26aufirst%3DC.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DGrod%26aufirst%3DJ.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DWeber%26aufirst%3DJ.%2BM.%26aulast%3DBoschelli%26aufirst%3DF.%26atitle%3DOptimization%2520of%25204-phenylamino-3-quinolinecarbonitriles%2520as%2520potent%2520inhibitors%2520of%2520Src%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D3965%26epage%3D3977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span> </span><span class="NLM_article-title">Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">1754</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">13</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1754&publication_year=2005&pages=3-13&author=P.+W.+Manleyauthor=S.+W.+Cowan-Jacobauthor=J.+Mestan&title=Advances+in+the+structural+biology%2C+design+and+clinical+development+of+Bcr-Abl+kinase+inhibitors+for+the+treatment+of+chronic+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26atitle%3DAdvances%2520in%2520the%2520structural%2520biology%252C%2520design%2520and%2520clinical%2520development%2520of%2520Bcr-Abl%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520chronic%2520myeloid%2520leukaemia%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2005%26volume%3D1754%26spage%3D3%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Jabbour, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantarjian, H.</span><span> </span><span class="NLM_article-title">Treatment selection after imatinib resistance in chronic myeloid leukemia</span> <span class="citation_source-journal">Target Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1007%2Fs11523-008-0100-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A280%3ADC%252BD1M3ls1ShsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2009&pages=3-10&author=E.+Jabbourauthor=J.+Cortesauthor=H.+Kantarjian&title=Treatment+selection+after+imatinib+resistance+in+chronic+myeloid+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment selection after imatinib resistance in chronic myeloid leukemia</span></div><div class="casAuthors">Jabbour Elias; Cortes Jorge; Kantarjian Hagop</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-10</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chronic myeloid leukemia (CML) is a progressive and often fatal malignancy of the blood.  The harbinger of CML is a chromosomal translocation that results in the synthesis of the BCR-ABL fusion protein, a constitutively active tyrosine kinase.  The advent of imatinib, an inhibitor targeted specifically for BCR-ABL, represented a significant medical advance in CML therapy.  However, patients with CML can exhibit varying responses to first-line treatment with imatinib.  While most patients respond to treatment, some may experience a loss of response or require treatment discontinuation due to toxicity.  Frequent monitoring for resistance or intolerance is a requirement for recognition of suboptimal response.  Mutational analysis of the patient's BCR-ABL alleles is also informative and may be predictive of a response to therapy.  Published physician guidelines have highlighted these recommendations, but it is not clear if these guidelines are universally followed.  One option in patients showing poor response to standard-dose imatinib of 400 mg is to escalate the dose.  However, this option should be reserved for patients with minimal disease burden.  Clinically available options mainly include second-generation tyrosine kinase inhibitors, such as dasatinib and nilotinib.  Allogenic stem cell transplantations (for eligible patients) also should be considered.  The disease and patient characteristics at the time of imatinib failure should be evaluated before choosing second-line therapy to optimize the therapeutic benefit without unnecessary delay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRWQ8OirUTX9q_dlEzl_fBafW6udTcc2eanqJTYssKqm7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3ls1ShsA%253D%253D&md5=1481eff66a60910fc8243055af8fa924</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1007%2Fs11523-008-0100-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-008-0100-y%26sid%3Dliteratum%253Aachs%26aulast%3DJabbour%26aufirst%3DE.%26aulast%3DCortes%26aufirst%3DJ.%26aulast%3DKantarjian%26aufirst%3DH.%26atitle%3DTreatment%2520selection%2520after%2520imatinib%2520resistance%2520in%2520chronic%2520myeloid%2520leukemia%26jtitle%3DTarget%2520Oncol.%26date%3D2009%26volume%3D4%26spage%3D3%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Quintas-Cardama, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J.</span><span> </span><span class="NLM_article-title">Therapeutic options against BCR-ABL1 T315I positive chronic myelogenous leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">4392</span><span class="NLM_x">–</span> <span class="NLM_lpage">4399</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1158%2F1078-0432.CCR-08-0117" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=18628453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=4392-4399&author=A.+Quintas-Cardamaauthor=J.+Cortes&title=Therapeutic+options+against+BCR-ABL1+T315I+positive+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Options Against BCR-ABL1 T315I-Positive Chronic Myelogenous Leukemia</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Cortes, Jorge</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4392-4399</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Despite the efficacy of imatinib therapy in chronic myelogenous leukemia, the development of resistance continues to challenge the treatment of this disease.  Mutations within the kinase domain of BCR-ABL1 constitute the most frequent mechanism of resistance in patients with chronic myelogenous leukemia treated with imatinib or the second generation tyrosine kinase inhibitors nilotinib and dasatinib.  Of particular concern is the substitution of the threonine residue at the highly conserved gatekeeper residue 315 with a bulkier hydrophobic isoleucine amino acid.  This mutation causes steric hindrance precluding the access ATP-competitive inhibitors to the ATP-binding pocket.  To expedite the identification of strategies to override the resistance imposed by the T315I mutation, several strategies have been pursued, including the exploitation of BCR-ABL1 kinase sites distant from the ATP-binding pocket to cripple the kinase activity of the enzyme and inhibiting signaling pathways downstream from BCR-ABL1.  Recent insights gained regarding the structural biol. of T315I have led to the development of a variety of compds. against this mutant.  We herein summarize the most clin. promising anti-T315I therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplJ8bpmJXGkrVg90H21EOLACvtfcHk0lh8DvCExK406Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXosFGit74%253D&md5=01688b0795daf1ca29c7ad4a98e3977b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0117%26sid%3Dliteratum%253Aachs%26aulast%3DQuintas-Cardama%26aufirst%3DA.%26aulast%3DCortes%26aufirst%3DJ.%26atitle%3DTherapeutic%2520options%2520against%2520BCR-ABL1%2520T315I%2520positive%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D4392%26epage%3D4399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuntland, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mestan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span> </span><span class="NLM_article-title">A type-II kinase inhibitor capable of inhibiting the T315I “gatekeeper” mutant of Bcr-Abl</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5439</span><span class="NLM_x">–</span> <span class="NLM_lpage">5448</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm901808w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5439-5448&author=H.+G.+Choiauthor=P.+Renauthor=F.+Adrianauthor=F.+Sunauthor=H.+S.+Leeauthor=X.+Wangauthor=Q.+Dingauthor=G.+Zhangauthor=Y.+Xieauthor=J.+Zhangauthor=Y.+Liuauthor=T.+Tuntlandauthor=M.+Warmuthauthor=P.+W.+Manleyauthor=J.+Mestanauthor=N.+S.+Grayauthor=T.+Sim&title=A+type-II+kinase+inhibitor+capable+of+inhibiting+the+T315I+%E2%80%9Cgatekeeper%E2%80%9D+mutant+of+Bcr-Abl"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1021%2Fjm901808w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901808w%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRen%26aufirst%3DP.%26aulast%3DAdrian%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DSim%26aufirst%3DT.%26atitle%3DA%2520type-II%2520kinase%2520inhibitor%2520capable%2520of%2520inhibiting%2520the%2520T315I%2520%25E2%2580%259Cgatekeeper%25E2%2580%259D%2520mutant%2520of%2520Bcr-Abl%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5439%26epage%3D5448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ding, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wojciechowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bursulaya, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rummel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Expanding the diversity of allosteric Bcr-Abl inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6934</span><span class="NLM_x">–</span> <span class="NLM_lpage">6946</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6934-6946&author=Q.+Dingauthor=J.+Zhangauthor=Y.+Choiauthor=F.+J.+Adrianauthor=A.+Wojciechowskiauthor=G.+Zhangauthor=J.+Cheauthor=B.+Bursulayaauthor=S.+W.+Cowan-Jacobauthor=G.+Rummelauthor=T.+Simauthor=N.+S.+Gray&title=Expanding+the+diversity+of+allosteric+Bcr-Abl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%26aulast%3DAdrian%26aufirst%3DF.%2BJ.%26aulast%3DWojciechowski%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DChe%26aufirst%3DJ.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DRummel%26aufirst%3DG.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExpanding%2520the%2520diversity%2520of%2520allosteric%2520Bcr-Abl%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6934%26epage%3D6946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 3-(1<i>H</i><sup>–</sup>1,2,3-triazol-1-yl)benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine<sup>315</sup>→isoleucine<sup>315</sup> mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">10033</span><span class="NLM_x">–</span> <span class="NLM_lpage">10046</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2012&pages=10033-10046&author=Y.+Liauthor=M.+Shenauthor=Z.+Zhangauthor=J.+Luoauthor=X.+Panauthor=X.+Luauthor=H.+Longauthor=D.+Wenauthor=F.+Zhangauthor=F.+Lengauthor=Y.+Liauthor=Z.+Tuauthor=X.+Renauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+3-%281H%E2%80%931%2C2%2C3-triazol-1-yl%29benzamide+derivatives+as+potent+pan+Bcr-Abl+inhibitors+including+the+threonine315%E2%86%92isoleucine315+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLeng%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25203-%25281H%25E2%2580%25931%252C2%252C3-triazol-1-yl%2529benzamide%2520derivatives%2520as%2520potent%2520pan%2520Bcr-Abl%2520inhibitors%2520including%2520the%2520threonine315%25E2%2586%2592isoleucine315%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D53%26spage%3D10033%26epage%3D10046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leng, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">She, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region–Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">879</span><span class="NLM_x">–</span> <span class="NLM_lpage">894</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301581y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=879-894&author=X.+Renauthor=X.+Panauthor=Z.+Zhangauthor=D.+Wangauthor=X.+Luauthor=Y.+Liauthor=D.+Wenauthor=H.+Longauthor=J.+Luoauthor=Y.+Fengauthor=X.+Zhuangauthor=F.+Zhangauthor=J.+Liuauthor=F.+Lengauthor=X.+Langauthor=Y.+Baiauthor=M.+Sheauthor=Z.+Tuauthor=J.+Panauthor=K.+Ding&title=Identification+of+GZD824+as+an+orally+bioavailable+inhibitor+that+targets+phosphorylated+and+nonphosphorylated+breakpoint+cluster+region%E2%80%93Abelson+%28Bcr-Abl%29+kinase+and+overcomes+clinically+acquired+mutation-induced+resistance+against+imatinib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8d&amp;dbid=16384&amp;doi=10.1021%2Fjm301581y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301581y%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DX.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLong%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DZhuang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLeng%26aufirst%3DF.%26aulast%3DLang%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DShe%26aufirst%3DM.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DIdentification%2520of%2520GZD824%2520as%2520an%2520orally%2520bioavailable%2520inhibitor%2520that%2520targets%2520phosphorylated%2520and%2520nonphosphorylated%2520breakpoint%2520cluster%2520region%25E2%2580%2593Abelson%2520%2528Bcr-Abl%2529%2520kinase%2520and%2520overcomes%2520clinically%2520acquired%2520mutation-induced%2520resistance%2520against%2520imatinib%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D879%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Lu, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">2146</span><span class="NLM_x">–</span> <span class="NLM_lpage">2157</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.2174%2F092986711795656135" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=21517764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8e&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=2146-2157&author=X.+Y.+Luauthor=Q.+Caiauthor=K.+Ding&title=Recent+developments+in+the+third+generation+inhibitors+of+Bcr-Abl+for+overriding+T315I+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8eR"><div class="casContent"><span class="casTitleNuber">8e</span><div class="casTitle"><span class="NLM_cas:atitle">Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation</span></div><div class="casAuthors">Lu, X. Y.; Cai, Q.; Ding, K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2146-2157</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  In the treatment of chronic myeloid leukemia (CML) with Bcr-Abl kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents, such as imatinib, nilotinib and dasatinib, by disrupting important contact interactions between the inhibitors and the enzyme.  To overcome this particular resistance, several different strategies have been explored and many mols. have been investigated as capable of potently inhibiting Bcr-Abl T315I.  Herein, this review reports on some predominant examples of third generation inhibitors of Bcr-Abl active against the T315I mutation, and special attentions are paid to the "hybrid-design" strategy for creating type-II class ATP-competitive inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFoM774pVEqrVg90H21EOLACvtfcHk0lioYx0ZnsY1MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmvFegs7k%253D&md5=23109d1eb81a48f93cdf9ffbb4728c7a</span></div><a href="/servlet/linkout?suffix=cit8e&amp;dbid=16384&amp;doi=10.2174%2F092986711795656135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711795656135%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%2BY.%26aulast%3DCai%26aufirst%3DQ.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DRecent%2520developments%2520in%2520the%2520third%2520generation%2520inhibitors%2520of%2520Bcr-Abl%2520for%2520overriding%2520T315I%2520mutation%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D2146%26epage%3D2157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8f"><span><span class="NLM_label">(f) </span><span class="NLM_contrib-group">Weisberg, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ray, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sim, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debiec-Rychter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayeda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moreno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khosravi-Far, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melo, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manley, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adamia, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span> </span><span class="NLM_article-title">Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">4206</span><span class="NLM_x">–</span> <span class="NLM_lpage">4216</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=4206-4216&author=E.+Weisbergauthor=H.+G.+Choiauthor=A.+Rayauthor=R.+Barrettauthor=J.+Zhangauthor=T.+Simauthor=W.+Zhouauthor=M.+Seeligerauthor=M.+Cameronauthor=M.+Azamauthor=J.+A.+Fletcherauthor=M.+Debiec-Rychterauthor=M.+Mayedaauthor=D.+Morenoauthor=A.+L.+Kungauthor=P.+A.+Janneauthor=R.+Khosravi-Farauthor=J.+V.+Meloauthor=P.+W.+Manleyauthor=S.+Adamiaauthor=C.+Wuauthor=N.+Grayauthor=J.+D.+Griffin&title=Discovery+of+a+small-molecule+type+II+inhibitor+of+wild-type+and+gatekeeper+mutants+of+BCR-ABL%2C+PDGFRalpha%2C+Kit%2C+and+Src+kinases%3A+novel+type+II+inhibitor+of+gatekeeper+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8f&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWeisberg%26aufirst%3DE.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DRay%26aufirst%3DA.%26aulast%3DBarrett%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DSeeliger%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DM.%26aulast%3DAzam%26aufirst%3DM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DMayeda%26aufirst%3DM.%26aulast%3DMoreno%26aufirst%3DD.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26aulast%3DKhosravi-Far%26aufirst%3DR.%26aulast%3DMelo%26aufirst%3DJ.%2BV.%26aulast%3DManley%26aufirst%3DP.%2BW.%26aulast%3DAdamia%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DGray%26aufirst%3DN.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520small-molecule%2520type%2520II%2520inhibitor%2520of%2520wild-type%2520and%2520gatekeeper%2520mutants%2520of%2520BCR-ABL%252C%2520PDGFRalpha%252C%2520Kit%252C%2520and%2520Src%2520kinases%253A%2520novel%2520type%2520II%2520inhibitor%2520of%2520gatekeeper%2520mutants%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D4206%26epage%3D4216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8g"><span><span class="NLM_label">(g) </span><span class="NLM_contrib-group">Modugno, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soncini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosettani, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombo, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fancelli, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carpinelli, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isacchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moll, J.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">7987</span><span class="NLM_x">–</span> <span class="NLM_lpage">7990</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=7987-7990&author=M.+Modugnoauthor=E.+Casaleauthor=C.+Sonciniauthor=P.+Rosettaniauthor=R.+Colomboauthor=R.+Lupiauthor=L.+Rusconiauthor=D.+Fancelliauthor=P.+Carpinelliauthor=A.+D.+Cameronauthor=A.+Isacchiauthor=J.+Moll&title=Crystal+structure+of+the+T315I+Abl+mutant+in+complex+with+the+aurora+kinases+inhibitor+PHA-739358"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8g&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DModugno%26aufirst%3DM.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DSoncini%26aufirst%3DC.%26aulast%3DRosettani%26aufirst%3DP.%26aulast%3DColombo%26aufirst%3DR.%26aulast%3DLupi%26aufirst%3DR.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DFancelli%26aufirst%3DD.%26aulast%3DCarpinelli%26aufirst%3DP.%26aulast%3DCameron%26aufirst%3DA.%2BD.%26aulast%3DIsacchi%26aufirst%3DA.%26aulast%3DMoll%26aufirst%3DJ.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520Abl%2520mutant%2520in%2520complex%2520with%2520the%2520aurora%2520kinases%2520inhibitor%2520PHA-739358%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D7987%26epage%3D7990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8h"><span><span class="NLM_label">(h) </span><span class="NLM_contrib-group">Young, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seeliger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">1007</span><span class="NLM_x">–</span> <span class="NLM_lpage">1014</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8h&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1158%2F0008-5472.CAN-05-2788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8h&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=16424036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8h&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD28XlsFOhtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=1007-1014&author=M.+A.+Youngauthor=N.+P.+Shahauthor=L.+H.+Chaoauthor=M.+Seeligerauthor=Z.+V.+Milanovauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhartauthor=C.+L.+Sawyersauthor=J.+Kuriyan&title=Structure+of+the+kinase+domain+of+an+imatinib-resistant+Abl+mutant+in+complex+with+the+Aurora+kinase+inhibitor+VX-680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8hR"><div class="casContent"><span class="casTitleNuber">8h</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Kinase Domain of an Imatinib-Resistant Abl Mutant in Complex with the Aurora Kinase Inhibitor VX-680</span></div><div class="casAuthors">Young, Matthew A.; Shah, Neil P.; Chao, Luke H.; Seeliger, Markus; Milanov, Zdravko V.; Biggs, William H., III; Treiber, Daniel K.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.; Sawyers, Charles L.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1007-1014</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We present a high-resoln. (2.0 Å) crystal structure of the catalytic domain of a mutant form of the Abl tyrosine kinase (H396P; Abl-1a numbering) that is resistant to the Abl inhibitor imatinib.  The structure is detd. in complex with the small-mol. inhibitor VX-680 (Vertex Pharmaceuticals, Cambridge, MA), which blocks the activity of various imatinib-resistant mutant forms of Abl, including one (T315I) that is resistant to both imatinib and BMS-354825 (dasatinib), a dual Src/Abl inhibitor that seems to be clin. effective against all other imatinib-resistant forms of BCR-Abl.  VX-680 is shown to have significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples.  The Abl kinase domain bound to VX-680 is not phosphorylated on the activation loop in the crystal structure but is nevertheless in an active conformation, previously unobserved for Abl and inconsistent with the binding of imatinib.  The adoption of an active conformation is most likely the result of synergy between the His396Pro mutation, which destabilizes the inactive conformation required for imatinib binding, and the binding of VX-680, which favors the active conformation through hydrogen bonding and steric effects.  VX-680 is bound to Abl in a mode that accommodates the substitution of isoleucine for threonine at residue 315 (the "gatekeeper" position).  The avoidance of the innermost cavity of the Abl kinase domain by VX-680 and the specific recognition of the active conformation explain the effectiveness of this compd. against mutant forms of BCR-Abl, including those with mutations at the gatekeeper position.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNV6YSmt1NWrVg90H21EOLACvtfcHk0lioYx0ZnsY1MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlsFOhtw%253D%253D&md5=a31ed99bdc51cf266c8c10dfceb1800c</span></div><a href="/servlet/linkout?suffix=cit8h&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-2788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-2788%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DM.%2BA.%26aulast%3DShah%26aufirst%3DN.%2BP.%26aulast%3DChao%26aufirst%3DL.%2BH.%26aulast%3DSeeliger%26aufirst%3DM.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520kinase%2520domain%2520of%2520an%2520imatinib-resistant%2520Abl%2520mutant%2520in%2520complex%2520with%2520the%2520Aurora%2520kinase%2520inhibitor%2520VX-680%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D1007%26epage%3D1014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><div class="note"><p class="first last">During preparation of manuscript, ponatinib was recently approved by the FDA for the treatment of CML patients.</p></div></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=During+preparation+of+manuscript%2C+ponatinib+was+recently+approved+by+the+FDA+for+the+treatment+of+CML+patients."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loriaux, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span> </span><span class="NLM_article-title">AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">412</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2009&pages=401-412&author=T.+O%E2%80%99Hareauthor=W.+C.+Shakespeareauthor=X.+Zhuauthor=C.+A.+Eideauthor=V.+M.+Riveraauthor=F.+Wangauthor=L.+T.+Adrianauthor=T.+Zhouauthor=W.+S.+Huangauthor=Q.+Xuauthor=C.+A.+Metcalfauthor=J.+W.+Tynerauthor=M.+M.+Loriauxauthor=A.+S.+Corbinauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+A.+Keatsauthor=Y.+Wangauthor=R.+Sundaramoorthiauthor=M.+Thomasauthor=D.+Zhouauthor=J.+Snodgrassauthor=L.+Commodoreauthor=T.+K.+Sawyerauthor=D.+C.+Dalgarnoauthor=M.+W.+Deiningerauthor=B.+J.+Drukerauthor=T.+Clackson&title=AP24534%2C+a+pan-BCR-ABL+inhibitor+for+chronic+myeloid+leukemia%2C+potently+inhibits+the+T315I+mutant+and+overcomes+mutation-based+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DLoriaux%26aufirst%3DM.%2BM.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%2BA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DSnodgrass%26aufirst%3DJ.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DClackson%26aufirst%3DT.%26atitle%3DAP24534%252C%2520a%2520pan-BCR-ABL%2520inhibitor%2520for%2520chronic%2520myeloid%2520leukemia%252C%2520potently%2520inhibits%2520the%2520T315I%2520mutant%2520and%2520overcomes%2520mutation-based%2520resistance%26jtitle%3DCancer%2520Cell%26date%3D2009%26volume%3D16%26spage%3D401%26epage%3D412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Huang, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metcalf, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sundaramoorthi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lentini, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wardwell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ning, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broudy, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russian, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commodore, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimhan, N. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohemmad, Q. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iuliucci, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyer, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clackson, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W. C.</span><span> </span><span class="NLM_article-title">Discovery of 3-[2-(imidazo[1,2-<i>b</i>]pyridazin-3-yl)ethynyl]-4-methyl-<i>N</i>-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4701</span><span class="NLM_x">–</span> <span class="NLM_lpage">4719</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm100395q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4701-4719&author=W.+S.+Huangauthor=C.+A.+Metcalfauthor=R.+Sundaramoorthiauthor=Y.+Wangauthor=D.+Zouauthor=R.+M.+Thomasauthor=X.+Zhuauthor=L.+Caiauthor=D.+Wenauthor=S.+Liuauthor=J.+Romeroauthor=J.+Qiauthor=I.+Chenauthor=G.+Bandaauthor=S.+P.+Lentiniauthor=S.+Dasauthor=Q.+Xuauthor=J.+Keatsauthor=F.+Wangauthor=S.+Wardwellauthor=Y.+Ningauthor=J.+T.+Snodgrassauthor=M.+I.+Broudyauthor=K.+Russianauthor=T.+Zhouauthor=L.+Commodoreauthor=N.+I.+Narasimhanauthor=Q.+K.+Mohemmadauthor=J.+Iuliucciauthor=V.+M.+Riveraauthor=D.+C.+Dalgarnoauthor=T.+K.+Sawyerauthor=T.+Clacksonauthor=W.+C.+Shakespeare&title=Discovery+of+3-%5B2-%28imidazo%5B1%2C2-b%5Dpyridazin-3-yl%29ethynyl%5D-4-methyl-N-%7B4-%5B%284-methylpiperazin-1-yl%29methyl%5D-3-%28trifluoromethyl%29phenyl%7Dbenzamide+%28AP24534%29%2C+a+potent%2C+orally+active+pan-inhibitor+of+breakpoint+cluster+region-Abelson+%28BCR-ABL%29+kinase+including+the+T315I+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=10.1021%2Fjm100395q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100395q%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DW.%2BS.%26aulast%3DMetcalf%26aufirst%3DC.%2BA.%26aulast%3DSundaramoorthi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DD.%26aulast%3DThomas%26aufirst%3DR.%2BM.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DL.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DRomero%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DI.%26aulast%3DBanda%26aufirst%3DG.%26aulast%3DLentini%26aufirst%3DS.%2BP.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSnodgrass%26aufirst%3DJ.%2BT.%26aulast%3DBroudy%26aufirst%3DM.%2BI.%26aulast%3DRussian%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DCommodore%26aufirst%3DL.%26aulast%3DNarasimhan%26aufirst%3DN.%2BI.%26aulast%3DMohemmad%26aufirst%3DQ.%2BK.%26aulast%3DIuliucci%26aufirst%3DJ.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DDalgarno%26aufirst%3DD.%2BC.%26aulast%3DSawyer%26aufirst%3DT.%2BK.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DShakespeare%26aufirst%3DW.%2BC.%26atitle%3DDiscovery%2520of%25203-%255B2-%2528imidazo%255B1%252C2-b%255Dpyridazin-3-yl%2529ethynyl%255D-4-methyl-N-%257B4-%255B%25284-methylpiperazin-1-yl%2529methyl%255D-3-%2528trifluoromethyl%2529phenyl%257Dbenzamide%2520%2528AP24534%2529%252C%2520a%2520potent%252C%2520orally%2520active%2520pan-inhibitor%2520of%2520breakpoint%2520cluster%2520region-Abelson%2520%2528BCR-ABL%2529%2520kinase%2520including%2520the%2520T315I%2520gatekeeper%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4701%26epage%3D4719" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Eide, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrian, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tyner, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mac Partlin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petillo, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flynn, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Hare, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">3189</span><span class="NLM_x">–</span> <span class="NLM_lpage">3195</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=3189-3195&author=C.+A.+Eideauthor=L.+T.+Adrianauthor=J.+W.+Tynerauthor=M.+Mac+Partlinauthor=D.+J.+Andersonauthor=S.+C.+Wiseauthor=B.+D.+Smithauthor=P.+A.+Petilloauthor=D.+L.+Flynnauthor=M.+W.+Deiningerauthor=T.+O%E2%80%99Hareauthor=B.+J.+Druker&title=The+ABL+switch+control+inhibitor+DCC-2036+is+active+against+the+chronic+myeloid+leukemia+mutant+BCR-ABLT315I+and+exhibits+a+narrow+resistance+profile"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEide%26aufirst%3DC.%2BA.%26aulast%3DAdrian%26aufirst%3DL.%2BT.%26aulast%3DTyner%26aufirst%3DJ.%2BW.%26aulast%3DMac%2BPartlin%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DD.%2BJ.%26aulast%3DWise%26aufirst%3DS.%2BC.%26aulast%3DSmith%26aufirst%3DB.%2BD.%26aulast%3DPetillo%26aufirst%3DP.%2BA.%26aulast%3DFlynn%26aufirst%3DD.%2BL.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DO%25E2%2580%2599Hare%26aufirst%3DT.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DThe%2520ABL%2520switch%2520control%2520inhibitor%2520DCC-2036%2520is%2520active%2520against%2520the%2520chronic%2520myeloid%2520leukemia%2520mutant%2520BCR-ABLT315I%2520and%2520exhibits%2520a%2520narrow%2520resistance%2520profile%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D3189%26epage%3D3195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Park, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Nocodazole is a high-affinity ligand for the cancer-related kinases ABL, c-KIT, BRAF, and MEK</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">56</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=53-56&author=H.+Parkauthor=S.+Hongauthor=S.+Hong&title=Nocodazole+is+a+high-affinity+ligand+for+the+cancer-related+kinases+ABL%2C+c-KIT%2C+BRAF%2C+and+MEK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DHong%26aufirst%3DS.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DNocodazole%2520is%2520a%2520high-affinity%2520ligand%2520for%2520the%2520cancer-related%2520kinases%2520ABL%252C%2520c-KIT%252C%2520BRAF%252C%2520and%2520MEK%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D53%26epage%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">De Brabander, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van de Veire, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aerts, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janssen, P. A.</span><span> </span><span class="NLM_article-title">The effects of methyl (5-(2-thienylcarbonyl)-1<i>H</i>-benzimidazol-2-yl) carbamate, (R 17934; NSC 238159), a new synthetic antitumoral drug interfering with microtubules, on mammalian cells cultured in vitro</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1976</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">905</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1976&pages=905-916&author=M.+J.+De+Brabanderauthor=R.+M.+Van+de+Veireauthor=F.+E.+Aertsauthor=M.+Borgersauthor=P.+A.+Janssen&title=The+effects+of+methyl+%285-%282-thienylcarbonyl%29-1H-benzimidazol-2-yl%29+carbamate%2C+%28R+17934%3B+NSC+238159%29%2C+a+new+synthetic+antitumoral+drug+interfering+with+microtubules%2C+on+mammalian+cells+cultured+in+vitro"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBrabander%26aufirst%3DM.%2BJ.%26aulast%3DVan%2Bde%2BVeire%26aufirst%3DR.%2BM.%26aulast%3DAerts%26aufirst%3DF.%2BE.%26aulast%3DBorgers%26aufirst%3DM.%26aulast%3DJanssen%26aufirst%3DP.%2BA.%26atitle%3DThe%2520effects%2520of%2520methyl%2520%25285-%25282-thienylcarbonyl%2529-1H-benzimidazol-2-yl%2529%2520carbamate%252C%2520%2528R%252017934%253B%2520NSC%2520238159%2529%252C%2520a%2520new%2520synthetic%2520antitumoral%2520drug%2520interfering%2520with%2520microtubules%252C%2520on%2520mammalian%2520cells%2520cultured%2520in%2520vitro%26jtitle%3DCancer%2520Res.%26date%3D1976%26volume%3D36%26spage%3D905%26epage%3D916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Drumma, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deiningera, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tirana, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wanga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grillota, A.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liaoa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ronkina, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stamosa, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanga, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiana, S.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver-Shafferb, P.</span><span> </span><span class="NLM_article-title">Facile preparation of fused ring azolylureas</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">5535</span><span class="NLM_x">–</span> <span class="NLM_lpage">5538</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2007&pages=5535-5538&author=J.+E.+Drummaauthor=D.+D.+Deiningeraauthor=A.+L.+Tiranaauthor=T.+Wangaauthor=A.-L.+Grillotaauthor=Y.+Liaoaauthor=S.+M.+Ronkinaauthor=D.+P.+Stamosaauthor=Q.+Tangaauthor=S.-K.+Tianaauthor=P.+Oliver-Shafferb&title=Facile+preparation+of+fused+ring+azolylureas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDrumma%26aufirst%3DJ.%2BE.%26aulast%3DDeiningera%26aufirst%3DD.%2BD.%26aulast%3DTirana%26aufirst%3DA.%2BL.%26aulast%3DWanga%26aufirst%3DT.%26aulast%3DGrillota%26aufirst%3DA.-L.%26aulast%3DLiaoa%26aufirst%3DY.%26aulast%3DRonkina%26aufirst%3DS.%2BM.%26aulast%3DStamosa%26aufirst%3DD.%2BP.%26aulast%3DTanga%26aufirst%3DQ.%26aulast%3DTiana%26aufirst%3DS.-K.%26aulast%3DOliver-Shafferb%26aufirst%3DP.%26atitle%3DFacile%2520preparation%2520of%2520fused%2520ring%2520azolylureas%26jtitle%3DTetrahedron%2520Lett.%26date%3D2007%26volume%3D48%26spage%3D5535%26epage%3D5538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittekind, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzillerri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span> </span><span class="NLM_article-title">The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">5790</span><span class="NLM_x">–</span> <span class="NLM_lpage">5797</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5790-5797&author=J.+S.+Tokarskiauthor=J.+A.+Newittauthor=C.+Y.+J.+Changauthor=J.+D.+Chengauthor=M.+Wittekindauthor=S.+E.+Kieferauthor=K.+Kishauthor=F.+Y.+F.+Leeauthor=R.+Borzillerriauthor=L.+J.+Lombardoauthor=D.+Xieauthor=Y.+Zhangauthor=H.+E.+Klei&title=The+structure+of+dasatinib+%28BMS-354825%29+bound+to+activated+ABL+kinase+domain+elucidates+its+inhibitory+activity+against+imatinib-resistant+ABL+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DC.%2BY.%2BJ.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DWittekind%26aufirst%3DM.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DF.%2BY.%2BF.%26aulast%3DBorzillerri%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26atitle%3DThe%2520structure%2520of%2520dasatinib%2520%2528BMS-354825%2529%2520bound%2520to%2520activated%2520ABL%2520kinase%2520domain%2520elucidates%2520its%2520inhibitory%2520activity%2520against%2520imatinib-resistant%2520ABL%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D5790%26epage%3D5797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Zhou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parillon, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keats, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamore, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakespeare, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalgarno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span> </span><span class="NLM_article-title">Crystal structure of the T315I mutant of AbI kinase</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">171</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1111%2Fj.1747-0285.2007.00556.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=17718712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2007&pages=171-181&author=T.+Zhouauthor=L.+Parillonauthor=F.+Liauthor=Y.+Wangauthor=J.+Keatsauthor=S.+Lamoreauthor=Q.+Xuauthor=W.+Shakespeareauthor=D.+Dalgarnoauthor=X.+Zhu&title=Crystal+structure+of+the+T315I+mutant+of+AbI+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the T315I mutant of Abl kinase</span></div><div class="casAuthors">Zhou, Tianjun; Parillon, Lois; Li, Feng; Wang, Yihan; Keats, Jeff; Lamore, Sarah; Xu, Qihong; Shakespeare, William; Dalgarno, David; Zhu, Xiaotian</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">171-181</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Imatinib (Gleevec) is currently the frontline therapy for chronic myeloid leukemia (CML), a disease characterized by the presence of a constitutively activated chimeric tyrosine kinase protein Bcr-Abl.  However, drug resistance often occurs at later stages of the disease, principally because of the occurrence of mutations in the kinase domain.  Second generation Bcr-Abl inhibitors, such as dasatinib and nilotinib are capable of inhibiting many imatinib-resistant forms of the kinase but not the form in which threonine is mutated to isoleucine at the gatekeeper position (T315I).  In this study, we present the crystal structure of the kinase domain of the c-Abl T315I mutant, as well as the wild-type form, in complex with a pyrrolopyridine inhibitor, PPY-A.  The side chain of Ile315 is accommodated in the Abl T315I mutant structure without large conformational changes proximal to the site of mutation.  In contrast to other inhibitors, such as imatinib and dasatinib, PPY-A does not occupy the hydrophobic pocket behind the gate-keeper residue.  This binding mode, coupled with augmented contacts with the glycine-rich loop, appears to be crit. for its ability to override the T315I mutation.  The data presented here may provide structural guidance for the design of clin. useful inhibitors of Bcr-Abl T315I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcbSxFWWpadbVg90H21EOLACvtfcHk0lijKpepwiDiug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtVels73F&md5=b15c60121b02e33d71783db3abd5ce72</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.1747-0285.2007.00556.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1747-0285.2007.00556.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DParillon%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DKeats%26aufirst%3DJ.%26aulast%3DLamore%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DQ.%26aulast%3DShakespeare%26aufirst%3DW.%26aulast%3DDalgarno%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DX.%26atitle%3DCrystal%2520structure%2520of%2520the%2520T315I%2520mutant%2520of%2520AbI%2520kinase%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2007%26volume%3D70%26spage%3D171%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Schindler, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornmann, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellicena, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarkson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span> </span><span class="NLM_article-title">Structural mechanism for STI-571 inhibition of abelson tyrosine kinase</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">289</span><span class="NLM_x">, </span> <span class="NLM_fpage">1938</span><span class="NLM_x">–</span> <span class="NLM_lpage">1942</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Fjm301891t&amp;key=10.1126%2Fscience.289.5486.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Fjm301891t&amp;key=10988075" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=289&publication_year=2000&pages=1938-1942&author=T.+Schindlerauthor=W.+Bornmannauthor=P.+Pellicenaauthor=W.+T.+Millerauthor=B.+Clarksonauthor=J.+Kuriyan&title=Structural+mechanism+for+STI-571+inhibition+of+abelson+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase</span></div><div class="casAuthors">Schindler, Thomas; Bornmann, William; Pellicena, Patricia; Miller, W. Todd; Clarkson, Bayard; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">289</span>
        (<span class="NLM_cas:issue">5486</span>),
    <span class="NLM_cas:pages">1938-1942</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The inadvertent activation of the Abelson tyrosine kinase (Abl) causes chronic myelogenous leukemia (CML).  A small-mol. inhibitor of Abl (STI-571) is effective in the treatment of CML.  We report the crystal structure of the catalytic domain of Abl, complexed to a variant of STI-571.  Crit. to the binding of STI-571 is the adoption by the kinase of an inactive conformation, in which a centrally located "activation loop" is not phosphorylated.  The conformation of this loop is distinct from that in active protein kinases, as well as in the inactive form of the closely related Src kinases.  These results suggest that compds. that exploit the distinctive inactivation mechanisms of individual protein kinases can achieve both high affinity and high specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9eAZqIQ1aebVg90H21EOLACvtfcHk0lijKpepwiDiug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXms1altLc%253D&md5=56bb233f010f099d0073020ac6b9db59</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1126%2Fscience.289.5486.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.289.5486.1938%26sid%3Dliteratum%253Aachs%26aulast%3DSchindler%26aufirst%3DT.%26aulast%3DBornmann%26aufirst%3DW.%26aulast%3DPellicena%26aufirst%3DP.%26aulast%3DMiller%26aufirst%3DW.%2BT.%26aulast%3DClarkson%26aufirst%3DB.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DStructural%2520mechanism%2520for%2520STI-571%2520inhibition%2520of%2520abelson%2520tyrosine%2520kinase%26jtitle%3DScience%26date%3D2000%26volume%3D289%26spage%3D1938%26epage%3D1942" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittekind, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzillerri, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klei, H. E.</span><span> </span><span class="NLM_article-title">The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">5790</span><span class="NLM_x">–</span> <span class="NLM_lpage">5797</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=5790-5797&author=J.+S.+Tokarskiauthor=J.+A.+Newittauthor=C.+Y.+Changauthor=J.+D.+Chengauthor=M.+Wittekindauthor=S.+E.+Kieferauthor=K.+Kishauthor=F.+Y.+Leeauthor=R.+Borzillerriauthor=L.+J.+Lombardoauthor=D.+Xieauthor=Y.+Zhangauthor=H.+E.+Klei&title=The+structure+of+dasatinib+%28BMS-354825%29+bound+to+activated+ABL+kinase+domain+elucidates+its+inhibitory+activity+against+imatinib-resistant+ABL+mutants"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DCheng%26aufirst%3DJ.%2BD.%26aulast%3DWittekind%26aufirst%3DM.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DBorzillerri%26aufirst%3DR.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKlei%26aufirst%3DH.%2BE.%26atitle%3DThe%2520structure%2520of%2520dasatinib%2520%2528BMS-354825%2529%2520bound%2520to%2520activated%2520ABL%2520kinase%2520domain%2520elucidates%2520its%2520inhibitory%2520activity%2520against%2520imatinib-resistant%2520ABL%2520mutants%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D5790%26epage%3D5797" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Park, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, S.</span><span> </span><span class="NLM_article-title">Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure</span> <span class="citation_source-journal">J. Chem. Inf. Model.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">2986</span><span class="NLM_x">–</span> <span class="NLM_lpage">2993</span></span><div class="citationLinks">[<a href="/doi/10.1021/ci200378s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm301891t&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlGjt7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2986-2993&author=H.+Parkauthor=O.+Chiauthor=J.+Kimauthor=S.+Hong&title=Identification+of+novel+inhibitors+of+tropomyosin-related+kinase+A+through+the+structure-based+virtual+screening+with+homology-modeled+protein+structure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Novel Inhibitors of Tropomyosin-Related Kinase A through the Structure-Based Virtual Screening with Homology-Modeled Protein Structure</span></div><div class="casAuthors">Park, Hwangseo; Chi, Okyung; Kim, Jinhee; Hong, Sungwoo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2986-2993</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tropomyosin-related kinase A (TrkA) is a promising target for the development of cancer and pain therapeutics.  Here, we report the first successful example of the use of a structure-based virtual screening to identify novel TrkA inhibitors.  The accuracy of the virtual screening was improved by introducing an accurate solvation free energy term into the original AutoDock scoring function.  We applied a drug design protocol involving homol. modeling, docking anal. of a large chem. library, and enzyme inhibition assays to identify six structurally diverse TrkA inhibitors with Kd values ranging from 3 to 40 μM.  The significant potencies and good physicochem. properties of these drug candidates strongly support their consideration in a development effort that would involve structure-activity relationship (SAR) studies to optimize the inhibitory activities.  We also addressed the structural and energetic features assocd. with binding of the newly identified inhibitors in the ATP-binding site of TrkA.  The results indicate that any structural modifications introduced for the purpose of enhancing the activity of TrkA inhibitors should maximize the attractive interactions within the ATP-binding site and simultaneously minimize the desolvation cost for complexation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbeYo4P3Dw-LVg90H21EOLACvtfcHk0lijKpepwiDiug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlGjt7nE&md5=24656238aa8c161dcf1cc2967054ca35</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fci200378s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200378s%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DH.%26aulast%3DChi%26aufirst%3DO.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DHong%26aufirst%3DS.%26atitle%3DIdentification%2520of%2520novel%2520inhibitors%2520of%2520tropomyosin-related%2520kinase%2520A%2520through%2520the%2520structure-based%2520virtual%2520screening%2520with%2520homology-modeled%2520protein%2520structure%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2986%26epage%3D2993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="note"><p class="first last">POC determinations were performed by the Ambit Bioscience Corp. (San Diego, CA, USA).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Oda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaney, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagopian, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okuda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">269</span><span class="NLM_x">, </span> <span class="NLM_fpage">22925</span><span class="NLM_x">–</span> <span class="NLM_lpage">22928</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1994&pages=22925-22928&author=T.+Odaauthor=C.+Heaneyauthor=J.+R.+Hagopianauthor=K.+Okudaauthor=J.+D.+Griffinauthor=B.+J.+Druker&title=Crkl+is+the+major+tyrosine-phosphorylated+protein+in+neutrophils+from+patients+with+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOda%26aufirst%3DT.%26aulast%3DHeaney%26aufirst%3DC.%26aulast%3DHagopian%26aufirst%3DJ.%2BR.%26aulast%3DOkuda%26aufirst%3DK.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DCrkl%2520is%2520the%2520major%2520tyrosine-phosphorylated%2520protein%2520in%2520neutrophils%2520from%2520patients%2520with%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1994%26volume%3D269%26spage%3D22925%26epage%3D22928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Shuai, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halpern, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ten Hoeve, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">254</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1996&pages=247-254&author=K.+Shuaiauthor=J.+Halpernauthor=J.+ten+Hoeveauthor=X.+Raoauthor=C.+L.+Sawyers&title=Constitutive+activation+of+STAT5+by+the+BCR-ABL+oncogene+in+chronic+myelogenous+leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShuai%26aufirst%3DK.%26aulast%3DHalpern%26aufirst%3DJ.%26aulast%3Dten%2BHoeve%26aufirst%3DJ.%26aulast%3DRao%26aufirst%3DX.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DConstitutive%2520activation%2520of%2520STAT5%2520by%2520the%2520BCR-ABL%2520oncogene%2520in%2520chronic%2520myelogenous%2520leukemia%26jtitle%3DOncogene%26date%3D1996%26volume%3D13%26spage%3D247%26epage%3D254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">La Rosée, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corbin, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoffregen, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deininger, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571)</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">7149</span><span class="NLM_x">–</span> <span class="NLM_lpage">7153</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=7149-7153&author=P.+La+Ros%C3%A9eauthor=A.+S.+Corbinauthor=E.+P.+Stoffregenauthor=M.+W.+Deiningerauthor=B.+J.+Druker&title=Activity+of+the+Bcr-Abl+kinase+inhibitor+PD180970+against+clinically+relevant+Bcr-Abl+isoforms+that+cause+resistance+to+imatinib+mesylate+%28Gleevec%2C+STI571%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLa%2BRos%25C3%25A9e%26aufirst%3DP.%26aulast%3DCorbin%26aufirst%3DA.%2BS.%26aulast%3DStoffregen%26aufirst%3DE.%2BP.%26aulast%3DDeininger%26aufirst%3DM.%2BW.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DActivity%2520of%2520the%2520Bcr-Abl%2520kinase%2520inhibitor%2520PD180970%2520against%2520clinically%2520relevant%2520Bcr-Abl%2520isoforms%2520that%2520cause%2520resistance%2520to%2520imatinib%2520mesylate%2520%2528Gleevec%252C%2520STI571%2529%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D7149%26epage%3D7153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GQG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2GQG','PDB','2GQG'); return false;">PDB: 2GQG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QOH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2QOH','PDB','2QOH'); return false;">PDB: 2QOH</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i77"><a href="/doi/suppl/10.1021/jm301891t">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_23366"></div></div></div></div></div><hr /></hr><p class="last">Spectra, more chemical information, and biological data. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm301891t/suppl_file/jm301891t_si_001.pdf">jm301891t_si_001.pdf (12.7 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm301891t&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-9%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Fjm301891t%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm301891t" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799a50729de21a6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
